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Abstract  
Drug induced liver injury (DILI) is a major cause of patient morbidity and mortality inferring 
considerable burdens onto healthcare and pharmaceutical sectors. As a consequence, 
substantial resources are directed towards triaging potentially dangerous new compounds 
at all stages of drug development. However, despite these efforts, hepatotoxic compounds 
remain the greatest cause of post-marketing drug withdrawal. One of the major factors 
preventing efficacious screening of new compounds is the lack of a truly representative in 
vitro model of hepatotoxicity. This thesis describes our efforts to utilise innovative and 
emerging techniques to further understand and develop in vitro models of hepatotoxicity.   
One such technique is the generation of hepatocyte-like cells from induced pluripotent 
stem cells (iPSCs).  iPSC-derived hepatocyte-like cells offer a reproducible, physiologically-
relevant, genotypically normal and population-representative model of hepatotoxicity; 
however, current differentiation protocols are not capable of producing hepatocyte-like 
cells beyond a relatively immature phenotype, limiting their use for toxicological studies. As 
part of the cellular reprogramming process the epigenome of the somatic cell undergoes 
dramatic changes; however, the  studies have shown that this ‘resetting’ of the epigenome 
to a pluripotent state is an imperfect process, resulting in an altered differentiation 
propensity skewed towards the lineage of origin. We evaluated if using human hepatocytes 
as the starting cell type and utilising the inherent ‘epigenetic memory’ associated with 
iPSCs could enhance the maturity of hepatocyte-like cells. Despite a trend towards 
improvement in phenotype, no significant differences were found between isogenic 
hepatocyte-derived and fibroblast-derived iPSCs.  
The further development of hepatocyte-like cells is limited by the inability of current 
culture systems to adequately support the hepatic phenotype. Once placed into culture, 
primary human hepatocytes, the gold standard model of hepatotoxicity, quickly lose the 
metabolic qualities required for modelling drug induced liver injury. Thus, without a culture 
system which supports the hepatic phenotype, the differentiation of hepatocyte-like cells 
will remain sub-optimal. Using iTRAQ proteomics we attempted to identify the driving 
factors responsible for the process of hepatocyte dedifferentiation. Our results identified 
numerous novel factors, including HSF2, SMARCB1, ZEB1 and FOXO1 which may drive the 
selective loss of metabolic phenotype.  
The proteomic assessment of hepatocyte dedifferentiation also highlighted the loss of 
Nrf2-related proteins during culture. Further investigation of Nrf2 in hepatocytes revealed 
a potentially negative relationship between Nrf2 induction and the key metabolic enzyme, 
CYP3A4. Furthermore, Nrf2 gene and protein expression was shown to increase during 
hepatocyte-like cell differentiation. Taken together, these results suggest that Nrf2 may 
negatively regulate the hepatic phenotype, potentially preventing the establishment of a 
mature phenotype during hepatocyte-like cell differentiation. A mechanistic evaluation of 
Nrf2 during differentiation and dedifferentiation is therefore required to gain a fuller 
insight into the role it plays in the maintenance and acquisition of the hepatic phenotype.  
In summary, this thesis presents our contribution to the further understanding, 
development and enhancement of in vitro hepatotoxicity models, using innovative 
techniques to assess the impact of epigenetic memory on HLC differentiation, identifying 
novel influencing factors driving the loss of phenotype in hepatocyte culture systems and 
evaluating the influence of Nrf2 on the hepatic phenotype during differentiation and 
dedifferentiation.      
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1.1 Introduction 
Drug induced liver injury is a major cause of drug attrition and patient mortality, conferring 
significant burden to all who are involved with the development and administration of 
drugs, including pharmaceutical companies, regulators, clinicians and patients (Russo et al., 
2004; Sgro et al., 2002). Despite these concerns being well-acknowledged, attempts to 
reduce the incidence of DILI have thus far been unsuccessful. One of the major causes of 
these failings is the lack of a translational in vitro model with relevant physiological, 
pharmacological and toxicological phenotypes; consequently, these models lack the 
capacity to reliably screen and predict incidences of DILI in high throughput assays at the 
early stages of drug development (Godoy et al., 2013). Furthermore, retrospective studies 
investigating drugs which have known toxicological liability, particularly studies which 
require chronic exposure, are also hampered by currently available models lacking 
phenotypic similarity with the clinical situation, (Godoy et al., 2013). Much work is 
therefore required to develop these in vitro systems in order to increase the similarity to 
the in vivo situation and consequently the predictive and mechanistic endpoints required of 
toxicity studies.   
This thesis describes our attempts to better understand and further develop currently 
available in vitro models of hepatotoxicity using innovative approaches with regard to 
proteomics, induced pluripotent stem cells and clustered regularly interspaced short 
palindromic repeats (CRISPR)/Cas9 technologies to investigate our hypotheses.  
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1.2.1 Adverse drug reactions and drug induced liver injury 
Adverse drug reactions (ADRs) remain a considerable burden to clinicians, regulators and 
the pharmaceutical industry. These reactions may be split into two groups: predictable 
(type I) where there is a known dose-dependent toxicity, or idiosyncratic (type II) where the 
ADR is seen at therapeutic levels, often in a very small sub-population (Pirmohamed et al., 
1998). However, while characterisation of the ADR type is relatively straightforward, 
understanding many of the underlying mechanisms and causes of toxicity remains an 
unsurmounted challenge, making ADR prediction and preventative measures difficult to 
develop or regulate.  
Clinically, 6.7% of US hospital patients suffer serious ADRs, with 4.7% of these the initial 
cause of admission and 0.32% resulting in patient death (Lazarou et al., 1998). This was 
corroborated by a subsequent UK study, which reported that 6.5% of hospital admissions 
were related to ADRs (Pirmohamed et al., 2004). Furthermore, the financial burden to the 
NHS was estimated to be £466 million in 2004, with the majority of reactions suffered 
deemed avoidable (Pirmohamed et al., 2004). Once admitted, in-hospital ADRs were found 
to increase both with the number of medications taken by the patient and the length of 
time spent in hospital (Davies et al., 2009). A more recent study found that between 1999 
and 2008 0.9% of English hospital admissions were related to ADRs; more concerning, 
however, was the admission trend over the examined period, with ADR-related admissions 
rising by 76.8% (Wu et al., 2010). ADRs are not only a burden in terms of admission to 
hospital, but also to the mortality rate. A Swedish study reported ADRs to be the 7th most 
common cause of death, accounting for 3.1% of total deceased study subjects and 6.4% of 
hospital fatalities (Wester et al., 2008). 
Drug induced liver injury (DILI) is one of the most common ADRs. Two French studies 
provide the best estimate to the clinical burden of DILI, reporting an incidence of 13.9 per 
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100,000 (Sgro et al., 2002) and 1.4% (Meier et al., 2005), respectively. Both these reports 
state that the currently utilised measurements used by the French authorities likely under-
estimate the true incidence of DILI, due to it often being asymptomatic in nature, and was 
not detected or noted in ~50% of initial diagnoses reported in the latter study (Meier et al., 
2005). DILI is also the leading cause of acute liver failure (ALF) in the US and the UK 
(Ostapowicz et al., 2002). The rate of ALF as a result of acetaminophen overdose in 
particular showed a concerning upward trend between 1998 and 2003 from 23% to 51% of 
total ALF (Larson et al., 2005). As such, DILI places a huge burden on transplant units and 
was responsible for 15% of liver transplants between 1990 and 2002 in the US (Russo et al., 
2004).  
However, the impact of DILI is not limited to the clinic, with the pharmaceutical industry 
also suffering, mainly due to late stage clinical trial or post-market drug withdrawals as a 
consequence of hepatotoxicity (Watkins, 2005; Wilke et al., 2007). DILI is the largest cause 
of such post-marketing withdrawals (Wilke et al., 2007) and, given the costs to bring a drug 
to market, is an extremely expensive concern (Collier, 2009; Preziosi, 2004; DiMasi et al., 
2003); thus, much effort is being placed on reducing the occurrence of DILI. 
1.2.2 Liver anatomy, cell types and drug induced liver injury 
To understand the mechanisms of DILI it is important to understand the architecture and 
functional roles of the liver. The liver is one of the most multi-functional organs in the body, 
with many unique feature, including: managing energy substrate levels (e.g. glucose and 
fatty acids), producing cholesterol and bile salts, metabolising xenobiotics, amino acid and 
ammonia, modulating hematopoietic, hormone and immune functions and storing vitamins 
(Fraczek et al., 2013). Furthermore, up to 40% of known genes are expressed in the liver, 
making it second-only to the brain in terms of transcriptomic complexity (Shackel et al., 
2002).  
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Anatomically, the functional units of the liver are termed lobules which have a distinct 
hexagonal microstructure, incorporating several cell types with specific roles (Figure 1.1). 
Of these, hepatocytes account for the majority of cell number (60%) and mass (80%) and 
perform as the major metabolic unit of the liver (Godoy et al., 2013). Within the lobule, 
hepatocytes are arranged in cords, interconnected by tight junctions, running from the 
central vein, in the centre of the hexagon, to the portal triad, which includes the hepatic 
portal vein, hepatic artery and bile duct at the vertex. The hepatocytes are bordered by 
liver sinusoids which carry the blood from the portal vein to the central vein (Godoy et al., 
2013).  
Hepatocytes are remarkably versatile cells. The varying conditions to which they are 
subjected to along the porto-central lobule axis (e.g. oxygen tension), give rise to 
hepatocytes with specialised functions according to their location, termed zones 1-3 
(Jungermann and Kietzmann, 1997; Allen and Bhatia, 2003). Zone 1 is found around the 
portal triad and is characterised by high oxygen tension, glycogen synthesis, β-oxidation, 
cholesterol biosynthesis and ureogenesis. Zone 3 is located around the central vein and is 
associated with low oxygen tension, glycolysis, xenobiotic metabolism, lipo- and keto-
genesis and bile acid, glutamine and heme biosynthesis. Zone 2 incorporates a middle-
ground between these two zones, demonstrating a gradient of function (Kietzmann et al., 
2006; Godoy et al., 2013). 
One of the most important roles of the hepatocyte is the detoxification and clearance of 
compounds and toxins which may be harmful to the body (Gomez-Lechon et al., 2003). 
These may be generated through endogenous homeostatic functions such as the various 
energy producing/storage pathways associated with the liver (Hodges and Minich, 2015), 
or exogenous sources, such as medicinal and recreational drugs and other inhaled or 
ingested toxins (Godoy et al., 2013). As a generalisation, these toxins are commonly 
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lipophilic and thus, for ease of excretion, the liver is required to alter the chemical 
properties of the compound to a water soluble product (Guengerich, 2001). 
The compound is intially taken up by the hepatocyte via influx transporters. These consist 
of the organic anion transporting polypeptide (OAT), organic anion transporter (OATP) and 
organic cation transporter (OCT) families (Giacomini et al., 2010). The process of 
detoxification may then be split into three main phases. Phase I is orchestrated by 
cytochrome P450s (CYPs), alcohol dehydrogenases, aldehyde/xanthine oxidases, FAD-
containing monooxygenases, monoamine oxidases, aldo-ketoreductases and epoxide 
hydrolases and esterases (Prakash and Vaz, 2008), and involves the oxidation, reduction, 
hydration, hydrolysis or dethioacetylation of the compound, resulting in neutralisation or 
the formation of an active intermediate (Guengerich, 2001; Jakoby and Ziegler, 1990; 
Fraczek et al., 2013).  
Phase II enzymes neutralise these active intermediates through conjugation of the 
compound, reducing the potential for toxicity and increasing the water-solubility of the 
intermediate, allowing for excretion. The most commonly used phase II pathway is UDP-
glucuronosyltransferase-mediated glucuronidation (Prakash and Vaz, 2008); however, 
glutathione S-transferases, sulfotransferases, N-acetyltransferases and methyltransferases 
also contribute through sulfation, acetylation, methylation and glutathione conjugation of 
the metabolite (Jakoby and Ziegler, 1990; Prakash and Vaz, 2008).  
These water soluble compounds may then be removed from the hepatocyte by phase III 
transporters (Homolya et al., 2003; Konig et al., 1999) into the biliary (via BSEP, multiple 
drug resistance protein (MDR) 1, multidrug resistance-related protein (MRP) 2, breast 
cancer resistance protein and multidrug and toxin extrusion 1 transporters) or circulatory 
systems (via MRP3, MRP4, MRP6 transporters) and excreted from the body via bile or the 
kidneys, respectively (Giacomini et al., 2010). 
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Drug induced liver injury occurs when this process of metabolism and clearance becomes 
dysfunctional. In some instances, compounds undergo bio-activation and form chemically 
reactive metabolites, which can covalently bind to cellular proteins (Park et al., 2011). It has 
been estimated that ~85% of drugs withdrawn because of hepatotoxicity form chemically 
reactive metabolites (Nallani et al., 2008; Fraczek et al., 2013). These adducts negatively 
affect cell function, activating molecular initiating events (MIE) such as Nrf2 activation, 
mitochondrial perturbation, DNA damage, BSEP inhibition and the unfolded protein 
response. Although the toxicity profile is often drug-specific and ill-defined, through these 
MIEs, chemically reactive metabolites can result in cell death and the presentation of 
hepatotoxicity in the clinic (Park et al., 2011).  
Hepatocytes are polarised cells, displaying varied functions at different membranes (Meier, 
1988). One such function is bile acid section which takes place at the canalicular membrane 
of the hepatocyte and is associated with expression of the bile salt export pump (BSEP) 
(Hofmann, 2009; Meier and Stieger, 2002). This allows the export of bile salts into the bile 
canaliculi. The cells which line the bile canaliculi are termed cholangiocytes. Cholangiocytes 
secrete bicarbonate and water which, together with the bile salts, form bile. This is carried 
along the canaliculi towards the portal triad where it drains into the bile duct. This 
mechanism is important for the removal of many of the toxic products associated with 
normal liver function (Hofmann, 2009). The role of cholangiocytes in DILI remains largely 
unexplored. Research has previously shown that cholangiocytes can be damaged by parent 
compounds and hepatocyte-derived metabolite products (e.g. Flucloxacillin (Lakehal et al., 
2001)) (Padda et al., 2011); however, further work has shown that they may be able to 
actively participate in DILI through the ability to detect (damage-associated molecular 
pattern) DAMPs released by damaged cells and secrete inflammatory cytokines, such as 
TNFα and IL-6 (O’Hara et al., 2013).   
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Figure 1.1: Schematic representation of the liver lobule highlighting the contribution of zonation, 
microvasculature and the native multi-cellular environment to hepatocyte function and the molecular 
initiating events leading to toxicity. Following injury, other non-native immune cells migrate to the 
liver (e.g. NK cells, leukocytes and macrophages) and can alleviate or potentiate the injury. These 
subsequent events are well reviewed by (Godoy et al., 2013). 
Abbreviations: DAMPs:  Damage-associated molecular pattern; TLR: Toll-like receptor; IL: Interleukin; 
TNF: Tumour necrosis factor; NK: Natural killer cell; α-SMA: alpha-smooth muscle actin; ECM: 
Extracellular matrix 
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The sinusoid and the surrounding area hold host to a multi-cellular environment and are 
key to maintaining healthy function of the liver. Liver sinusoidal endothelial cells (LSEC) line 
the lumen, forming a protective barrier between the lumen contents and the hepatocytes 
(Godoy et al., 2013). LSECs differ from other endothelial cells in their cytoplasmic 
projections contain fenestrations which are key to the selective uptake of molecules from 
the blood supply (Kmiec, 2001). Following insult to the liver, LSECs can detect DAMPs 
through toll-like receptors, (e.g. TLR9 detection of CpG-DNA released form damaged cells) 
(Martin-Armas et al., 2006) and consequently alter their phenotype, resulting in the 
enlargement or loss of fenestrations, IL-1 secretion and enhanced tethering of leukocytes 
(McCuskey et al., 2005; Neubauer et al., 2000). The changes permit the infiltration of 
leukocytes from the sinusoid to the site of injury and also result in the haemorrhage of 
erythrocytes into the space of Disse (McCuskey et al., 2005). LSECs are also thought to be 
important during post-injury regeneration, providing mitogenic growth factors (e.g. HGF) 
and a framework for the replacement hepatocytes (the origin of which is greatly contested) 
to grow in to (Hoehme et al., 2010; Ding et al., 2010).     
Liver-resident macrophages, termed Kupffer cells, are located within the sinusoidal lumen 
adherent to the LSECs and are the first immune-defence point of contact with bacteria, 
endotoxins and micro-bacterial debris from the gastrointestinal tract (Bilzer et al., 2006; 
Fox et al., 1987). Kupffer cell roles and size are dependent on their location along the 
porto-central lobule axis, with those nearer the portal vein being grater in size, phagocytic 
capacity and secretion of inflammatory mediators such as TNF-α; whereas, mid and peri-
central Kupffer cells secrete greater amounts of nitric oxide (Hoedemakers et al., 1995; 
Sleyster and Knook, 1982). Kupffer cells have been implemented in both liver injury and 
regeneration, and are thought to be key in the development and outcome of DILI (Tsutsui 
and Nishiguchi, 2014); however, the exact mechanisms are ill-defined. Reports have 
demonstrated that the inflammatory factors secreted by Kupffer cells following injury 
Chapter 1 
10 
 
results in the apoptosis of hepatocytes, increase fibrin deposition and the attraction of non-
resident immune cells (Roberts et al., 2007). Notwithstanding these factors, depletion of 
Kupffer cells has been shown to exacerbate toxicity in a paracetamol injury model (Ju et al., 
2002; Campion et al., 2008). This protective role of Kupffer cells is thought to be due to the 
secretion of the anti-inflammatory cytokine IL-10 and/or the induction of a protective 
phenotype in hepatocytes (Campion et al., 2008; Ju et al., 2002).  
Between the endothelial cells and the hepatocytes lies the space of Disse, which contains a 
varied array of extracellular matrix, consisting of collagens, glycoproteins, proteoglycans 
and glycosaminoglycans (Godoy et al., 2013). The space of Disse also contains stellate cells, 
which are predominantly known to function as vitamin A storing cells (Kordes et al., 2009); 
however, upon injury stellate cells become activated and take on a myofibroblast-like 
phenotype, losing their vitamin A storage capacity (Reeves and Friedman, 2002). Stellate 
cell activation can occur through the detection of DAMPs released by damaged cells 
(Watanabe et al., 2007). The activated stellate cells up-regulate the production of collagen I 
and fibrogenic factors, such as TGF-β (Watanabe et al., 2007). In the short term, this limits 
the progression of injury, but in the longer term can lead to liver fibrosis (Bataller and 
Brenner, 2005). Moreover, it has been suggested that stellate cells are liver-resident 
mesenchymal stem cells, with the capacity to and secrete pro- and/or anti-inflammatory 
cytokines, modulating the progression of injury (Weiskirchen and Tacke, 2014), 
differentiate towards hematopoietic and osteogenic lineages (Castilho-Fernandes et al., 
2011; Kordes et al., 2013) and influence liver regeneration (Kordes et al., 2012).   
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1.2.3 Models of drug induced liver injury 
Much work is focussed on better understanding the mechanisms which underpin DILI, with 
the aim of identifying dangerous compounds at earlier stages of drug development and a 
consequent reduction in financial outlay and therapeutic burden.  
To achieve this, there is a need for in vitro models which are readily available, stably 
encapsulate the unique metabolic competencies of the liver and, most importantly with 
regard to DILI, correlate with the toxicity seen in man. However, despite continued efforts, 
a model which possesses the physiological, pharmacological and toxicological phenotypes 
of the liver has yet to be achieved. Furthermore, whilst it is clear that the non-parenchymal 
cell types of the liver are key to the manifestation of DILI, the hepatocyte remains central 
to the toxicity profile of the majority of known hepatotoxic compounds, either through 
direct hepatocyte toxicity or through the production of metabolites which damage other 
cell types. As a consequence, the development of in vitro models of DILI has, in the main, 
focused on the production of hepatocytes or hepatocyte-like cell models to understand the 
molecular initiating events of toxicity.  
Immortalised cell lines  
Cell lines offer a readily available, easy to culture and reproducible model for the 
investigation of hepatotoxicity in vitro. Various cell types are currently used throughout 
academia and in pharmaceutical drug safety testing, including HepG2s and Huh7s (Castell 
et al., 2006); however, these cell types lack many of the key enzymes required for the 
effective modelling of DILI (Godoy et al., 2013; Castell et al., 2006). Some groups have 
attempted to overexpress selected enzymes or hepatic nuclear factors (Nibourg et al., 
2010; Kuang et al., 2015); however, this represents a model which differs in both 
physiological and pharmacological phenotype to the liver (Castell et al., 2006). Thus, whilst 
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the compound of interest may show turnover and reactive metabolite production, the 
resulting effect on cell and the toxicological phenotype is likely to differ greatly from what 
is found in vivo. 
The HepaRG is a bipotent cell line isolated from a hepatocellular carcinoma and represents 
a more metabolically competent cell type (Marion et al., 2010). These cells are thought to 
be equivalent to progenitor cells with their capacity to divide and become quiescent upon 
confluence; this, in tandem with dimethyl sulfoxide (DMSO) and other growth factors, 
induces hepatic differentiation allowing for the investigation of hepatotoxicity (Marion et 
al., 2010). However, these cells also exhibit higher expression of certain absorption, 
distribution, metabolism, and excretion (ADME) functions, increasing resistance to toxicity 
and reducing their translatability to the clinical situation (Sison-Young et al., 2015). 
Most importantly for the modelling of DILI, cell lines represent a single, albeit unstable, 
genotype. Given the large variance in metabolic competence across the population and 
that idiosyncratic reactions are often incredibly rare, a single-genotype model is highly 
unlikely to be predicative of DILI in all situations (Pirmohamed et al., 1998).  Using a panel 
of cell lines to increase the diversity of toxicity screens is one option; however, the 
variation in derivation technique (i.e. how the cell was immortalised), cancer-vs-liver 
phenotype and the cell type of origin would likely add large degrees of variability to the 
assays. Therefore a model which is phenotypically similar across a panel of selectable 
genotypes would be an invaluable resource.   
Primary human hepatocytes 
The current gold standard for investigating DILI is the primary human hepatocyte (PHH). 
These cells are usually isolated from waste tissue following liver resection or donor livers 
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which are unsuitable for transplant and demonstrate the highest metabolic competency of 
the available models (Bhogal et al., 2011).   
PHH also have limitations as a model. The aforementioned supply of liver tissue is a major 
bottleneck to PHH application. Due to the nature of surgery and transplants, the supply is 
often unpredictable in frequency and yield, making experimental planning and high 
throughput investigations difficult (Bhogal et al., 2011). Furthermore, the quality of the 
liver tissue is also variable. As these specimens are either not suitable for transplant or 
resected from ‘healthy’ sections of diseased tissue, it is unlikely that any PHH used are truly 
representative of the normal condition. Furthermore, variation can be attributed to donor 
genotype and lifestyle which can have major effects on the experimental outcome (Bhogal 
et al., 2011). Whilst these concerns are common in many human-derived primary cells, it is 
particularly pertinent in PHH as they do not divide in culture and rapidly lose their 
metabolic competence following isolation (Elaut et al., 2006).  
Such characteristics make genotype-controlled repeats reliant on cryopreserved 
hepatocytes. Hepatocytes are known to suffer from poor resuscitation following 
cryopreservation, which has led to the development of specialist techniques to improve the 
yield and reproducibility of plating efficiency following thawing (Alexandre et al., 2002). 
These developments have allowed for cryopreserved hepatocytes to be used as part of 
drug development with the advantage of a pre-determined knowledge of cell yield and 
repeatable genotypic/phenotypic characteristics. Whilst cryopreservation removes some of 
the concerns with availability, resources will always remain finite and consequently 
expensive. Additionally, these cells are known to have a reduced metabolic capacity when 
compared to freshly isolated PHH and still undergo the process of dedifferentiation 
following thawing and plating (Richert et al., 2006).  
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Dedifferentiation is a phenomenon that has been well described in hepatocytes (Elaut et 
al., 2006; Fraczek et al., 2013). Following isolation the cells lose their essential hepatic 
phenotype, rapidly down-regulating many of the key metabolic enzymes required for 
modelling DILI. Understanding this process has been a key area of research with the aim of 
improving hepatic culture conditions and the stability of the hepatic phenotype and 
consequently the relevance to DILI. The main driving forces behind the loss-of-phenotype 
are thought to be inflammatory and proliferative responses, particularly NF-κB and MAP 
kinase associated pathways (Fraczek et al., 2013). However, as yet, the underlying 
mechanisms of the global process remain incompletely understood. Hepatocyte 
dedifferentiation is investigated further in chapter 5.  
The most successful method of reducing the impact of dedifferentiation has been through 
the development of culture systems which better model the hepatic niche. The most widely 
adopted of these is the sandwich culture, i.e. the overlaying of cells with an extracellular 
matrix mimicking substrate, such as Matrigel or collagen. This has been shown in numerous 
studies to improve cell polarisation, maintenance of metabolic competence and enhanced 
survival in culture (Fu et al., 2013; Kim et al., 2010b; Rowe et al., 2010). 
Further recapitulation and enhancement of phenotype has been achieved using 3D or co-
culture systems. As demonstrated in figure 1.1, the hepatic niche is a highly organised, 
multi-cellular environment with variable environmental conditions depending on the 
location of the cell (e.g. oxygen concentration, xenobiotic exposure, etc.) (Godoy et al., 
2013).  
Spheroid culture allows for the relatively simple formation of 3D clusters of hepatocytes 
with or without non-parenchymal or other non-liver stromal cells (No et al., 2012; Tostoes 
et al., 2012; Abu-Absi et al., 2004; Lu et al., 2005; Brophy et al., 2009; Ambrosino et al., 
2005). In all cases, these papers report an enhancement in phenotype, most commonly 
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determined via increased and/or better maintained albumin secretion and phase I 
metabolism. This enhanced phenotype is thought to be due to the restoration of cell 
polarity and close cell-to-cell contact (Ambrosino et al., 2005). Further advancements in 
spheroid technology has led to the development of nanopillar-based culture systems 
(Takahashi et al., 2010). However, the inconsistent use of comparators means that any 
improvements between different spheroid systems are hard to quantify (Kia et al., 2013). In 
comparison to other 3D culture techniques, such as bioreactors (Tostoes et al., 2011), 
spheroids allow for an improved cost-efficiency and would consequently allow for scale-up 
possibilities (Goldring et al., 2015).  
The effect of non-parenchymal and stromal cells has also been studied in non-spheroid 
culture systems. Micropatterned culture allows the maintenance of hepatocytes in various 
‘islands’ of cells across the well, with stromal fibroblasts cultured in the surrounding spaces 
(Bhatia et al., 1997; Ukairo et al., 2013).  This culture system has been shown to support 
albumin secretion, ADME functions and cell polarity for up to four weeks (Ukairo et al., 
2013) and has the capacity for scale-up culture for use in high content screening (Trask et 
al., 2014). Furthermore, inflammatory conditions using co-culture with Kupffer cells have 
also been modelled, demonstrating a physiological-like reaction to perturbation, with 
inflammatory cytokines detected and subsequent loss of CYP3A4 expression described 
(Nguyen et al., 2015). 
A move towards an increasingly physiological-like culture environment may therefore hold 
great promise in terms of better replicating the pharmacological and toxicological 
mechanisms of DILI. For example, the use of 3D bio-printing has the potential to fully 
replicate the complexity of the hepatic niche in terms of cell type and cell locations 
(Murphy and Atala, 2014). Notwithstanding this potential, complex 3D and multicellular 
models are likely to remain prohibitively expensive/complex for the large-scale screening of 
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compound libraries required by pharmaceutical companies (Goldring et al., 2015). Thus 
understanding the mechanisms by which these techniques improve phenotype and 
developing small molecules and other supplements/inducers to mimic their effects may be 
more cost effective. A high-throughput screen by Shan et al., demonstrated that a select 
number of the compounds tested could boost hepatic phenotype and also encourage 
proliferation (Shan et al., 2013), a characteristic which remains elusive in standard in vitro 
culture systems. Such results point towards the possibility of using the knowledge gained 
from more complex culture systems to enhance the simpler and more cost-effective in vitro 
models, bridging the gap between the requirements of academia and industry (Goldring et 
al., 2015).    
Pluripotent stem cells 
Pluripotent stem cells offer a scalable, reproducible and genotypically normal cell model 
combining cell line-like availability and the potential for producing physiologically-relevant 
cell types. There are two main types of human pluripotent stem cell available to 
researchers: embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs). The 
relative advantages and disadvantages to these cell types are presented in table 1.1. 
Human ESCs were first isolated from the blastocyst of human embryos in 1998 by James 
Thompson (Thomson et al., 1998); this process uses discarded fertilised eggs leftover from 
in vitro fertilisation treatment and is consequently limited by ethical constraints in certain 
countries and a restricted genotypic range. The isolation of human ESCs owed much to the 
techniques developed during the isolation and culture of embryonic carcinoma cells (Evans 
and Kaufman, 1981; Martin and Evans, 1974; Martin and Evans, 1975; Kleinsmith and 
Pierce, 1964; Stevens, 1958) and mouse ESCs (Evans and Kaufman, 1981; Martin, 1981). 
Much of the culture conditions and differentiation protocols described in this thesis were 
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first optimised using ESCs; however, whilst ESCs are used as a positive control in some 
instances, the main body of work regards iPSCs. 
iPSCs were first reported in 2006 by Shinya Yamanaka, demonstrating the reprogramming 
of somatic cells from mice (Takahashi and Yamanaka, 2006) and later humans (Takahashi et 
al., 2007), using 4 retrovirally inserted transcription factors: Oct4, Sox2, Klf4 and c-Myc 
(OSKM).  
Since the first reports, a range of techniques have been demonstrated for generating iPSCs. 
Traditional techniques relied on genomic integrations using retroviruses or lentiviruses for 
the insertion of the OSKM factors (Sommer et al., 2009; Takahashi et al., 2007; Yu et al., 
2007). However, these insertions bring concerns with regard to the potential phenotypic 
alterations associated with genomic disruptions. The development of non-integrative 
reprogramming techniques, utilising direct transfection of proteins (Kim et al., 2009) or 
mRNAs (Warren et al., 2010), Sendai viruses (Fusaki et al., 2009) or episomal plasmids (Yu 
et al., 2009), or through the use of small molecules (Hou et al., 2013) has reduced concerns 
regarding incomplete promoter silencing and genomic disruptions of traditional 
techniques. 
Some have also replaced the potentially oncogenic OSKM reprogramming factors with 
microRNAs to reprogram somatic cells (Miyoshi et al., 2011; Anokye-Danso et al., 2011). 
These techniques used the embryonic stem cell enriched microRNA cluster 302/367 either 
alone, or in combination with others to reprogram somatic cells, reporting the negation of 
OSKM factors and either an enhanced efficiency or integration-free reprogramming. These 
techniques are investigated in chapter 3.   
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Given that ESCs, unlike iPSCs, are derived directly from human embryos without need for 
genetic or phenotypic manipulation, they are often considered to be a more accurate 
representation of development. Comparisons between these two cell types have found 
differences in the genetic and epigenetic landscapes (Mallon et al., 2014; Guenther et al., 
2010; Chin et al., 2009); however, despite slight differences required in some protocols, 
these do not appear translate to major functional differences in the differentiated products 
(Jozefczuk et al., 2011; Sullivan et al., 2010). 
The major advantage of iPSCs over ESCs is the ability to capture the genotype of the donor 
cell, consequently allowing for the modelling of complex conditions, such as Alzheimer’s 
disease (Kondo et al., 2013) or Down’s syndrome (Chang et al., 2015), without the need for 
invasive and dangerous biopsies. With regard to DILI, this also allows for the creation of 
iPSC lines from patients who have suffered idiosyncratic reactions or a condition of 
interest, with the aim of replicating the reaction in vitro, and to create a panel of 
hepatocyte-like cells with a range of phenotypes to better represent the population during 
early compound screens (Takayama et al., 2014; Kia et al., 2013).  
Once exogenously expressed within the cell, the OSKM factors set off a chain of events 
which lead to a pluripotent stem cell-like state; however, the mechanisms which underlie 
these changes and the specific roles that each OSKM factor plays are far from understood, 
Table 1.1: Assessment of the inherent properties of hiPSCs and hESCs relative to each other. Green 
indicates that the cell type is thought to have greater capacity/less risk in the given category relative 
to the other cell type; Red indicates that the cell type has a reduced capacity/greater risk in the 
given category relative to the other cell type. The differences between the cell types is further 
reviewed by (Heslop et al., 2015) 
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with the process appearing to be partly stochastic in nature (Buganim et al., 2012) and 
others describing it as an ordered probabilistic process (Chung et al., 2014).  
Single cell PCR analysis has aimed to investigate the reprogramming process in greater 
detail (Buganim et al., 2012). These studies have shown a three-stage dynamic process. c-
Myc has been shown as a key determinant of reprogramming efficiency but not 
reprogramming outcome i.e. the transcriptional effect of c-Myc is non-essential for 
reprogramming, but allows for increased efficiency through the generic enhancement of 
gene expression during the first initiation stage of reprogramming (Nakagawa et al., 2008). 
This stage is supported by Klf4 and, to a lesser degree, Oct4 and Sox2 which bind to openly 
accessible chromatin, activating or repressing the corresponding gene (Polo et al., 2012; 
Schmidt and Plath, 2012). The binding of the reprogramming factors drives increased 
proliferation, mesenchymal-to-epithelial transition, histone mark changes, activated DNA 
repair and RNA processing (Sancho-Martinez and Belmonte, 2013; Buganim et al., 2013). 
These changes appear to be stochastic, showing no conventional or conserved route to the 
acquisition of these characteristics (Buganim et al., 2012).  
This is also true of the intermediate phase of reprogramming in which pluripotency and 
developmental regulators, along with glycolysis are activated through interactions with 
Oct4, Sox2 and Klf4 (Buganim et al., 2013). During the final two stages of reprogramming 
there is a gradual increase in the expression of Oct4 and Sox2 target genes (Buganim et al., 
2012). The final stage of reprogramming has a more defined pattern of activation. This is 
instigated by the transcription factor Sox2 and leads to the expression of pluripotency-
associated genes including Lin28, Sall4 and Esrrb, inducing the core endogenous 
pluripotency circuit (e.g. Oct4, Sox2, Nanog) and silencing of the exogenous transgene 
promoters (Buganim et al., 2012).  
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During reprogramming, the epigenetic landscape of the cells changes dramatically. These 
changes are brought about by a complex and incompletely understood set of mechanisms 
which reset the somatic epigenome to that of an embryonic stem cell-like state (Papp and 
Plath, 2013). Much of the epigenetic changes found during the reprogramming of somatic 
cells are related to the over-expression of the OSK factors, but not c-Myc which is thought 
to enhance the transcription at sites of already open chromatin (Rahl et al., 2010). These 
OSK factors are ‘pioneer factors’ and have the capacity to bind to unmarked and closed 
chromatin (Soufi et al., 2012). Binding to closed chromatin within nucleosomes makes up 
70% of OSK binding in the early stages of fibroblast reprogramming (Soufi et al., 2012). This 
is proposed to be achievable by OSK due to their 3D structure, which allows binding to one 
side of the DNA helix and through a capacity to interact with nucleosome DNA (Soufi et al., 
2012). This binding is thought to alter the chromatin state at enhancer regions from closed 
to either open or poised, a necessary pre-requisite for gene expression changes. In fact, a 
greater amount of histone modifications are found when compared to gene expression 
changes during the first stages of reprogramming, particularly in the enhancer and, to a 
lesser degree, promoter regions of genes which are not yet active, but are required in the 
later stages of reprogramming (Koche et al., 2011).   
Methylation is another epigenetic mechanism and key determinant of gene expression. 
Interestingly, whilst changes to histone modifications and gene expression occur 
throughout the reprogramming process, Koche et al., reported that the respective hyper- 
and hypo-methylation changes to the somatic and pluripotency genes occurs very late in 
the reprogramming process and may in fact be non-essential to the induction of 
pluripotency (Koche et al., 2011). The regions of DNA which combine a shift from closed to 
OSK bound and methylation changes were also found to contain nearly all 20 reported 
hotspots for differences between iPSC and ESC methylation status; suggestive of an 
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incomplete process of epigenome reprogramming and that a ‘memory’ of the cell type of 
origin may remain imprinted (Lister et al., 2014).   
In most cases, incomplete reprogramming of the epigenetic landscape would be 
detrimental, with studies using iPSCs attempting to recapitulate development for various 
endpoints; however, some have investigated whether this incomplete reprogramming, 
termed ‘epigenetic memory’ can be used as an advantage. Research has revealed an 
altered differentiation propensity, favouring the cell type or lineage of origin, depending on 
the source of the iPSCs. This heightened differentiation capacity was first described in 2010 
using mouse iPSCs (Polo et al., 2010; Kim et al., 2010a), with different cell types showing 
enhanced differentiation to different lineages. This was also to be found to be true of the 
spontaneous differentiation propensity of pancreatic beta cells in comparison to non-beta 
pancreatic iPSCs, non-pancreatic iPSCs and ESCs (Bar-Nur et al., 2011). The influence 
epigenetic memory has on hepatocyte-like cell differentiation is investigated in chapter 4. 
Differentiation of pluripotent stem cells to hepatocyte-like cells 
By definition, a pluripotent stem cell can be expanded indefinitely and differentiate into 
cell types from all three germ layers, including fully functional hepatocytes. Therefore, 
pluripotent stem cells offer an attractive combination of availability and the capacity for 
metabolic competence.  
To generate hepatocyte-like cells in vitro, most differentiation protocols attempt (selected 
examples are presented in table 1.2) to recapitulate the conditions found during the 
normal developmental process (Summarised in figure 1.2 (Baxter et al., 2010)). Whilst the 
nomenclature varies across the literature, the process is usually divided into 3 main 
checkpoints: definitive endoderm, hepatic endoderm and hepatocyte-like cells. Early 
techniques relied upon embryoid body formation, i.e. culturing the pluripotent stem cells in 
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suspension, encouraging the initiation of differentiation. These embryoid bodies were 
formed in conditions which promoted specification towards definitive endoderm; however, 
a relatively poor differentiation efficiency of 6-15% was reported across various studies 
(Lavon et al., 2004; Duan et al., 2007). Subsequent work used monolayer differentiation, 
demonstrating a slightly improved differentiation efficiency of 20% (Hay et al., 2007); 
however, larger increases in efficiency were found utilising Activin A and Wnt3A for 
differentiation of ESCs and iPSCs towards definitive endoderm (70-90%) (D'Amour et al., 
2005; Hay et al., 2008b; Hay et al., 2008a; Sullivan et al., 2010). Interestingly, it has also 
been suggested that the differentiation to definitive endoderm is also influenced by the 
expression of expression of Wnt3, with higher endogenous expression significantly 
correlated with enhanced differentiation purity (Jiang et al., 2013).  
  Figure 1.2:  Schematic diagram demonstrating in vitro attempts to recapitulate liver development 
and the factors and cell types which are used to generate HLCs from pluripotent stem cells.  
Abbreviations: Wnt: Wingless-type MMTV integration site family; DMSO: Dimethyl sulfoxide; HGF: 
Hepatocyte growth factor; Dex: Dexamethasone; OSM: Oncostatin M; BMP: Bone morphogenetic 
protein; FGF: Fibroblast growth factor; PI3K: Phosphoinositide 3-kinase; GSK3: Glycogen synthase 
kinase 3 
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The commitment to hepatic endoderm has been achieved using a much greater range of 
growth factor/compound variations and combinations. In general this stage is attempting 
to replicate the factors derived from the cardiac mesoderm during differentiation, most 
commonly with the factors which are known to play a role in this stage of development: 
fibroblast growth factor 2 and 4 (FGF2/4) and bone morphogenetic protein 2 and 4 
(BMP2/4)(Si-Tayeb et al., 2010). Other groups have used dimethyl sulfoxide (DMSO) 
(Sullivan et al., 2010), which has been shown to enhance pregnane X receptor (PXR), 
constitutive androstane receptor (CAR), hepatic nuclear factor (HNF) -4α and 
CCAAT/enhancer binding protein (C/EBP) -α expression (Su and Waxman, 2004; Mizuguchi 
et al., 1998) and inhibit cell division, encouraging differentiation towards a hepatic lineage 
(Mizuguchi et al., 1998).    
The specification and maturation of hepatocyte-like cells is the final stage of 
differentiation. This is widely achieved using the growth factors hepatocyte growth factor 
and oncostatin M; however, the concentrations used vary greatly between protocols 
(Sullivan et al., 2010; Hannan et al., 2013). Further variation between protocols at this point 
of differentiation is the time taken for maturation. Some have reported peaks at days 18-22 
(Sullivan et al., 2010), followed by a loss of phenotype, whilst others have reported 
continued maturation up to day 35 and beyond (Hannan et al., 2013; Sjogren et al., 2014).  
Despite large improvements in efficiency, the development of an in vitro protocol that can 
produce hepatocyte-like cells with a mature metabolic phenotype has yet to be achieved 
and, despite incremental improvements, the field is currently limited to an immature 
differentiation product more comparable to a foetal rather than a mature hepatic 
phenotype (Baxter et al., 2015). Furthermore, it is made harder to identify any step-wise 
change in phenotypic maturity by the inconsistency between comparators used. Kia et al., 
compared a selection of available protocols in terms of reported differentiation efficiency, 
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hepatic expression and functional capabilities and demonstrated the difficulty in comparing 
between these protocols when the comparators used vary so greatly (Kia et al., 2013). 
Given the lack of a clear step-wise change in phenotype using traditional methods, groups 
have attempted numerous new methods for identifying improvements to protocols. 
Recently, a report was published describing the stem cell derived formation of a liver bud 
(Takebe et al., 2013). By combining HLCs differentiated from iPSCs with mesenchymal stem 
cells and human umbilical vascular endothelial cells (HUVECs), the cells self-organised into 
a vascularised 3D structure with significantly improved function over 2D comparators 
(Takebe et al., 2013). Others have shown the benefit of small molecules with a high-
throughput screen looking for enhancement of albumin secretion showed beneficial effects 
in HLC differentiation (Shan et al., 2013). However, the caveat remains with the screens is 
that it is often unclear which mechanisms are being activated and supressed to enhance 
the phenotype. More recently, microbial-derived lithocholic acid and vitamin K2 was shown 
to further boost HLC phenotype through activation of PXR (Avior et al., 2015) and exploring 
the effect of the microbiome and other external influences may lead to further 
enhancements of the hepatic phenotype. Together with co-culture and 3D models 
discussed with relation to primary hepatocyte culture, these novel approaches represent 
the current best attempts to boost HLC maturity (figure 1.3).  
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Figure 1.3: The development of hepatocyte-like cell differentiation protocols. Timeline 
showing the advances reported in the generation of protocols to enhance differentiation 
efficiency, maturity and scalability of HLC production.   
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Ref. Stem cell Type Differentiation method Differentiation factors used Differentiation efficiency 
(Author/year) ESC/iPSC (EB, monolayer, 
 co-culture) (HGF, DMSO, etc.) % Albumin positive cells (method) 
(Cai et al., 2007) ESC (H1 and H9) Monolayer and EB AA, ITS, BMP2, FGF4, HGF, OSM, Dex 70% (ICC) 
(Ek et al., 2007) ESC (SA002, SA002.5 and SA167) Monolayer FGF2, VitroHES medium - 
(Hay et al., 2008a) ESC (H1 and H9) Monolayer AA, Wnt3A, sodium butyrate, DMSO, HGF, OSM, hydrocortisone 21-
hemisuccinate, Insulin 90% (ICC) 
(Shiraki et al., 2008) ESC (Khes-1) Monolayer (Previously coated with 
feeder cells) AA, FGF2, DMSO, HGF, Dex, BMP4, LY294002 9% (ICC) 
(Agarwal et al., 2008) ESC (H1, H9 and WA09) Monolayer AA, FGF4, HGF, OSM, Dex 67.4% (ICC) 
(Moore and Moghe, 2009) ESC (H1) Monolayer and EB AA, Wnt3A, Dex, OSM, HGF  72.8% (ICC) 
(Basma et al., 2009) ESC (H1) Monolayer and EB AA, FGF2, DMSO, HGF, Dex 55% (ICC) 
(Song et al., 2009) iPSC Monolayer AA, ITS, FGF4, BMP2, KGF, OSM, Dex 60% (ICC) 
(Duan et al., 2010) ESC (H9) Monolayer AA, sodium butyrate, FGF4 , HGF, BMP2, BMP4, DMSO 90% (FACs/ICC) 
(Synnergren et al., 2010) ESC (SA002, SA167, and SA461) Monolayer AA,  FGF2, FGF1, BMP2, BMP4, HGF, ITS, Dex, OSM - 
(Touboul et al., 2010) ESC (H9) Monolayer Ly294002, AA, FGF2, BMP4, FGF10, Retonic acid, SB431542, FGF4, 
HGF, EGF - 
(Brolen et al., 2010) ESC (SA001, SA002, SA002.5 and 
SA167) Monolayer AA, FGF1/2, Wnt3A, BMP2/4, Dex, HGF, OSM - 
(Bone et al., 2011) ESC (Shef1 and 3) Monolayer GSK-3 inhibitor, OSM, Dex, HGF, FGF4  - 
(Ghodsizadeh et al., 2010) iPSC EB AA, FGF-2, DMSO, HGF, Dex 50% (FACS) 
(Liu et al., 2010a) iPSC  Monolayer AA, HGF, FGF4, Dex, OSM - 
(Si-Tayeb et al., 2010) iPSC Monolayer AA, FGF2, BMP4, OSM 80% (FACS) 
(Sullivan et al., 2010) iPSC Monolayer AA, Wnt3A, DMSO, HGF, OSM, hydrocortisone 21-hemisuccinate, 
Insulin 70%-90%(ICC) 
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(Rashid et al., 2010)  iPSC Monolayer CHIR99021, Ly294002, AA, FGF2, BMP4, HGF, OSM 83% (FACS) 
(Zhang et al., 2011) iPSC Monolayer AA, OSM, BMP2, FGF4, HGF, KGF,  Dex, 60-80% (ICC and FACS) 
(Chen et al., 2012) ESC (H9), iPSC  Monolayer AA, ITS, HGF, Wnt3A, OSM, 
DMSO, DEX ─ 
(Cayo et al., 2012) iPSC  Monolayer AA, BMP4, FGF2, OSM ─ 
(Schwartz et al., 2012) iPSC  Monolayer AA, BMP4, FGF2, HGF, OSM 80 (ICC) 
(Takayama et al., 2012) ESC (H9), iPSC Monolayer AA, HEX, BMP4, FGF4, HNF1α, FOXA2, HGF, OSM, DEX ─ 
(Choi et al., 2013) iPSC Monolayer AA, FGF4, HGF, OSM, DEX ─ 
(Ramasamy et al., 2013) ESC (H1) Monolayer & 3D culture  AA, DMSO, HGF, OSM ─ 
(Gieseck III et al., 2014) iPSC  Monolayer, 3D-single cell or Clump 
culture 
AA, FGF2,BMP4, LY-294002, lipid concentrate, insulin, transferrin, 
HGF, OSM ─ 
(Jia et al., 2014) iPSC Monolayer, EB formation AA, FGF4, BMP2, HGF, KGF, OSM, DEX 64 (FACS) 
(Avior et al., 2015) ESC  (I3) Monolayer AA, Wnt3A, HGF, DMSO, DEX, OSM, FGF2, LCA, MK4 83 (FACS) 
(Chien et al., 2015) iPSC  Co-culture with MEF, EB formation  AA, FGF4, BMP2, HGF, KGF, OSM, DEX, miR122 ─ 
(Siller et al., 2015) 
ESCs (H1 and 207) 
iPSC 
Monolayer CHIR99021, DMSO, Dihexa, Dex 72% and 79% (ICC) 
Table 1.2: Selected hepatocyte-like cell differentiation protocols and reported differentiation efficiencies. Adapted from (Kia et al., 
2013).  
Abbreviations: EB: Embryoid body; AA: Activin A; FGF: Fibroblast growth factor; BMP: Bone Morphogenetic Protein; HGF: Hepatocyte growth 
factor; ITS: Insulin-transferrin-selenium; Dex: Dexamethasone; OSM: Oncostatin M; LCA: Lithocholic acid; MK4: Vitamin K; KGF: Keratinocyte 
growth factor; DMSO: dimethyl sulfoxide; HNF: Hepatocyte nuclear factor; FOX: Forkhead Box; ICC: Immunocytochemistry 
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1.2.4 Cytochrome P450s 
Despite continued efforts, no in vitro model of hepatotoxicity has comparable phase I 
metabolism with that seen in man, most notably with regard to CYP expression. The 
majority of phase I xenobiotic metabolism (~75%) is performed by CYPs, a key family of 
phase I enzymes which contribute to the metabolic competence of the hepatocyte (Zanger 
and Schwab, 2013; Guengerich, 2008). CYPs are the terminal oxidase enzymes of the 
membrane-bound microsomal monooxygenase system that catalyse the oxygenation of 
both exogenous and endogenous substrates (Zangar et al., 2004). CYPs can also lead to the 
formation of chemically reactive metabolites, a key component in many forms of DILI and 
therefore a necessity in any model of hepatotoxicity.  
In humans, CYPs may be grouped based on their structure into 18 distinct families. Families 
are grouped by number if they have ≥40% homology in structure and by letter if the 
homology is ≥55%. The CYP families 1, 2 and 3 are responsible for 70-80% of drug 
detoxification (Figure 1.3)(Prakash and Vaz, 2008). Of these, ~30% of clinically-available 
drugs are metabolised by CYP3A4/5 (Zanger and Schwab, 2013).       
CYP-dependent oxygenation requires an input of electrons. These are provided by 
cytochrome b5, or more commonly by the oxidation of NADPH by NADPH-P450 reductase 
(Zangar et al., 2004). The transfer of electrons is often inefficient, usually ~50% but has 
been reported to be as low as 0.5%, and causes substantial oxidative stress on the cell as a 
result (Gruenke et al., 1995; Kuthan and Ullrich, 1982). This production of ROS continues 
even when the CYPs are not bound by substrates (Bondy and Naderi, 1994). 
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Regulation of Cytochrome P450s 
An effective in vitro model of DILI requires an in vivo-like ADME expression profile; 
however, as discussed, no current in vitro model has the capacity to fully acquire or 
maintain a mature metabolic phenotype which has PHH-comparable CYP expression. 
Therefore, understanding the regulatory mechanisms governing the expression of these 
essential enzymes is a key component of any strategy aiming to enhance CYP expression.  
CYPs are a substantial source of oxidative and toxicological stress upon the cell and are 
therefore tightly regulated by numerous mechanisms (Zangar et al., 2004). Transcription 
(no known ligands) and nuclear (ligand-based activation) factors have the capacity to 
modulate CYP expression. Of particular importance are the liver enriched transcription 
factors (LETFs), such as HNF1α and HNF4α and C/EBPα, which have been shown to exert 
Figure 1.3: Pie chart representing the percentage of drugs which are metabolised by each of 
the CYPs. Adapted from (Zanger and Schwab, 2013) 
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regulatory control over a number of CYPs (Akiyama and Gonzalez, 2003). These factors are 
constitutively expressed and bind directly to the promoter regions which contain their 
specific binding sites.  Of the nuclear receptor family, the PXR, aryl hydrocarbon receptor 
(AhR) and CAR have particular relevance to xenobiotic metabolism-related CYPs (Czekaj and 
Skowronek, 2012; Xu et al., 2005). Once activated by ligand binding, nuclear receptors 
migrate from the cytosol to the nucleus and form heterodimers, most commonly in the 
case of PXR and CAR with retinoid X receptor (RXR), and bind to the corresponding binding 
site, driving transcription (Xu et al., 2005).  
The transcription of CYPs is multi-faceted and each individual factor does not act alone to 
drive CYP expression, with multiple transcription/nuclear factors thought to influence the 
expression of each CYP. Table 1.3 shows the binding sites for transcription factors which 
exist within each of the CYPs according to the BIObase database. The extensive number of 
different transcription factors associated with each CYP demonstrates the intricate and 
tightly controlled mechanisms which govern CYP expression. A further layer of complexity 
is added by the capacity of these factors to form heterodimers, altering the target and 
function of the factor (Xu et al., 2005).  
The LETFs and nuclear factors are also known themselves to be susceptible to transcription 
modulation, as demonstrated in table 1.4, further highlighting the complex nature of cross-
regulation which exists within the LETFs and associated factors. In addition, the expression 
of nuclear factors in particular can be modulated by a range of stimuli and ligands. For 
example, the presence of bile acids increases farnesoid X receptor (FXR) expression, 
causing down-regulation of CYP7A1, an enzyme which converts cholesterol into bile acids 
preventing the build-up of bile acids in the hepatocyte (Akiyama and Gonzalez, 2003). Such 
tightly controlled feedback loops are vital for homeostasis in vivo; however, these same 
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mechanisms likely contribute to the poor CYP expression in in vitro culture systems due the 
disruption of important processes, such as bile acid removal.     
CYPs are also thought to be regulated by microRNAs (miRNA). miRNAs bind to the 
transcribed mRNA of the gene and inhibit the translation to protein and/or target the 
mRNA for degradation (Shruti et al., 2011). However, these are not specific for a single 
mRNA and therefore one miRNA may have hundreds of targets and thus a wide-ranging 
effect on cell function (Shruti et al., 2011). Specific miRNAs have been shown to target 
CYPs, for example, CYP1A2 is targeted by miR-762, whilst CYP1B1 and CYP3A4 are targets 
of miR-27b (Betel et al., 2008; Pan et al., 2009; Tsuchiya et al., 2006). Furthermore, 
transcription and nuclear factors are also controlled via miRNA activity, with miR-34a 
shown to be target HNF4α (Takagi et al., 2010) and miR-148a found to target pregnane X 
receptor (PXR) (Takagi et al., 2008).   
Epigenetic control of CYP expression is far from understood. In silico work predicting the 
potential methylation sites of the promoter regions of CYPs has revealed little evidence of 
CpG islands within these genes, suggesting little-to-no direct involvement of methylation in 
CYP gene regulation (Ingelman-Sundberg et al., 2007). Notwithstanding these findings, 
studies investigating differences in gender have shown changes in methylation patterns of 
CYP2E1, CYP1A1 and CYP7B1 in response to different hormones (Penaloza et al., 2014). The 
use of a histone deacetylation inhibitor Trichostatin A has been demonstrated to improve 
the maintenance of the hepatic miRNA global phenotype in vitro (Bolleyn et al., 2011), 
although it is as yet unclear if this improvement is through epigenetic associated 
mechanisms or how this relates to CYP expression. A study using stem cell derived 
hepatocytes has shown that the lack of expression of CYP1A1, CYP1A2, CYP1B1, CYP2D6, 
and CYP2E1 in these cells may be explained by hypermethylation of the promoter regions 
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of these genes; whereas, the same regions are hypomethylated in primary hepatocytes 
(Park et al., 2015).  
Oxidative stress can also repress the expression of CYPs. This has been shown to be 
particularly true of CYP2E1 and CYP1A1. A study of promoter activity of these two CYPs 
demonstrated a down-regulation when oxidative stress was induced by the addition of 
H2O2 or glutathione depletion (Morel et al., 2000). Furthermore, the oxidative stress 
produced by the CYPs themselves also has consequences; the same study showed an 
increase in CYP1A1 resulted in a down-regulation of CYP2E1 promoter activity (Morel et al., 
2000). Thus, as CYP expression basally produces oxidative stress (Bondy and Naderi, 1994), 
the cell must tightly control and finely tune the expression to ensure homeostatic levels of 
oxidative stress are maintained during perturbation.   
Inflammation is another key determinant of CYP expression. Studies have shown a strong 
correlation between inflammatory cytokines, such as IL-6 and TNF-α, and the alteration of 
CYP expression (Aitken et al., 2006). A recent study found a reduction in CYP1A, 2C, 2D, 2E 
and 3A families expression (mRNA and protein) in an inflammatory model. These effects 
were associated with an up-regulation of NFκB nuclear translocation and reduction in 
CAR/PXR nuclear expression (Kusunoki et al., 2014). The type and pathway of inflammation 
also seems to determine the CYP response, with LPS-, but not anaphylaxis-induced 
inflammation, resulting in a down-regulation of CYP1A2 and CYP3A4 protein expression 
(Moriya et al., 2014).     
Post-translation, CYPs are continually degraded when inactive. This is exemplified by 
CYP2E1, which is bound and chaperoned to degradation by HSP90 when inactive; however, 
this mechanism is inhibited when CYP2E1 is active (Morishima et al., 2005). Such 
mechanisms provide a dynamic response which reduces cellular stress during times of low 
perturbation, but can react quickly upon exposure to a given compound.  
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The expression of CYPs, and consequently the capacity for PHH to metabolise the majority 
of xenobiotics, is tightly regulated by numerous complex and interacting variables. 
Therefore, any in vitro model of hepatotoxicity needs to recapitulate in vivo conditions, or 
successfully manipulate the discussed influencing factors, to ensure that the system is 
amenable and permissive to CYP expression. Without these, the model is likely to be poor 
in the prediction of hepatotoxicity and in the identification of the mechanisms underlying 
it. 
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Cytochrome 
P450 Transcription factors  with binding sites in the gene 
CYP1A2 AhR(h), AhR(m), RXR-alpha(h):CAR(h), AhR(h),  
CYP2A6 ER-alpha(h), Nrf2(h), POU2F1(h), POU2F1(r), C/EBPalpha(r), C/EBPalpha(r):C/EBPbeta(r), C/EBPbeta(r), HNF-4alpha(r), HNF-4alpha(m.s.), HNF-4alpha(h), HNF-4alpha(h):GR(h), POU2F1(h),  
CYP2C8 POU2F1(h), PXR(h):RXR(h), CAR(h):RXR(h), PXR(h):RXR(h), CAR(h):RXR(h), RORalpha1(h), RORgamma-isoform1(m), RORalpha-4(m), RORalpha1(h), RORgamma-isoform1(m), RORalpha-4(m), HNF-4alpha(h), HNF-4(h),  
CYP2C19 PXR(h):RXR(h), CAR(h):RXR(h), HNF-4alpha(h), GATA-6(h), GATA-4(h), ER-alpha(h), HNF-4alpha(h),  
CYP2D6 HNF-4alpha(h), HNF-4(h), HNF-4(r), COUP-TF1(h),  
CYP2E1 CYP2E1GATA-4(h), NF-AT5(h), NF-AT5c(h),  
CYP3A4 
HNF-4alpha(h), HNF-1alpha-A(h), HNF-4alpha(h), AP-1(h), USF1(h), HNF-4alpha2(h), COUP-TF2(h), RXR-alpha(h):PPARalpha-isoform1(h), HNF-4alpha(h), HNF-4alpha(r), RXR-alpha(h):PPARalpha-isoform1(h), PXR-
isoform1A(h):RXR-alpha(h), PXR(h):RXR-alpha(h), RXR-alpha(h):T3R-alpha1(h), (COUP-TF2(h), 2FXR(h):RXR-alpha(h), VDR(h):RXR-alpha(h), RXR-alpha(h):LXR-alpha(h), (COUP-TF1(h), ), 2PXR(h):RXR-alpha(h), RXR-
alpha(h):T3R-beta1(h), RXR-alpha(h):CAR(h), RXR-alpha(h):COUP-TF2(h), CAR(h), VDR(h):RXR-alpha(h), VDR(h):RXR-alpha(m.s.), C/EBPbeta(m.s.), C/EBPbeta(m.s.), C/EBPbeta(m.s.), RXR-alpha(h):PPARalpha-
isoform1(h), RXR-alpha(h):PPARalpha-isoform1(h), HNF-3gamma(h), C/EBPalpha(r), C/EBPalpha(r), NFI/CTF(h), HNF-4alpha2(h), C/EBPalpha(h), HNF-3alpha(m.s.), HNF-3(h), PXR(h), CAR2(m):RXR-alpha(m), 
SXR(h):RXR-alpha(h), PXR-isoform1A(h):RXR-alpha(h), PXR-isoform1A(h):RXR-beta(h), PXR-isoform1(m):RXR-alpha(m), CAR(h):RXR-alpha(h), PXR(h):RXR-alpha(h), RXR-alpha(h):CAR(h), PXR(m), (RXR-alpha(h), ), 
2CAR(h):RXR-alpha(h), VDR-isoform1(h):RXR-alpha(m.s.), PXR(h):RXR-alpha(h), PXR(h):RXR(h), PXR(h):RXR-alpha(h), PXR-isoform1(m):RXR-alpha(m), VDR(h):RXR(h), RXR(m.s.):PXR(h), PTS1R(m.s.), PXR(h), VDR(h), 
VDR(h):RXR-alpha(h), PXR(h):RXR-alpha(h), RXR-alpha(h):T3R-alpha1(h), VDR(h):RXR-alpha(m.s.), (T3R-beta1(h), ), 2FXR(h):RXR-alpha(h), VDR(h):RXR-alpha(h), RXR-alpha(h):LXR-alpha(h), (COUP-TF1(h), ), 2RXR-
alpha(h):T3R-beta1(h), RXR-alpha(h):CAR(h), RXR-alpha(h):COUP-TF1(h), NF-1C(h), C/EBPalpha(r), C/EBPalpha(h), C/EBPalpha(m.s.), Sp1(m.s.), Sp1(h), USF1(h), DEC1(m.s.), DEC1(h), Sp1(h), Sp3(h), PXR(h):RXR-
alpha(h), VDR(h):RXR-alpha(h), PXR(h):RXR-alpha(h), PXR(h):RXR-alpha(h),  
CYP27A1 PXR(h):RXR-alpha(h), PXR(h):RXR-alpha(h), GR-alpha(h), GR-alpha(h), CREB-H(h), Sp1(h), Sp3(h), HNF-4alpha(m), HNF-4alpha(h), HNF-4alpha(h), PXR(h):RXR-alpha(h), Sp1(h), Sp3(h), Sp1(h), Sp3(h),  
CYP2B6 
CAR(h):RXR-alpha(h), PXR(h):RXR-alpha(h), CAR(h):RXR-alpha(h), PXR(h):RXR-alpha(h), RXR-alpha(h):CAR(h), c-Fos(h):c-Jun(h), PXR-isoform1A(h):RXR-alpha(h), CAR(h):RXR-alpha(h), T3R-alpha(c):RXR-alpha(h), 
VDR(h):RXR-alpha(h), PXR-isoform1A(h):RXR-alpha(h), PXR-isoform1(m):RXR-alpha(m), CAR(h):RXR-alpha(h), CAR(m):RXR-alpha(m), VDR(h):RXR-alpha(m.s.), PXR(h), CAR(h):RXR-alpha(h), PXR(h):RXR(h), 
CAR(h):RXR(h), CAR(m):RXR(h), PXR(h):RXR-alpha(h), CAR(h), Egr-1(h), Egr-1(h), Egr-1(h), SMC1(h), Egr-1(h), HNF-4alpha(h), POU2F1(h),  
CYP2C9 PXR(h):RXR-alpha(h), PXR(h):RXR(h), CAR(h):RXR(h), CAR(m):RXR(h), PXR(h):RXR(h), CAR(h):RXR(h), CAR(m):RXR(h), PXR(h):RXR-alpha(h), CAR(m):RXR(h), PXR-isoform1A(h):RXR-alpha(h), CAR(h):RXR-alpha(h), 
VDR(h):RXR-alpha(m.s.), GR(h), HNF-4alpha(r), HNF-4alpha2(m), HNF-4alpha(h), GATA-6(h), GATA-4(h), ER-alpha(h), HNF-4alpha2(m), HNF-4alpha(h), HNF-4(h), HNF-4(r), POU2F1(h),  
CYP2J2 
Nrf2(m.s.):c-Jun(m.s.), Nrf2(h):c-Jun(h), c-Fos(h), c-Jun(h), c-Jun(h), POU2F1(h),  
CYP4F2 NR1B1(h):RXR-alpha(h), SREBP-1(m.s.), SREBP-1(m.s.), 
CYP4F3 SIP1-isoform1(h),  
CYP7B1 Sp1(h), Sp1(h), Sp3(h),  
CYP51A1 CREB1(r), CREM(r), CREMtau(m.s.), CREB (h), CREM(r), ATF-1(h), SREBP-1(m.s.), SREBP(pg), SREBP-1(h), SREBP-1a(h), Sp1(h), Sp3(h), 
Table 1.3: Transcription factors with binding sites within selected CYP genes.  
Abbreviations: (h): human; (ms) mouse; (r): rat; CYP: cytochrome P450; AhR: aryl hydrocarbon receptor;  RXR: retinoid X receptor;  CAR: constitutive androstane receptor;  ER: estrogen 
receptor;  Nrf2: nuclear factor (erythroid-derived 2)-like 2;  POU2F1: POU Class 2 homeobox 1;  HNF: hepatic nuclear receptor;  GR: glucocorticoid receptor;  PXR: pregnane X receptor;  ROR: 
RAR-related orphan receptor;  GATA: GATA binding protein;  COUP-TF1: chicken ovalbumin upstream promoter-transcription factor;  NF-AT: Nuclear Factor Of Activated T-Cells;  AP-1: 
activator protein 1;  USF1: upstream transcription factor;  PPAR: peroxisome proliferator-activated receptors;  T3R: thyroid hormone receptor;  FXR: farnesoid X receptor;  VDR: vitamin D 
receptor;  C/EBP: CCAAT/enhancer binding protein;  CREB: cAMP responsive element-binding protein;  Egr: early growth response protein;  SMC1: structural Maintenance of Chromosomes;  
NR1B1: retinoic acid receptor alpha;  SREBP: sterol regulatory element-binding proteins; CREM: CAMP Responsive Element Modulator;  ATF: activating transcription factor. 
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Transcription factor Transcription factors  with binding sites in the gene 
HNF1a RXR-alpha(h), HNF-4alpha(h), (HNF-4alpha(r), ), 2HNF-4alpha(r), HNF-4alpha(h), HNF-4alpha1(h),  
HNF4a 
NF-AT(h), GATA-6(r), GATA-6(h), HNF-6alpha(r), HNF-6(h), SREBP-2(m.s.), RXR-alpha(h), COUP-TF(h), COUP-TF(r), NR1B1(r):RXR-alpha(r), HNF-4alpha(r), COUP-TF2(h), HNF-4alpha(m), 
HNF-4alpha(h), HNF-4alpha(r), HNF-1alpha(m), HNF-1alpha(m), HNF-1alpha(h), HNF-1alpha(r), ipf1(r), Sp1(h), Sp1(r), HNF-1alpha(h), HNF-1alpha-A(h), HNF-1alpha(r), Sp1(h), SREBP-
2(m.s.),  
HNF6 - 
FOXA1 - 
FOXA2 HNF-6(r), HNF-6(m), HNF-6(m), HNF-6(gl), HNF-6(HA), Smad3(m.s.), Smad3(h),  
FOXA3 - 
CEBPa HNF-1(h), HNF-4(h), HNF-3(h), USF2(m.s.), usf1(m.s.), USF2(m.s.), usf1(m.s.), HIF-1alpha(h), HIF-1alpha(h), HIF-1alpha(h), USF1(h), AP-2alphaA(h), AP-2alpha(m), Gfi1(r), Gfi1(r),  
CEBPb XBP-1(h), ATF-6(m.s.), FOXO1A(m), FOXO1A(m),  
PXR HNF-4alpha(h), PPARalpha(m.s.), PPARalpha(h),  
CAR GR(h), HNF-4alpha1(h), HNF-4alpha7(h), HNF-4alpha(r), NR1B1(h):RXR-alpha(h),  
RXRa - 
FXR HNF-1alpha(h), STAT1(h), STAT1(h),  
LXR RXR-alpha(h):LXR-alpha(h), RXR-alpha(h):LXR-beta(h), RXR-alpha(h):LXR-alpha(h), RXR-alpha(h):LXR-alpha(h), LXR-alpha(h):RXR-alpha(h), LXR-beta(h):RXR-alpha(h), RXR-
alpha(m.s.):LXR-alpha(h), RXR-alpha(h):LXR-alpha(h), PPARgamma(m):RXR-alpha(m),  
LXRb c-Ets-1(m.s.), c-Ets-1(r), Elk-1(m.s.), Elk-1(h), Elk-1(r), SRF(m.s.), SRF(r),  
VDR Cdx-2(m), Cdx-2(h), C/EBPalpha(m.s.), ICER-IIgamma(m.s.), Pit-1(h), JunB(h), c-Jun(h), Fra-1(h), Fra-2(h), FOSB(h), ATF-2(h),  
RARa AR(h), Sp1(h), Sp1(m.s.), Sp1(h), Sp1(h), ER(h), ER(m), NR1B1(m):RXR-beta(m),  
LRH-1 ER-alpha(h), ipf1(m), ipf1(m), HNF-1(m.s.), SF-1(r), LRH-1(h), LRH-1(r), SF-1(h), Sp1(h), Sp3(h), Sp3(r), Sp1(r), ipf1(m), ipf1(m), ipf1(m), ipf1(m),  
 
 
Table 1.4: Transcription factors with binding sites within selected liver enriched transcription factor genes.  
Abbreviations: (h): human; (ms) mouse; (r): rat;  LXR: liver X receptor; RXR: retinoid X receptor;  HNF: hepatic nuclear receptor ;  NF-AT: nuclear factor of activated T-cells;  
GATA: GATA binding protein;  SREBP: sterol regulatory element-binding proteins;  COUP-TF: chicken ovalbumin upstream promoter-transcription factor;  NR1B1: retinoic acid 
receptor alpha;  ipf1: insulin promoter factor 1;  Smad3: mothers against decapentaplegic homolog;  USF: upstream transcription factor, C-Fos Interacting;  HIF-1: hypoxia-
inducible factor;  Gfi1: growth factor independent 1 transcription repressor;  ATF: Activating transcription factor;  FOX: Forkhead Box;  PPAR: peroxisome proliferator-activated 
receptors;  GR: glucocorticoid receptor;  Elk-1: ETS domain-containing protein;  SRF: serum response factor;  ICER-II: inducible cAMP early repressor;  Pit-1: growth hormone 
factor 1;  Fra-1: Activator Protein 1 transcription factor Fos-related antigen 1;  AR: androgen receptor;  ER: estrogen receptor;  SF-1: steroidogenic factor 1. 
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Aims of thesis 
Drug induced liver injury remains a considerable burden on the health sector and 
pharmaceutical industry. Models which are able to predict these reactions are not currently 
available, with many large toxicological screens in vitro performed in cells with little 
translational relevance.  
Induced pluripotent stem cells have the inherent capacity to form all cells of the human 
body, including fully functional hepatocytes, thus providing a uniquely expandable and 
potentially metabolically relevant phenotype for toxicology screens; however, despite 
incremental improvements using a myriad of differentiation techniques, the caveat 
remains that this inherent capacity has yet to be ‘unlocked’ in vitro. Given the incomplete 
epigenetic remodelling which occurs during reprogramming and the various reports of 
enhanced differentiation capacity in other cell types, the investigation of altered 
differentiation propensity towards hepatocyte-like cells in iPSCs derived from hepatocytes 
and other cell types is an area of interest which has yet to be fully assessed is an isogenic 
context. 
The current gold standard for toxicology screening is primary human hepatocytes; 
however, these cells have several drawbacks, most pertinently, the rapid loss of metabolic 
phenotype, termed dedifferentiation. Understanding how to culture hepatocytes to best 
maintain their functional capacity is an area of research which has been ongoing for many 
years; however, whilst improvements have been reported, the mechanistic understanding 
of the process remains incompletely understood. The advent of omics technology allows 
for a global investigation of this process, allowing for novel insights into whole cell changes. 
Moreover, by further understanding the process of dedifferentiation, the same information 
may then be used to inform advances in the differentiation protocols used to derive 
hepatocyte-like cells from pluripotent stem cells.   
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Another emerging concept in the differentiation of hepatocyte-like cells is the roles of 
previously non-associated transcription factors, such as Nrf2. The targeting of traditional 
LETFs during differentiation is well-described; however, emerging evidence points towards 
additional roles of these non-liver specific/enriched factors, which may have particular 
relevance to in vitro differentiation protocols. Understanding how these can influence the 
hepatic phenotype is another key question which has not been addressed with regard to 
hepatocyte-like cells.  
Therefore, given the aims outlined above, this thesis will set out to assess the following 
hypotheses: 
Hypothesis 1:  
The use of primary human hepatocyte-derived iPSCs to generate hepatocyte-like cells 
yields an improved maturity in hepatocyte-like cell maturity when compared to HDF-
derived iPSCs from the same donor.    
Hypothesis 2: 
Mechanistic evaluation of the primary human hepatocyte proteome during monolayer 
culture will yield novel information and hypotheses regarding the dedifferentiation and 
differentiation of hepatocytes. 
Hypothesis 3: 
Nrf2 regulates the hepatocyte phenotype during differentiation and dedifferentiation 
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2.1. Methods 
  
Table 2.1: Information regarding the cell types used to generate the data presented in this 
thesis. Further information regarding the use of these cells and the companies from which the 
materials were purchased can be found in the text.  
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2.1.1 Primary cell isolation techniques 
Primary human hepatocyte and dermal fibroblast isolation and culture 
Liver and skin resections were received as surgical waste (Aintree hospital, Liverpool, 
United Kingdom) with full patient consent and ethical approval from the relevant 
institutional review boards (National Research Ethics Service REC ref: 11/NW/0327).  
Primary human hepatocytes were isolated using a modified version of the previously 
described 2-step collagenase method (LeCluyse et al., 2005). Briefly, liver resections were 
received as surgical waste. The resections were perfused with 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES)-buffered saline (HBS; 10mM HEPES (Sigma Aldrich, 
St. Louis, MO), 5mM KCl, 136mM NaCl, 0.5% (w/v) glucose (Thermo Fisher Scientific, 
Pittsburgh, PA), followed by digestion with 0.5mg/ml Collagenase IV (400-600 collagenase 
digesting units/mg; Sigma Aldrich) in HBS containing 700µM CaCl2 (Thermo Fisher 
scientific). The capsule was then opened and the digested cells separated using nylon 
monofilament 125µm (Clarcor UK, Warrington, United Kingdom). The cell suspension was 
centrifuged twice at 80 x g for 5 minutes at 4oC, and resuspended in Williams E medium 
(Sigma Aldrich). Cells were plated onto Collagen-I coated plates (Corning, Corning, NY) at 
2.5x105 cells/cm2 to achieve full confluency in Williams E supplemented with 1% (v/v) 
insulin-transferrin-selenium (ITS; Life Technologies, Carlsbad, CA), 2mM L-glutamine (Sigma 
Aldrich), 100nM dexamethasone (Sigma-Aldrich) and 1% (v/v) penicillin (final 
concentration: 100units/ml)/streptomycin (final concentration: 100µg/ml) (Sigma Aldrich). 
After 3 hours, non-attached cells were washed away and the culture medium was replaced. 
Human dermal fibroblasts (HDFs) were isolated using a previously published protocol 
(Aasen and Belmonte, 2010). Skin biopsies were cut using scalpel and forceps into 
approximately 1cm2 pieces and placed into a 6 well plate (3 pieces/well). Two drops of 
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Dulbecco's modiﬁed Eagle's medium (DMEM; Sigma Aldrich) supplemented with 10% (v/v) 
foetal bovine serum (FBS; Life technologies), 2mM L-glutamine and 1% (v/v) 
penicillin/streptomycin (HDF media) were placed on top of each segment and left to attach 
overnight. Drops of HDF media were replaced daily to keep the pieces submerged. After 7 
days, 1ml of media added/well and changed every 48 hours. After 2 weeks HDF outgrowths 
were observable. Once confluent, HDFs were detached with 0.05% trypsin (Sigma Aldrich) 
and expanded for reprogramming and cryopreservation.  
2.1.2. hiPSC generation from different somatic cells 
Sendai virus reprogramming 
PHH were plated on embryonic stem cell (ESC)-qualified Matrigel (Corning) at a density of 
1x105 – 5x105 cells/well in a 6 well plate. Cells were cultured in Williams E medium 
supplemented with 2.5% (v/v) FBS, 50ng/ml hepatocyte growth factor (HGF; Promokine, 
Heidelberg, Germany), 50ng/ml epidermal growth factor (EGF Life technologies), 15mM 
HEPES buffer (Sigma-Aldrich), 100nM dexamethasone, 0.2% (v/v) insulin-transferrin-
selenium and 0.5% (v/v) penicillin/streptomycin (PHH reprogramming media). Following 3 
days of culture, Sendai viruses containing Oct4, Sox2, Klf4 and c-Myc transcription factors 
(Life technologies) were added at multiplicities of infection (MOI) 3-10. After 24 hours, 
media was replaced with non-virus containing PHH reprogramming media and culture 
continued for a further 2 days. Subsequently, cells were then cultured in Essential 6 media 
(Life technologies) containing basic fibroblast growth factor (bFGF; 100ng/ml; Life 
technologies) and 0.5% (v/v) penicillin/streptomycin for 25-30 days, replacing the media 
every 24 hours.  
BJ neonatal fibroblasts (CRL-2522, ATCC, Middlesex, United Kingdom) or HDFs were plated 
in a 6 well plate at 5x106 cells/well or 3x105 cells/ well, respectively. After 48 hours of 
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culture, cells were transduced with Sendai viruses containing Oct4, Sox2, Klf4 and c-Myc at 
MOI 3 or 5. After 24 hours, media was replaced and changed every 48 hours for 7 days. On 
day 7 of reprogramming, cells were trypsinised (0.05% trypsin) and replated onto 10cm2 
dishes coated with mouse embryonic fibroblasts (MEFs; Globalstem, Rockville, MD) or 6 
well plates coated with Matrigel. Cells were plated in HDF media which was replaced with 
either DMEM/F12 media supplemented with 20% (v/v) KnockOut serum replacement 
media, 1x non-essential amino acids, 50µM 2-mercaptoethanol (Life technologies) and 
0.5% (v/v) penicillin/streptomycin on MEF cultures or Essential 6 media supplemented 
100ng/ml basic-FGF (Life technologies) for Matrigel cultures. Media was changed daily and 
colonies formed from day 21 onwards. 
iPSC clone isolation, expansion and culture 
Colonies from PHH and fibroblast cultures formed between days 25 and 40 and were 
picked using a dissection microscope (EVOS XL Core Cell Imaging System; Life technologies). 
Clones expanded and maintained on either Matrigel with Essential 8 media (Life 
technologies) or MEFs with DMEM/F12 supplemented with 20% (v/v) KnockOut serum 
replacement media, 1x non-essential amino acids, 50µM 2-mercaptoethanol and 0.5% (v/v) 
penicillin/streptomycin.  
Cells were split using gentle cell disassociation reagent (GCD; Stem cell technologies; 
Vancouver, Canada) according to the manufacturer’s protocol. Briefly, differentiated cells 
were removed using a dissection microscope. Cells were then washed once with 1ml GCD 
and then incubated in 1ml GCD at room temperature for 5-8 minutes. Once breaks in cell 
adhesion were observable using light microscopy, GCD was removed and 2mls stem cell 
media added. Cells were then removed from the plate and suspended in the media using a 
cell scraper (Greiner bio-one, Monroe, NC). For feeder-free, cells were transferred directly 
to Matrigel coated plates; for feeder dependent cultures, cells were transferred to 15ml 
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tube (Greiner bio-one) and iPSCs and feeder cells separated by allowing the larger MEFs to 
settle to the bottom of the tube and transferring the remaining cell suspension to freshly 
plated MEFs. Depending on cell confluence and line, iPSCs were split 1:3 to 1:10. 
MEFs were plated 24 hours prior to iPSC splitting. For 6 well plates, 1ml attachment factor 
(Life technologies) was added to each well and incubated at 37oC for 30 minutes. MEFs 
were taken from liquid nitrogen storage and submerged in a 37oC water bath until vial 
contents were mostly defrosted. Subsequently, the vial contents was transferred to a 15 ml 
tube and 5ml MEF medium (DMEM, 15% (v/v) ESC-qualified FBS (Life Technologies), 2mM 
L-glutamine and 1% (v/v) penicillin/streptomycin) was added drop-wise. Cells were 
centrifuged at 200 x g for 5 minutes. The cell pellet was resuspended and counted using 
trypan blue exclusion. Cells were plated at 3x104 cells/cm2.  
miR302/367 lentivirus production and transduction 
PCR reactions were performed using forward and reverse primers for miR-302/367 
sequence (Forward: TGG CTT AAC AAT CCA TCA CCA TTG; Reverse: GGG TAA AAG GCA GGG 
ACT TCA GCC; Eurofins, Luxembourg), and template DNA isolated from Hues8 and Panc2 
cell lines. These reactions were performed using the GeneAmp PCR system 9700 thermal 
cycler system (Applied biosystems, Waltham, MA) using the following conditions: 94oC for 5 
minutes followed by 35 cycles of: 94oC for 1 minute, 57oC for 1 minute, 72oC for 2 minutes 
and 72oC for 8 minutes, followed by a 4oC hold. 
Once amplified, the samples were separated by ethidium bromide agarose gel 
electrophoresis (1% (w/v) agarose (Thermo Fisher Scientific) gel, 70pM ethidium bromide 
(Sigma-Aldrich)) and visualised using a EC3 gel imaging system with transilluminator (Ultra-
Violet Products, Cambridge, United Kingdom). The sample was then manually extracted 
from the gel using a UV light box and cleaned using the gel extraction kit (QIAgen Venlo, 
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Netherlands), following the manufacturer’s protocol. The following steps were then 
performed using the pCR8/GW/TOPO TA Cloning Kit (Life technologies). Briefly, 3’ 
overhangs were added to the PCR product using TAQ polymerase at 72oC for 10 minutes. 
The product was then immediately incubated for 5 minutes at room temperature for 
insertion into the TOPO entry vector. 
The TOPO vector was then used to transform one shot competent E.coli. Briefly, a mix of 
TOPO vector containing the miR302/367 PCR product and E. coli was heat shocked for 30 
seconds at 42oC. 250µl of SOC medium was then added and incubated at 37oC and 200rpm 
in a rotating incubator for 1 hour. Transformed E. coli was then spread across 100µg/ml 
spectinomycin (Sigma-Aldrich) containing agar plates and incubated at 37oC overnight. 
Following growth, 10 colonies were picked and grown in spectinomycin (100µg/ml) 
containing Lysogeny broth (LB) broth (Sigma-Aldrich) overnight at 37oC, rotating at 200rpm.  
Plasmids were extracted using QIAgen extraction kit and assessed by restriction digest by 
incubating the plasmid at 37oC for 2 hours with the ECOR1 and KPN1 enzymes (Promega, 
Madison, WI). The digested samples were then run on a 1% (w/v) agarose gel containing 
ethidium bromide for assessment of integration. Plasmids with the correct digestion 
patterns were sent for sequencing (Eurofins). 
Plasmids with greatest homology to the target sequence (>99%) were chosen and 
subsequently transferred to the pLenti6/V5-DEST entry vector (Life technologies). Briefly, 
chosen clones were incubated with the entry vector at 37oC for 90 minutes. Transformed E. 
coli was derived as previously described and then spread across (100µg/ml) ampicillin 
(Sigma-Aldrich) agar plates. Clones were then picked and incubated at 37oC in a rotating 
incubator at 200rpm overnight in LB broth containing 100µg/ml ampicillin. Plasmids were 
subsequently isolated using the QIAgen extraction kit.  
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The extracted plasmids were then subjected to restriction digest analysis using the 
enzymes Xho I and Afl II (Promega) in and incubated at 37oC for 90 minutes. The resulting 
products were assessed using an ethidium bromide containing 1% (w/v) agarose gel and 
the correct digestion patterns identified. Selected plasmids were then sent for sequencing 
analysis (Eurofins) and the correctly sequenced plasmids then further expanded and 
isolated using QIAgen MaxiPrep kit.  
Production of lentiviral particles 
Lentivirus particles were produced in accordance with commercially available ViraPower™ 
Lentiviral Expression Systems kit (Life technologies). 293FT cells were cultured in DMEM 
supplemented with 10% (v/v) FBS, 2mM L-glutamine 1% (v/v) penicillin/streptomycin and 
1x non-essential amino acids. Briefly, 293FT cells were plated in a 10cm2 plate at 5x106 
cells/plate. The following day, cells were transfected 9µg of packaging plasmid and 3µg of 
plasmid with Lipofectamine 2000. After 24 hours, media replaced and cultured for a further 
24 hours before collection of virus containing media. Viral supernatant was concentrated 
using a 45µm PVDF filter with centrifugation (Merck Millipore, Billerica, MA).  
Blasticidin (Life technologies) and polybrene (Sigma-Aldrich) toxicity assays were 
performed using concentrations ranging from 0-10µg/ml. Cells were plated at 2.5x104 
cells/well in a 24 well plate. Following 24 hour culture, media was changed to polybrene 
and blasticidin containing growth media respectively. polybrene was examined following 1 
and 3 days of culture. Blasticidin toxicity was examined over 14 days with media 
replenished every 3-4 days.  
HepG2s were used to titre the viral supernatant and were cultured in DMEM supplemented 
with 10% (v/v) FBS and 1% (v/v) penicillin/streptomycin. Cells were plated at 2x105 
cells/well in a 6 well plate. 24 hours later, cells were transduced with the virus at 10-2, 10-3, 
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10-4, 10-5 and 10-6 with 6µg/ml polybrene. Following 24 hour incubation, the virus 
containing media was removed and replaced with normal growth media and cultured for a 
further 24 hours. Subsequently, cells were cultured in media containing 4µg/ml blasticidin. 
These cells were cultured for 14 days and the media was changed every 3-4 days. After 14 
days, media was removed and 1% (w/v) crystal violet (Sigma Aldrich) in 10% (v/v) ethanol 
was added to the cells for 10 minutes. Stained wells were washed with Dulbecco's 
phosphate-buffered saline (DPBS) and colonies forming units (CFU) counted and 
multiplicity of infection (MOI) was determined using the formula below: 
MOI = the volume of the virus used (ml) x virus titre (CFU/ml) / cell number 
miR302/367 lentivirus reprogramming followed a previously published protocol (Anokye-
Danso et al., 2011). Briefly, PHH and human neonatal fibroblasts in their corresponding 
media and juvenile dermal fibroblasts (jHDFs; a kind gift from Dr. Michael Cross; C-12300, 
Promocell, Heidelberg, Germany) in fibroblast growth medium 2 (Promocell) were plated at 
1x105 cells/well in 6 well plates. The following day, cells were transduced in the presence of 
polybrene (6µg/ml). Following 2 days of transduction, viral media was removed and cells 
trypsinised, centrifuged, resuspended in stem cell medium and placed onto MEF coated 6 
well plates. Media was changed every 24 hours. 
Reprogramming using the direct transfection of miRNAs  
Optimising transfection conditions using BlockIT fluorescent oligonucleotide 
HepG2s, jHDFs and PHH were plated at a range of densities/conditions and transfected 
with 100nM BlockIT fluorescent transfection reagent (Life technologies) for between 4 and 
24 hours with Lipofectamine RNAimax (Life technologies). Fluorescence was detected using 
Axio Observer Z1 fluorescence microscope (Carl Zeiss) 24 hours after transfection. 
Transfection efficiency was estimated using ImageJ cell counting (Schneider et al., 2012).  
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Transfecting cells with miR-302a/b/c/d, miR-369-3p/5p and miR-200 
Transfections were performed as previously described by Miyoshi et al., (Miyoshi et al., 
2011). Briefly, cells were plated at 1x105 cells/well in a 24 well plate in standard culture 
media. Following culture for 24 hours, cells were transfected with each of the 7 microRNAs 
(10-30nm; Thermo Fisher Scientific) using Lipofectamine RNAiMAX (Life technologies) for 
either 4 or 24 hours. This was repeated every 48 hours for 4 cycles. After 8 days, cells were 
transferred to stem cell culture and maintained for up to 40 days. Any changes in 
morphology were monitored closely using light microscopy.  
Embryonic stem cell comparator 
The embryonic stem cell line, Hues7 was a kind gift from Dr. Patricia Murray. These cells 
were cultured on Matrigel coated plates in Essential 8 media and used as a positive control 
for the characterisation and embryoid body studies.  
2.1.3 Hepatocyte-like cell differentiation 
Optimisation of single cell plating and definitive endoderm generation 
The neonatal fibroblast-derived iPSC line Liv1W was cultured on Matrigel in Essential 8 
media. Cells were disassociated using Accutase (Life technologies) and plated at 5x104, 
1x105 and 1.5x105 cells/cm2 onto Matrigel coated 48 well plates in RPMI media (Life 
technologies) supplemented with 1x B27 (Life technologies), 100ng/ml Activin A and 
50ng/ml Wnt3a (RnD systems, McKinley Place, MI) and 10 µM Y-27632 Rho-associated 
protein kinase inhibitor (ROCK inhibitor; Merck Millipore). After 24 hours, cells were 
cultured in the plating media without ROCK inhibitor for three to five days in various 
combinations of Activin A and Wnt3a. Cells were then fixed and examined for SOX17 
expression by immunofluorescence. The differentiation efficiency was estimated by 
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ascertaining the percentage of positive cells using ImageJ cell counting plugin across 10 
images taken of each condition.  
Optimisation of hepatocyte-like cell differentiation 
Cells were cultured on Matrigel in Essential 8 media. Upon confluence, cells were washed 
once with DPBS and disassociated with Accutase at 37oC for ~5 minutes (until cell 
detachment was observed). Accutase was then diluted with RPMI media supplemented 
with 0.5% (v/v) penicillin/streptomycin and 1x B27 supplement. Cells were then centrifuged 
at 200 x g for 5 minutes and re-suspended in RPMI media supplemented with 1x  B27, 0.5% 
(v/v) penicillin/streptomycin and 10µM ROCK inhibitor. Cells were the counted and plated 
at 1.5x105 cells/cm2 on Matrigel coated 24 well plates in RPMI media supplemented with 1x 
B27, 0.5% (v/v) penicillin/streptomycin, 10µM ROCK inhibitor, 100ng/ml Activin A and 
50ng/ml Wnt3a. At this point, several protocols were adapted and compared for the 
differentiation of iPSCs to HLCs for comparison (figure 2.1) (Chen et al., 2013; Kajiwara et 
al., 2012; Sullivan et al., 2010).  
Sullivan protocol: following overnight plating, cell media was replaced daily with RPMI 
Figure 2.1: Schematic representation of the protocols used to compare HLC differentiation.  
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media containing 1x B27, 100ng/ml Activin A and 50ng/ml Wnt3a. After 3 days, Wnt3a was 
omitted from the media for a further 2 days. At day 5, media was replaced with KnockOut 
DMEM (Life technologies) containing 20% (v/v) KnockOut serum, 1mM L-glutamine, 0.5% 
(v/v) penicillin/streptomycin, 1x non-essential amino acids, 100µM 2-mercaptoethanol and 
1% (v/v) dimethyl sulfoxide (DMSO; Thermo fisher scientific). Media was changed every 48 
hours for 5 days. At day 10, media was replaced with Hepatozyme culture media (Life 
technologies) supplemented with 0.5% (v/v) penicillin/streptomycin, 20ng/ml HGF, 
20ng/ml oncostatin M (OSM; Promokine) and 100nM dexamethasone. 
Chen protocol: HGF (10ng/ml) included during the three day definitive endoderm culture. 
The differentiation conditions were then the same as the Sullivan protocol, with the 
exception of a 14 day maturation phase. 
Kajiwara protocol: sodium butyrate (0.5mM; Sigma Aldrich) was added for a 7 day 
definitive endoderm differentiation stage. Both the hepatic endoderm and maturation 
stages used the same conditions as the Sullivan and Chen protocols; however, both stages 
were 7 days. Media was changed and collected every 48 hours before lysing for 
comparisons at day 22. 
Differentiation to hepatocyte-like cells 
Cells were transferred to Matrigel culture 1:1 from MEF culture and cultured in Essential 8 
media. Upon confluence, cells were washed once with DPBS and disassociated with 
Accutase at 37oC for ~5 minutes (until cell detachment is observed). Accutase was then 
diluted with RPMI media supplemented with 0.5% (v/v) penicillin/streptomycin and 1x B27 
supplement. Cells were then centrifuged at 200 x g for 5 minutes and re-suspended in RPMI 
media supplemented with 1x B27 and 10µM ROCK inhibitor. Cells were then counted and 
plated at 1.5x105 cells/cm2 on Matrigel coated 24 well plates in RPMI media supplemented 
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with 1x B27, 0.5% (v/v) penicillin/streptomycin, 10µM ROCK inhibitor, 100ng/ml Activin A 
and 50ng/ml Wnt3a. Following overnight plating, cell media was replaced daily with RPMI 
media containing 1x B27, 0.5% (v/v) penicillin/streptomycin, 100ng/ml Activin A and 
50ng/ml Wnt3a. After 3 days, Wnt3a was omitted from the media for a further 2 days. At 
day 5 media was replaced with KnockOut DMEM media containing 20% (v/v) KnockOut 
serum, 1mM L-glutamine, 0.5% (v/v) penicillin/streptomycin, 1x non-essential amino acids, 
100µM 2-mercaptoethanol and 1% (v/v) DMSO. Media was changed every 48 hours for 7 
days. At day 12, media was replaced with HepatoZyme culture media supplemented with 
2mM L-glutamine, 0.5% (v/v) penicillin/streptomycin, 20ng/ml HGF, 20ng/ml OSM and 
100nM dexamethasone. At day 22, cells were lysed for HLC comparisons. Samples were 
also taken at definitive endoderm (day 5) and hepatic endoderm (day 12) stages.  
Spontaneous differentiation assays 
Cells in 6 well plate format were disassociated using gentle cell disassociation reagent and 
scraped in to DMEM/F12 media supplemented with 20% (v/v) KnockOut serum, 1x non-
essential amino acids, 100µM 2-mercaptoethanol, 0.5% (v/v) penicillin/streptomycin and 
10µM ROCK inhibitor. MEFs were removed by gravitational separation and cells plated in 
12 well non-tissue culture treated plates (Corning) in triplicate (1:1 ratio). After 24 hours 
cells were resuspended and transferred to a new plate to reduce attachment. Media 
changed every 48 hours without ROCK inhibitor. For gene expression comparisons, cells 
were cultured for 16 days before lysing in QIAzol (QIAgen). For characterisation 
experiments, cells were cultured for 7 days, before transfer to attachment factor-coated 48 
well tissue-culture treated plates for re-attachment. Cells were cultured for a further 7 
days, before fixing with 4% (v/v) PFA for immunofluorescence assessment.  
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2.1.4 Proteomic assessment of PHH during culture 
Isobaric tags for relative and absolute quantitation (iTRAQ) analysis 
Freshly isolated PHH samples were collected directly after isolation, before cells were 
plated. Samples were centrifuged at 80 x g for 5 minutes and lysed in 100µl iTRAQ buffer. 
24, 72 and 168 hour timepoints were collected directly from 6 wells of a 24 well plate in a 
total of 100µl iTRAQ buffer. Protein concentration was determined by Bradford assay. 
Protein lysates derived from five donors were labelled according to the manufacturer’s 
instructions (Applied Biosystems, Foster City, CA). 100µg protein in 20µl of iTRAQ buffer 
was denatured and the protein cysteine residues reduced with tris(2-
carboxyethyl)phosphine for 1 hour at 60°C, and subsequently capped with 
methylmethanethiosulfate, before overnight digestion with reconstituted trypsin at 37°C. 
Isopropanol was then added to each sample, before labelling with differentially-weighted 
isobaric tags for 2 hours, at room temperature. The labelled samples were then pooled and 
made up to 5ml with 10 mM potassium dihydrogen phosphate/25% (w/v) acetonitrile. The 
pH was then adjusted using concentrated phosphoric acid to <pH3, before cation-exchange 
chromatography, followed by tandem mass spectrometry (MS/MS) of peptide-rich 
fractions was performed on a QSTAR Pulsar I hybrid mass spectrometer (AB Sciex, 
Framingham, MA) (Rowe et al., 2013; Rowe et al., 2010). Samples were run across three 8-
plex iTRAQ runs and results obtained relative to each donor’s fresh sample to control for 
inter-donor variation. 
Transcription factor binding analysis 
Mapper2 online software was used to compare the predicted transcription factor binding 
sites (Marinescu et al., 2005). Analysis was completed using the collated database, 
analysing the sequence of each gene 2000 base pairs upstream of the transcription start 
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site. The number of proteins of interest which interacted with each predicted transcription 
factor was then compared to determine the significance of each factor. Those factors which 
demonstrated enriched predicted binding within a subset of proteins (≥4 proteins) were 
classed as factors of interest.  
2.1.5 Mitochondrial assessment of PHH during culture 
Seahorse functional mitochondrial assay 
PHH were cultured on collagen-I coated (Life Technologies; 50 µg/ml in 0.02M acetic acid), 
XF 96-well cell culture microplates (Seahorse biosciences, North Billerica, MA; 2.5x104 cells/ 
well). OXPHOS stress test medium (Seahorse biosciences) was supplemented with 25mM 
D-glucose, 2mM L-glutamine and 1mM sodium pyruvate. The glycolytic stress test medium 
(Seahorse biosciences) was prepared by adding 2mM L-glutamine. Both media were pre-
warmed to 37°C. PHH culture medium was removed and replaced with OXPHOS or 
glycolytic stress test medium. Cells were incubated in a CO2 free incubator at 37°C for 1 
hour. 1µM oligomycin, 0.25µM Carbonyl cyanide-p-trifluoromethoxyphenylhydrazone 
(FCCP) and 1µM rotenone-antimycin-A (OXPHOS stress test) and 25mM glucose, 1µM 
oligomycin, and 100mM 2-deoxyglucose solutions (glycolytic stress test) were prepared. 
Prior to the rate measurements, the XFe96 Instrument (Seahorse biosciences) allowed the 
oxygen partial pressure to reach equilibrium. The oxygen consumption rate (OCR) and 
extracellular acidiﬁcation rate (ECAR) were measured simultaneously three times to 
establish a baseline rate. After each compound injection, conditions were allowed to return 
to normal oxygen tension and pH. The OCR and ECAR measurements for each well were 
recorded and reported as pmol/min and mpH/min, respectively by XF Wave software 
(Seahorse biosciences). Results were displayed as a percentage of maximal OCR and ECAR 
or as relative fold change of each parameter between time points.  
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Rotenone assay 
PHH were plated at 1x105 in 96 well Collagen-I coated plates. At 24 and 168 hours, serial 
concentrations (0-20mM) of rotenone (Sigma Aldrich) were made in DMSO. Then the 
compound solutions were added to culture media at 1/200 (v/v) ratio to make final dosing 
concentrations of 0-100µM (0.5% (v/v) DMSO). Culture media was removed and replaced 
with the media containing rotenone. Following incubation for 2 hours (37°C, 5% CO2), ATP 
content was assessed using the Cell-titre glo assay (Promega), according to the 
manufacturer’s instructions. Briefly, 30µl of ATP reagent was added to each well containing 
100µl of media.  The plate was shaken (1 minute), then 100µl of the well content was 
transferred to a white 96 well plate and the ATPase luminescence was measured using a 
plate reader (Varioskan, Thermo Fisher Scientific). Results were presented as percentage of 
control.  
2.1.6 Pyrosequencing of PHH and iPSCs 
DNA was extracted using the QIAamp DNA mini kit (QIAgen). Briefly, samples were 
defrosted and lysed with 300µl lysis buffer and 5µl RNAse (QIAgen). Samples were then 
heated 56oC for 15 minutes in a heat shaker followed by the addition 30µl protease and 
heated at 56oC for a further 15 minutes. 300µl of ETOH (Sigma-Aldrich) was then added and 
the samples vortexed, transferred to spin columns and centrifuged 14000 x g for 2 minutes 
at room temperature. Flow through was discarded and columns washed with supplied 
buffers. Extracted DNA was then eluted by placing filter into 1.5ml collection tube and 
adding 100µl of AE buffer. The filter was left to soak for 5 minutes before spinning at 14000 
x g for 2 minutes. Samples were then transferred to 500µl PCR tube and analysed using a 
NanoDrop spectrophotometer (Thermo Fisher Scientific).   
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Each sample was adjusted to 250ng sample DNA in 20µl distilled H2O. Samples were then 
bisulphite converted using the EZ DNA Methylation-Gold kit (Zymo, Irvine, CA) according to 
manufacturer’s protocol. Briefly, 130µl CT conversion reagent was added to each sample 
before briefly spinning and heating at 96oC for 10 minutes and 56oC for 5 hours using a 
GeneAmp PCR system 9700 thermal cycler. Upon completion, 600µl binding buffer was 
added to 1.5ml tubes and the conversion mix added. The sample-binding buffer mix was 
then added to columns attached to a vacuum pump to pull the mix through the column 
filter. The filter was washed with 500µl wash buffer and then soaked for 20 minutes in 
200µl desulphonation buffer at room temperature before being washed twice with 500µl 
wash buffer. Samples were then eluted by adding 25µl elution buffer directly onto the spin 
column membrane and soaking for 15 minutes. Samples were then spun at 14000 x g for 5 
minutes and transferred to PCR tubes.  
Genes with CpG islands within the promoter region were ascertained using the NCBI gene 
information and the online tool CpG island searcher (http://cpgislands.usc.edu/) using the 
default search settings. PCR and pyrosequencing primers (sequencing, biotinylated and 
non-biotinylated) were designed using the QIAgen pyrosequencing primer design tool and 
purchased from Eurofins (table 2.2). These primers were reconstituted to 100pmol/µl 
(10mM Tris-HCl pH 8.0, 1mM Ethylenediaminetetraacetic acid (EDTA) and 50% (v/v) 
Glycerol; Sigma Aldrich) and optimised using multiple annealing temperatures and assessed 
by 2% (w/v) agarose gel with 3µl/100ml SafeView (NBS Biologicals, Huntingdon, United 
Kingdom). PCR reactions products were then generated for all primer sets using the 
optimised conditions. Briefly, 3µl 10x Coral load buffer, 1.2µl 5nM DNTPs, 0.15µl Taq 
polymerase (All QIAgen) and 1.5µl primer mix (7.5µl non-biotinylated primer, 3.5µl 
biotinylated primer and 88.75µl ddH2O) was made up to 27µl with 21.15µl PCR-grade H2O 
per reaction. 3µl of each sample was then added and the PCR run on a GeneAmp PCR 
system 9700 thermal cycler as follows: 95oC for 10 minutes then 40 cycles of 94oC for 30 
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seconds, 50-55oC for 30 seconds, 72oC for 30 seconds followed by 72oC for 10 minutes, then 
a hold at 4oC. Samples were then checked for correct size and specificity using a 2% (w/v) 
agarose gel with SafeView. Images were taken using a EC3 gel imaging system with 
transilluminator. (Ultra-Violet Products, Cambridge, United Kingdom).  
Successfully generated PCR products were then subjected to pyrosequencing using 
reagents from QIAgen. Briefly, 75µl of binding buffer containing streptavidin beads (50µl 
binding buffer, 1.25µl streptavidin beads, 23.75µl dH2O/sample) were added to each 
sample and the resulting mixture transferred to a 96 well plate and vortexed for 10 
minutes. The sequencing primer mix was then made (43.5µl annealing buffer and 1.5µl 
10µM sequencing primer) and put into another 96 well plate (QIAgen). Samples were then 
run through the Pyromark q96 workstation (QIAgen) vacuum system to wash the beads-
PCR complexes through a sequence of 70% (v/v) ETOH, 0.2M NaOH and 10mM Tris acetate. 
The resulting samples were then added to the 96 well plate (QIAgen) containing the 
sequencing primer-annealing buffer mix and heated at 80oC for 2 minutes. The samples are 
allowed to cool for 2 minutes before placing into the PyroMark Q96 ID pyrosequencing 
(QIAgen) machine and running the assay designed with the primer design software 
(QIAgen).   
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 Name Sequence 5-3 Modification 
 
CYP2E1meth-Fb  ATATGGATATTAGTAGGAGGAAGG  5’ biotin 
 CYP2E1meth-R  TCCCTTTCCACAAAATTATC   
 
CYP2E1meth-S  TTTCCACAAAATTATCTC   
 
HNF1ameth-Fb  TTAGTTTGGTTAATATGGTGAA  5’ biotin 
 HNF1ameth-R  CCAATAAAACAATCTTAACTCACTAC   
 
HNF1ameth-S  AATAAAACAATCTTAACTCAC   
 HNF4ameth-F  TGGGTGATTAGAAGAATTAATAAG   
 
HNF4ameth-Rb  CAACACAACCACCAAAAAC  5’ biotin 
 
HNF4ameth-S  TGATTAGAAGAATTAATAAGATA   
 C/ebpameth-F  TTGGAGATTAGAGTTAGGAGA   
 
C/ebpameth-Rb  AACCAAAACCAAACCTATC  5’ biotin 
 
C/ebpameth-S  GGAGATTAGAGTTAGGAG   
 FOXA2meth-F  TGTGATTGAAAAGTAATTTTGAA   
 
FOXA2meth-Rb  CAAACAACCCCTCTAACAAC  5’ biotin 
 
FOXA2meth-S  GAAAAGTAATTTTGAAATA   
 CK18meth-F  TTTAGGTGGAGGAGGTGT   
 
CK18meth-Rb  CCCAAAATACTAAAATTACAAAC  5’ biotin 
 
CK18meth-S  TTAGGTGGAGGAGGTGTT   
 HNF6meth-F  GTAATAGAGTTATGGTTTAAGTTG   
 
HNF6meth-Rb  GTTCTTAAAATTCTAAAATCTCC  5’ biotin 
 
HNF6meth-S  AGTTATGGTTTAAGTTGGT   
 HNF1a-new-F GTTTGGAGTGTAGTGGAGTAA  
 HNF1a-new-Rb ACCTATAATCCCAACTACTCC 5’ biotin 
 HNF1a-new-S TAATTTTGGTTTATTGTAA  
 CYP2E1meth-S2 TCCACAAAATTATCTC  
Table 2.2: Primer sequences used for pyrosequencing analysis. 
: Sequencing primer; : Forward primer; : Reverse primer; / : Biotinylated primer. 
 
Chapter 2 
57 
 
2.1.7 Manipulation of Nrf2 in PHH and HLCs 
Non-Liverpool derived cell types were supplied as part of various consortia for collaborative 
work. The University of Bath supplied Shef3 ESC cells and corresponding HLCs generated as 
previously described (Bone et al., 2011) as part of the Stem Cells for Safer Medicines 
consortium (SC4SM). Cellectis supplied the ChiPSC-18 iPSC line and HLCs differentiated 
using a proprietary protocol as part of the MIP-DILI consortium.   
CDDO-me supplementation of PHH during culture 
PHH were isolated as described previously. For media supplementation, 100nM 
bardoxolone methyl (CDDO-me; Cayman Chemical, Ann Arbor, MI) was added to media at 
plating whereas control conditions were cultured as normal. Media, with or without CDDO-
me supplementation, was replaced every 24 hours and samples taken at 24, 48, 72 and 168 
hours in RIPA buffer (Sigma Aldrich).  
Inducing naïve PHH with CDDO-me at set timepoints during culture 
PHH isolated and plated as previously described. At 24, 48, 72 and 168 hours cells were 
dosed with 100nM CDDO-me or 0.5% (v/v) DMSO respectively for 2 hours. Cells were 
subsequently lysed with RIPA buffer.  
siRNA transfection during HLC differentiation 
Liv1W iPSCs were differentiated using the optimised HLC differentiation protocol described 
previously. At the hepatic endoderm stage cells were transfected with 20nM Nrf2 siRNA 
SMARTpool (Dharmacon, Lafayette, CO). For reverse transfection Lipofectamine RNAiMAX-
siRNA complexes were prepared and added to Matrigel coated plates. H.E cells were then 
detached using sequential incubation with 0.02% (v/v) EDTA (Sigma Aldrich) for 5 minutes 
followed by AccuMAX (Merck Millipore) for 20 minutes at 37oC. Detached cells were then 
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centrifuged at 100 x g. The resulting cell pellet was resuspended, counted using trypan blue 
exclusion and replated at 2x105 cells/cm2 in the HLC maturation media with 10µM ROCK 
inhibitor. Forward transfection complexes were prepared as described and added directly 
to H.E cells. Lipofectamine RNAiMAX only conditions used as a vehicle control. Media was 
replaced after 24 hours and cells lysed with RIPA buffer 48 hours later.  For multiple 
transfections during HLC maturations, cells were forward transfected as described above 
on day 12 and 17 (for x 2 transfections) or day 12, 15 and 18 (for 3x transfection). Samples 
were collected for comparison at day 22 of culture.   
CRISPR/Cas9 knockout of Nrf2 in A549s and iPSCs 
A549 cells were cultured in DMEM supplemented with 10% (v/v) FBS and 1% (v/v) 
penicillin/streptomycin. iPSCs were cultured on Matrigel as previously described. 
Puromycin concentration for selection was established by plating the iPSCs and A549s at 
80-90% confluence in 24 well plates. 24 hours after plating, 0, 0.5, 1, 1.5, 2, 4, 6, 8 and 
10µg/ml puromycin concentrations were tested in triplicate and cell viability assessed by 
phase contract light microscopy.  
Optimisation of clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 
transfection was achieved using a non-coding CRISPR/Cas9 plasmid (Santa Cruz) using the 
manufacturer’s protocol. Briefly, A549s were plated at ~80% confluency. The following day, 
cells were transfected with 250ng of the control plasmid using UltraCruz transfection 
reagent. 48 hours later, cells were visualised by fluorescence microscopy to confirm 
transfection via the expression of the GFP tag. iPSCs were plated at 1x105 and 1.25x105 
cells/cm2 and transfected with 250ng plasmid with or without 1% (v/v) DMSO using three 
different methods: forward-transfection, reverse-transfection and modified reverse-
transfection. Modified reverse transfection protocol involved plating the transfection 
complexes at the same time as the Matrigel to immobilise the complexes and plating the 
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iPSCs 1 hour later. In all conditions, cells were plated on Matrigel in the presence of 10µM 
ROCK inhibitor. UltraCruz and Lipofectamine 3000 reagents were used according to the 
manufacturer’s protocols with plasmid transfection (Santa Cruz) or Opti-MEM (Life 
technologies) media, respectively. Transfection efficiency was estimated 48 hours later 
using fluorescence microscopy to investigate the expression of the GFP reporter tag.  
For Nrf2 knockdown, A549s were plated at 80% confluence in a 6 well plate. 24 hours later, 
cells were transfected with 2.5µg CRISPR/Cas9 and 2.5µg of the homology directed repair 
(HDR) plasmid using UltraCruz transfection reagent. Media was replaced after 48 hours. 96 
hours after transfection 1.5µg/ml puromycin was added to the A549s. After 20 days of 
culture colonies of cells were notable throughout the well. These were picked using a 
dissection microscope out of the well and placed into 24 well plate wells for expansion.  
For iPSC knockdown, cells were plated on Matrigel in a 6 well plate at 1x105 and 1.25x105 
cells/cm2 in Essential 8 flex media (Life technologies) supplemented with 10µM ROCK 
inhibitor. After 24 hours, cells were transfected with 2.5µg Nrf2 CRISPR/Cas9 plasmid and 
2.5µg HDR plasmid. Media was replaced after 48 hours. 96 hours after transfection, 
0.5µg/ml puromycin was added to the media and light microscopy used to determine if any 
successfully generated clones were derived. After 30 days, immunofluorescence live 
staining with Tra-1-60 was used to determine if any clones were visible.  
2.1.8 Sample end-point analysis  
Immunofluorescence 
Cells were fixed with 4% (w/v) paraformaldehyde (Sigma Aldrich) for 15 minutes and 
subsequently washed three times with DPBS buffered with MgCl2 and CaCl2
 (DPBS+; Life 
technologies). Fixed cells were blocked with DPBS+ supplemented with 10% (v/v) donkey 
serum (Sigma Aldrich) and 0.01% (v/v) Triton X-100 (Sigma Aldrich) for 30 minutes. Primary 
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antibodies were diluted (table 2.3) in DPBS+ containing 1% (v/v) donkey serum 0.01% (v/v) 
Triton X-100 and incubated overnight at 4oC. Cells were washed three times with DPBS+ 
and alexafluor secondary antibody diluted 1:750 in DPBS+ supplemented with 1% (v/v) 
donkey serum with 0.01% (v/v) triton X-100 added and incubated at room temperature for 
2 hours. Cells were washed three times and Hoechst 33342 stain (1mg/ml; Sigma Aldrich) 
added at a 1:7500 dilution in DPBS+ (final concentration: 133.3ng/ml) for 10 minutes. Cells 
washed three times and imaged using the Axio Observer Z1 fluorescence microscope with 
the AxioCam MR digital camera. Images processed using Zen lite software (Carl Zeiss).    
For albumin staining, 10x blocking buffer (Abcam, Cambridge, United Kingdom) was used to 
replace donkey serum. Staining with Tra-1-60 and SSEA-4 conjugated antibodies performed 
without triton x-100 and with a single 90 minute incubation at room temperature following 
blocking with 10% (v/v) donkey serum in DPBS+.  
Western blotting  
Samples collected in iTRAQ or RIPA buffer were quantified by Bradford assay and assessed 
by western blot to validate iTRAQ results. Briefly, 5-40µg samples were denatured at 80oC 
in Laemmli sample buffer (Sigma Aldrich), separated in 10% hand-cast polyacrylamide gels 
(running buffer: Tris: 15mM, glycine: 115mM and sodium dodecyl sulphate (SDS): 2mM; 
Thermo Fisher Scientific) and then transferred (transfer buffer: glycine: 200mM, tris: 
25mM, 20% (v/v) ETOH) to nitrocellulose membranes (G.E Healthcare, Buckinghamshire, 
United Kingdom). Following 1 hour blocking in 10% (w/v) milk (Bio-Rad, Hercules, CA), 
primary antibodies (table 2.3) were added overnight or for 15 minutes (β-actin). Following 
washing, secondary antibodies (table 2.3) were subsequently added for 1 hour. 
Membranes were then washed and visualised using chemiluminescence. Washing, block 
and antibodies were made up in Tris buffered saline (NaCl: 150mM, KCl: 3mM, Tris: 25mM; 
Thermo Fisher Scientific) with 0.1% (v/v) tween-20 (Thermo Fisher Scientific). Samples were 
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normalised against β-actin wherever possible; however, during differentiation and 
dedifferentiation, ponceau red (Sigma-Aldrich) was used to confirm equal loading as β-
actin showed differential expression.  
Nrf2 western blots were performed as above with the following alterations. 4-12% pre-cast 
NuPAGE gels (Life technologies) were loaded with samples denatured in NuPAGE LDS 
sample buffer (Life technologies) and NuPAGE sample reducing reagent (Life technologies) 
in a 7:3 ratio. Gels were run in MOPs buffer (MOPs: 50mM, Tris: 50mM, SDS: 3.5mM, EDTA: 
1mM; Thermo Fisher Scientific). The membrane was blocked overnight and the primary 
antibody (table 2.3) incubated for 3 hours. 
Use Antibody Company Dilution Secondary Dilution 
Immunofluorescence 
Oct4 Abcam 1:100 
Anti-rabbit 
alexafluor 488 
 
1:750 
 
Sox2 Abcam 1:100 
Nanog Abcam 1:100 
AFP Dako 1:100 
α-SMA Abcam 1:100 
TUJ1 Abcam 1:500 
HNF4α Santa-Cruz 1:50 
Albumin Abcam 1:20 
Sox17 RnD systems 1:20 
Anti-goat 
alexafluor 568 
1:750 
Tra-1-60 BD Gentest 1:10 Conjugated 488 
N/A 
SSEA-4 BD Gentest 1:10 Conjugated 568 
Western blot 
CYP1A2 Abcam 1:3000 Anti-mouse 1:10,000 
CYP2D6 BD Gentest 1:1000 Anti-mouse 1:10,000 
CYP2E1 Abcam 1:5000 Anti-rabbit 1:5000 
CYP3A4 Santa Cruz 1:2000 Anti-mouse 1:10,000 
Nrf2 Abcam 1:400 Anti-rabbit 1:5000 
NQO1 Abcam 1:5000 Anti-Goat 1:10,000 
ENTDP5 Abcam 1:2000 Anti-rabbit 1:5000 
HO-1 Abcam 1:5000 Anti-rabbit 1:5000 
Keap1 Santa Cruz 1:1000 Anti-goat 1:2000 
β-actin Abcam 1:10,000 Anti-mouse 1:10,000 
  
Table 2.3: Antibodies used for immunofluorescence and western blotting 
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qRT-PCR analysis of gene expression 
Primers for use in quantitative reverse transcription polymerase chain reaction (qRT-PCR) 
gene expression studies were designed using the NCBI Primer BLAST tool 
(http://www.ncbi.nlm.nih.gov/tools/primer-blast/). Briefly, the mRNA RefSeq annotation 
associated with the gene of interest was used as the search term, with exon-exon spanning 
the only parameter which differed from the default settings. Primer quality was assessed 
using OligoCalc with regard to the estimated self-complementary scores and melting 
temperatures. Primers were purchased from Eurofins and the sequences are provided in 
table 2.4.  
Samples were collected in 700µl QIAzol (QIAgen), vortexed for 1 minute and stored at -
80oC. Total RNA was extracted using the miRNeasy extraction kit according to the 
manufacturer’s protocol (QIAgen) and partly automated using a QIAcube system (QIAgen). 
In brief, samples were defrosted and 140µl of chloroform (Thermo Fisher Scientific) added. 
Samples were then mixed by repeated inversion and left at room temperature for 3 
minutes, followed by centrifugation at 4oC for 15 minutes at 12000 x g. The upper aqueous 
phase was removed (350µl), placed into collection tubes and inserted into the QIAcube for 
automated extraction using the protocol: Purification of total RNA, including small RNAs, 
from animal tissues and cells (aqueous phase). This protocol involves the following steps. 
525µl of 100% (v/v) ETOH added the sample and transferred to the spin column containing 
the aqueous phase. The column is subsequently washed with the buffers supplied and 
eluted in 30µl PCR-grade water by centrifugation at 10000 x g for 1 minute. Extracted RNA 
content was measured using the NanoDrop spectrophotometer.   
RNA was reverse transcribed to complementary DNA (cDNA) using the ImProm-II reverse 
transcription kit (Promega). Briefly, 1µl of oligo DT was added to 1µg of RNA and heated to 
70oC for 5 minutes and cooled on ice. The mixture was subsequently added to a reaction 
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mix consisting of RT buffer, MgCl2, dNTPS, PCR-grade H2O and reverse transcriptase. 
Samples were heated at 25oC for 5 minutes, 42oC for 1 hour and 70oC for 15 minutes using 
a GeneAmp PCR system 9700 thermal cycler.  
Due to low RNA yield following extraction, whole transcriptome amplification was 
performed on selected samples using the QuantiTect Whole Transcriptome Kit (Qiagen), 
following the manufacturer’s protocol. Briefly, 100ng of starting RNA from each sample was 
mixed with reverse transcriptase kit component and incubated at 37oC for 30 minutes and 
95oC for 5 minutes. Ligation mix was then added to each samples and incubated for 2 hours 
at 22oC. Finally, the amplification mix was added and incubated for 8 hours at 30oC and 5 
minutes at 95oC. Temperature controlled steps were carried out using the GeneAmp PCR 
system 9700 thermal cycler system and amplification confirmed using the NanoDrop 
spectrophotometer. 
Gene expression analysis was performed using the SYBERGreen JumpStart Taq ReadyMix 
(Sigma Aldrich). Briefly, 10-100µg of cDNA was mixed with a reaction mix consisting of: 
10µM forward and reverse primers, SYBERGreen and Rox (Sigma Aldrich). Loading of 
samples in duplicate in 368 well plates was performed using QIAgility (QIAgen), an 
automated pipetting machine. qRT-PCR was performed as follows: 95oC for 10 minutes, 
then 40 cycles for 95oC 15 seconds and 60oC for 60 seconds using the ViiA7 qRT-PCR 
machine (Applied biosystems). Results were calculated using the Ct values generated, 
normalised against GAPDH or glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and 
succinate dehydrogenase (SDHA) and calculated relative to a calibrator sample (e.g. PHH) 
using 2-ΔΔCt method (Livak and Schmittgen, 2001). 
Sendai virus expression analysis of iPSCs was conducted using the TaqMan iPSC Sendai 
Detection Kit (Life technologies) according the manufacturer’s instructions. Results were 
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normalised using GAPDH and calculated relative to the reprogramming plate using 2-ΔΔCt 
method.  
   
Primer Sequence (5’ to 3’) 
ALB  
F CCTGTTGCCAAAGCTCGATG 
R ATCTCCATGGCAGCATTCGC 
A1AT 
F TCCGATAACTGGGGTGACCT 
R AGACGGCATTGTCGATTCACT 
CYP1A2 
F AGCACCTGCCTCTACAGTTGG 
R TGGTGGACTTTTCAGGCCTTT 
CYP3A4 
F AGAAATCTGAGGCGGGAGC 
R GGAATGGAAAGACTGTTATTGAGAG 
CYP2E1 
F ACCCTGAGATCGAAGAGAAGC 
R AAATGGTGTCTCGGGTTGCT 
CYP2D6 
F TTCCCAAGGGGTGTTCCTGG 
R TCACGGCTTTGTCCAAGAGA 
CK18 
F ACATCCGGGCCCAATATGAC 
R GGTGCTCTCCTCAATCTGCT 
GAPDH 
F CTATAAATTGAGCCCGCAGCC 
R GCCCAATACGACCAAATCCGT 
HNF4α 
F GTTGACGATGGGCAATGACAC 
R TCTTTGTCCACCACGCACTG 
AFP 
F GCGGCCTCTTCCAGAAACTA 
R AATAATGTCAGCCGCTCCCT 
SOX17 
F GGATACGCCAGTGACGACCA 
R GACTTGCCCAGCATCTTGCTC 
FOXA2 
F ATTGCTGGTCGTTTGTTGAGG 
R TTCATGCCGTTCATCCCCAG 
GATA4 
F CGACACCCCAATCTCGATATG 
R GTTGCACAGATAGTGACCCGT 
CXCR4 
F GAAACCCTCAGCGTCTCAGT 
R AGTAGTGGGCTAAGGGCACA 
WNT3 
F GAGCCCAGAGATGTGTACTGC 
R CTTCTAATGGAGCCCCACCT 
PDX1 
F CAAAGCTCACGCGTGGAAAG 
R TTTTTCCACTTCATGCGGCG 
ISL1 (Insulin) 
F ACAAGCAGCCGGAGAAGAC 
R TGGATATTAGTTTTGTCATTGGGCT 
SDHA 
F TGGTTGTCTTTGGTCGGG 
R GCGTTTGGTTTAATTGGAGGG 
Table 2.4: Primer sequences used for qRT-PCR analysis. 
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Metabolism studies 
Cells were incubated for 15 minutes at 37°C (5% CO2) in standard culture media with a final 
substrate cocktail concentration of 1mM testosterone (CYP3A4) and 0.25mM 
dextromethorphan (CYP2D6) (Sigma Aldrich) in MeOH or H20, respectively (Thermo Fisher 
Scientific). 0.5µM Phenacetin (Sigma Aldrich) in 100% MeOH was then added to the 
incubation media (1:1 v/v) as a stop solution and an internal standard for LC-MS-MS 
analysis. The media containing the respective metabolites, 6β-OH-testosterone and 
dextrorphan, was then filtered using 96-well filter plates (Merck Millipore). 
The samples were analysed using a quadrupole linear ion trap mass spectrometer (AB Sciex 
4000 QTrap) coupled to a Dionex Ultimate 3000 HPLC system (Thermo Fisher Scientific). 
10mL of each sample was separated using a Phenomenex Luna 5 µ C18(2) 100A 100 x 
2.00mm column and a gradient consisting of 0.1% formic acid in water (mobile phase A) 
and methanol (mobile phase B) with a 200ml/minute flow rate. The column oven and auto-
sampler were maintained at 30°C and 4°C respectively. The mass spectrometer was 
operated using the multiple reaction monitoring mode and the analytes detected and 
quantified using the most abundant transitions obtained during direct infusion of 
standards. Results were normalised by protein content of the well following quantification 
by Bradford assay. 
Albumin ELISA 
The albumin concentration was measured by ELISA following the manufacturer’s protocol 
(Bethyl laboratories, Montgomery, TX) protocol. Briefly, 96-well high-affinity binding plates 
(Thermo Fisher Scientific) were coated with coating antibody in coating buffer for 1 hour 
and subsequently blocked with 1% (w/v) bovine serum albumin (BSA; Sigma Aldrich) for 30 
minutes. Cell supernatants were added to wells at appropriate dilutions and incubated at 
Chapter 2 
66 
 
room temperature for 1 hour. Horseradish peroxidase detection antibody was then added 
to each well at a 1:50,000 concentration. Following a 1 hour incubation, 3,3′,5,5′-
Tetramethylbenzidine substrate solution was added, incubated for 20 minutes and the 
reaction stopped with a 0.18M sulphuric acid (Thermo Fisher Scientific). Plates were read at 
450nm using MRXe Revelation plate reader (Dynex Technologies, Chantilly, VA). 
Bradford assay 
Samples for protein quantification were collected in RIPA- or iTRAQ buffer. Briefly, samples 
were diluted between 1:20 and 1:100 with distilled H2O and 20µl of each sample loaded 
into a 96 well plate in duplicate. Standards were made up using a stock of 0.5mg/ml BSA to 
generate standard concentration of 0.25, 0.2, 0.15, 0.1, 0.05, 0.025 and 0mg/ml.  A 1:5 
dilution of Bradford reagent (BioRad) was made using distilled H2O and 200µl of diluted 
Bradford reagent was added to each well. Plates were read at 570nm using MRXe 
Revelation plate reader. 
Phase contrast light microscopy 
Phase contrast light microscopy (ECLIPSE TS100/100-F; Nikon, Tokyo, Japan) was used to 
examine cell morphology. Images of the cells were taken using the digital camera 
attachment (DS-Vi1, Nikon) and stand-alone control unit DS-L3 (Nikon). 
2.1.9 Data handling and statistical analysis 
Proteomic data analysis 
Following iTRAQ analysis, only proteins which were present in all samples, identified with 
95% confidence (2 or more peptides) or 99% confidence (single peptide) with a false 
detection rate (FDR) of less than 1% were statistically analysed using R open-source 
software (http://www.r-project.org/). The iTRAQ output was analysed and differentially 
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expressed proteins (DEPs) identified using the linear models for microarray data (LIMMA) 
and t-test (multtest) modules as described previously (Rowe et al., 2010). Statistical 
outputs (p-value, Benjamini-Hochberg and log fold change) of these modules were 
presented as volcano plots and proteins detected in all samples were subjected to 
hierarchical clustering and heatmap analysis. 
Individual trend analysis of CYPs and transporters detected in ≥3 donors were assessed by 
one-way ANOVA. Co-efficient of variance (CV) was calculated as (standard 
deviation/mean). The most variable proteins were defined as CV>1.3 and the most stable 
proteins were defined as CV<0.3 and a mean relative fold change >0.8 and <1.25. PANTHER 
analysis was used to categorise differential subsets of proteins into biological functional 
groups and displayed as a pie chart (Mi et al., 2013). 
Significant DEPs (p<0.05) were uploaded to the Ingenuity platform IPA (QIAgen) to 
investigate the associated pathways, networks and regulators. IPA uses a database of 
known protein interactions from scientific publications to associate and group the 
uploaded DEPs with pathways (Thomas and Bonchev, 2010). Using IPA algorithms, the 
software generates a p-value which relates to the likelihood that a particular pathway or 
network is linked to the DEPs in the dataset. Only pathways which were altered by p<0.05 
(Thermo Fisher exact T-test) were classed as significantly altered or linked. The Z-activation 
score, which additionally takes into account the directional change of the proteins, was 
used for biological function and upstream regulator analysis. Using the IPA algorithm, 
functions or regulators which have a Z-score of ≥2 are predicted to be activated and ≤-2 are 
predicted to be inhibited. 
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Non-proteomic data analysis 
Statistics were performed using the StatsDirect software package (Cheshire, United 
Kingdom). For direct comparisons, non-dependent and dependent samples were analysed 
using unpaired and paired T-tests, respectively. In comparisons of three or more groups, 
significance was calculated by one-way or two-way ANOVA. Correlations were assessed 
using linear regression correlation. In all cases P<0.05 was classed as significant.  
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Chapter 3 
Development of iPSC reprogramming and 
differentiation protocols. 
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3.1 Introduction 
The use of pluripotent stem cells is growing rapidly and the associated techniques and 
protocols are subject to constant development and improvements (Kia et al., 2013; 
Gonzalez et al., 2011). Pluripotent stem cells hold great potential for the development of 
better cell models and treatments for debilitating conditions. One potential use is a source 
of hepatocyte-like cells for assessing the toxicological profile of small compounds during 
drug development programmes (Kia et al., 2013).  
Induced pluripotent stem cells (iPSCs) were first described by Yamanaka et al., in 2006 and 
2007 and represent a step-forward in terms of phenotypic coverage of the population 
when compared to embryonic stem cells (ESCs) (Takahashi et al., 2007; Takahashi and 
Yamanaka, 2006). iPSCs may be reprogrammed from any donor of interest using readily 
available adult somatic cells, such as those derived from skin or blood samples. This allows 
for the possibility of personalised therapies, large coverage of HLA types in immune-related 
studies and, with relation to drug induced liver injury, panel-based assessment of the 
phenotypic variation seen in the population and, in the longer term, personalised 
toxicology studies (Krueger et al., 2014).  
Before these applications can be realised, iPSCs must first be generated and differentiated. 
Since the first report of cellular reprogramming using the retroviral insertion of Oct4, Sox2, 
Klf4 and c-Myc (OSKM), several different techniques have been published (Gonzalez et al., 
2011). These have focussed on delivering these transcription factors at higher efficiency 
and in a greater range of cell types or without genome insertion, e.g. direct transfection of 
mRNA or protein, episomal plasmids or non-integrating viruses such as adeno- or Sendai 
virus (Warren et al., 2010; Yu et al., 2009; Fusaki et al., 2009; Kim et al., 2009). Other 
groups have gone further and attempted to use alternative transcription factors, such as 
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Nanog or Lin28 (Yu et al., 2007), or even replace the OSKM factors completely with small 
molecules or microRNAs (Miyoshi et al., 2011; Anokye-Danso et al., 2011; Hou et al., 2013). 
Of those techniques using the OSKM factors, the Sendai virus offers a unique trade-off 
between high efficiency genome insertion-based techniques and low efficiency non-
insertion-based techniques (Fusaki et al., 2009). It is capable of delivering the OSKM factors 
at efficiencies similar or greater than lentiviral or retroviral techniques in a wide-range of 
cell types (Fujita et al., 2006) and, as it has an RNA-based viral cycle, no genome integration 
or disruption occurs (Fusaki et al., 2009).    
MicroRNA-based techniques offer a capacity to remove the oncogenic transcription factors 
associated with OSKM-based reprogramming. The use of the miR-302/367 cluster has been 
widely reported to enhance reprogramming efficiency when used in conjunction with 
OSKM factors (Subramanyam et al., 2011; Liao et al., 2011; Hu et al., 2013); however, in 
2011, Anokye-Danso et al., reported a microRNA only reprogramming technique (Anokye-
Danso et al., 2011). The authors demonstrated that the lentiviral transduction of 
miR302/367 had a 30% greater reprogramming efficiency (as measured by OCT4-GFP 
positive colonies) than standard OSKM factors in mouse cells, whilst human neonatal 
fibroblasts were reprogrammed at efficiencies ~2800 times greater than OSKM-techniques, 
as measured by counting colonies with ESC-like morphologies (Anokye-Danso et al., 2011).  
In the same issue of the journal, Miyoshi et al., found that reprogramming could be 
achieved via the direct transfection of seven microRNAs: miR302a/b/c/d, miR200c and 
miR369-3p/5p (Miyoshi et al., 2011). The authors reported a very low efficiency compared 
to previously reported viral methods; however, the lack of a need to introduce OSKM 
factors or use integrating-based techniques which may have negative effects on genome 
integrity is highly attractive for many groups wishing to generate iPSCs.  
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As a consequence of the great number of options available, choosing the correct 
reprogramming technique for the chosen application can prove difficult (Gonzalez et al., 
2011). Therefore, as part of this chapter, we assessed the three described techniques for 
the ability to reprogram both fibroblasts and hepatocytes required for the experiments 
described in chapter 4. Whilst fibroblasts are generally reported to be readily 
reprogrammable, very few publications have shown successful reprogramming of human 
hepatocytes (Hansel et al., 2014; Liu et al., 2010a). One potential cause of this is that 
human hepatocytes are known to become cell cycle arrested in current culture systems (Xu 
et al., 2013b); therefore, we required a reprogramming technique which is capable of 
delivering the required factors to a range of cell types, including a non-dividing cell type.  
The differentiation of iPSCs to hepatocyte-like cells has also been described using 
numerous techniques (Kia et al., 2013). Many different protocols have been published with 
regard to the production of HLCs and deciding which method best suits the requirements of 
the researcher is an imperative consideration. Therefore, within this chapter we also 
investigate three different protocols for HLC differentiation and assess which is most likely 
to allow for the differentiation of a wide number of cell types, as required in chapter 4.        
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3.2 Results 
Lentiviral transduction of miR302/367 to reprogram somatic cells to iPSCs 
We first looked to reproduce the work reported by Anokye-Danso et al, who demonstrated 
reprogramming at higher efficiency than OSKM-based techniques (Anokye-Danso et al., 
2011). In addition, the use of lentiviral constructs allows integration into a wider number of 
cell types, including non-dividing cells, than more traditional retroviral-based techniques 
(Gonzalez et al., 2011). Together, this suggests that a wide range of cell types may be 
amenable to this novel microRNA reprogramming technique. 
Generation of a lentivirus vector containing miR302/367 
To asses this novel technique, we generated a lentivirus construct encoding the 
miR302/367 cluster. Figure 3.1 shows the production of this virus. Firstly, the vector 
sequence was successfully amplified by PCR (Figure 3.1a.i). We then transferred this 
amplified product into a TOPO entry vector and confirmed that the correct sequence had 
been transferred using restriction digest analysis (Figure 3.1a.ii). The sequence was then 
transferred to the destination vector and again verified by restriction digest analysis (Figure 
3.1a.iii). The results from Figure 3.1a.iii were further assessed by sequencing analysis 
(Eurofins), confirming the correct sequence was present within the destination vector. 
Plasmids with the correct sequence and orientation were then expanded and viral particles 
produced using 293FT cells.  
Titration of lentiviral particles 
Once the viral particles were produced, the titre of the supernatant was then assessed. This 
was achieved using HepG2s, as this is a clonally expandable and non-migratory cell line, 
both of which are required for colony forming unit-based titration. HepG2s were 
transduced with viral particles at serial dilutions 10-2 -10-6 and subsequently selected out 
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using blasticidin. Following 2 weeks of selection, crystal violet analysis suggested that the 
initial titre was relatively low: 1.52x103, colony forming units (CFU). Therefore, the virus 
was concentrated using a centrifugal filtration method, resulting in an improved titre of 
8.9x105 CFU. It has been reported that miRNA-based lentiviruses produce lower titres as a 
result of various mechanisms (Liu et al., 2010b). We therefore compared our miRNA 
plasmid with a control plasmid to see if the miRNA was impacting on the viral titre. 
Following centrifugal concentration, the results demonstrated a large difference in viral 
concentration: 2.6x105 and 1.95x106 CFU for the miRNA (Figure 3.1c.i) and control plasmids 
(Figure 3.1c.ii), respectively. Consequently, the analysis of the miRNA lentivirus technique 
sequence across a single batch of virus was limited.  
Reprogramming of cells with the lentivirial vector 
Subsequently, cells were transduced with the viral particles. Analysis demonstrated 
successful integration and production of the miRNA-encoded sequence in HepG2s, as part 
of the titration experiment (Figure 3.2a) and in neonatal fibroblasts (Figure 3.2b and c). 
Interestingly, despite the cell morphology suggesting increased toxicity at the higher viral 
loads, particularly at MOI 10 (figure 3.2b); no increase in miR302b expression was observed 
(Figure 3.2c). 
Reprogramming of cells using this virus was then attempted at MOI 5 using the protocol 
described in the original publication (Anokye-Danso et al., 2011) (Figure 3.3a). However, 
despite numerous attempts in neonatal and juvenile fibroblasts and PHH, little to no colony 
formation was noted (Figure 3.2b and c). Of those colonies which did form, none displayed 
the morphological or growth characteristics associated with iPSCs. Some colonies were 
noted from the juvenile dermal fibroblasts (jHDFs); however, these had a different 
morphology than expected. Analysis of these colonies revealed high Sox2 expression, 
whereas Nanog and Oct4 were undetectable (Figure 3.3d).     
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Figure 3.1: Lentiviral miR302/367 construct production.  
a) Ethidium bromide gels. i) PCR amplicons of miR-302/367 sequence in cells lines Hues8 (H8), 
and Panc2 (P2) and no template control (NTC); ii) Restriction digest with ECOR1 and KPN1 of the 
miR-302/367 cluster inserted into the entry TOPO vector; iii) Restriction digest using Afl II and 
Xho I of the expression plasmid following enzymatic transfer from the entry TOPO vector. 
Highlighted in orange are the correctly inserted plasmids as determined by expected fragment 
size. b) Viral titre of transduced, Blasticidin selected and crystal violet stained HepG2s using 
serially diluted viral stock. i) non-concentrated viral titre; ii): concentrated virus. c) Viral titre of 
transduced, Blasticidin selected and crystal violet stained HepG2s using serially diluted viral 
stock i) miRNA-encoding virus; ii) Control virus. 
Abbreviations: H8: Hues8 (ESCs), P2: Panc 2 cell line 
 
Chapter 3 
76 
 
  
Figure 3.2: Successful lentiviral miR302/367 transduction of cells.  
a) Relative expression of miR302b expression following transduction of HepG2s (MOI 0.5) with lentiviral 
particles as detected by q-PCR. Results normalised to U6 and shown relative to Hues7, a ESC control of 
endogenous pluripotent levels of miR302b; n=1. b) Morphology of BJ fibroblasts 24 hours post-
transduction with miR302/367 lentivirus at MOI 1, 3, 5 and 10. Magnification x1000, scale bar: 100µm c) 
Relative expression of miR302b expression following transduction of BJ fibroblasts (MOI 1-10) with 
lentiviral particles as detected by q-PCR. Results normalised to U6 and shown relative to Hues7, an ESC 
control of endogenous pluripotent levels of miR302b; n=2. Error bars: SEM. 
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Figure 3.3: Lentiviral miR302/367 reprogramming of cells does not yield iPSCs. 
a) Schematic diagram of the protocol used to transduce primary cells using the miR302/367 lentivirus. b) 
Lentiviral transduction of PHH and jHDFs (MOI 1) pre-transduction (magnification x100, scale bar: 100µm) 
and potential colonies (magnification x200, scale bar: 10µm) forming 15 days post transduction. c) 
Attachment of jHDF colonies picked onto fresh MEFs at day 55 post transduction (magnification: x40, x100, 
x200, x400; scale bar: 100µm, 100µm, 10µm, 10µm, respectively). d) Q-PCR analysis of 3 picked colonies. 
Gene expression of pluripotency markers Sox2, Oct3/4 and Nanog shown relative to Hues7 control and 
against a non-transduced HDF culture. Each sample n=1 and run in duplicate.  
Abbreviations: Oct4: Octamer-binding transcription factor 4; Sox2: SRY (sex determining region Y)-box 2 
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Direct transfection of miRNA to reprogram somatic cells to iPSCs 
The use of direct transfection is an attractive method of reprogramming as it avoids the use 
of integrative vectors such as lenti- or retroviruses. Within our laboratory, we have shown 
that it is possible to manipulate hepatocytes with siRNA, a synthetic oligonucloetide which 
works in a similar way to mature miRNAs (unpublished data).  
Optimising the transfection efficiency 
To assess this reprogramming technique, we first optimised our transfection conditions for 
all cells used with a fluorescently labelled oligonucleotide. Our results suggested that 
HepG2s (Figure 3.4a.i) and dermal fibroblasts (figure 4a.ii) showed relatively high 
transfection efficiency. Interestingly, for hepatocytes, sandwich cultures incorporating a 
Matrigel overlay were not amenable to transfection, whereas monolayer cultures were 
(Figure 3.4a.iii). Furthermore, lower plating densities increased transfection efficiency 
(Figure 3.4a.vi). We then assessed the relative expression of a single miRNA to confirm 
successful transfection. Our results showed a large increase in the miRNA expression in the 
transfected fibroblasts which was ~15-fold above non-transfected cells and also above the 
levels of Hues7 ESCs (Figure 3.4b).  
Reprogramming using microRNA transfection 
Using the optimised conditions, we then plated neonatal and juvenile fibroblasts at the pre-
determined densities and transfected them with the seven microRNAs every 48 hours over 
4 cycles (Figure 3.5a). Following the final transfection, cells were transferred to feeder-
dependent stem cell culture. After extended culture of 50 days, no typical-iPSC colonies 
were detected in any of the cell types investigated (Figure 3.5b). Attempts to reprogram 
primary human hepatocytes were also unsuccessful, yielding no colonies which were 
demonstrative of an iPSC-like phenotype (Figure 3.5b).   
Chapter 3 
79 
 
 
  
Figure 3.4: Optimising transfection conditions with BlockIT fluorescent oligo and qRT-PCR 
a) Merged light and fluorescent microscopy of i) Low density HepG2s transfected with BlockIT (white) 
at 100nM; ii) Low density jHDFs transfected with BlockIT at 100nM iii) Fluorescence comparison of 
BlockIT accumulation in Matrigel overlaid and non-overlaid primary hepatocytes (green: BlockIt 
reagent); iv) Comparison of BlockIT accumulation in primary human hepatocytes plated at different 
cell densities. Magnification x100, scale bar: 100µm. b) Confirmation of transfection in BJ fibroblast 
cultures at various concentrations of miRNAs. miR302b relative expression measured by q-PCR and 
shown relative to Hues7; n=2 wells of a single experiment, error bars: SEM.  
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Figure 3.5: Reprogramming primary cells with direct transfection of miRNAs.  
a) Schematic of the protocol used for the transfection of primary cells. b) i) Primary human 
hepatocytes transfected with 7xmiRs and the subsequent culture and attempted expansion. Images 
taken at various points of culture. Magnification x200, scale bar: 100µm; ii) HDFs transfected with 
7xmiRNAs. Images represent the different morphology of transfected and control cells taken at day 12 
post initial transfection. Magnification x100, scale bar: 100µm 
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Use of Sendai virus to reprogram somatic cells to iPSCs 
As neither microRNA approach yielded iPSC colonies, we then attempted a more traditional 
approach using the OSKM factors delivered via Sendai virus. According to the 
manufacture’s suggestions, we first attempted reprogramming in the BJ neonatal (Figure 
3.6a). Using viral loads of MOI 3 in duplicate we were able to successfully generate iPSCs 
using the Sendai virus technique (Figure 3.6b). In total, 26 colonies were picked onto either 
feeder-dependent or feeder-independent culture and labelled Liv1A-Z (Figure 3.6c).  
Following expansion, two feeder-free (Liv1W and Liv1R) and 2 feeder-dependent (Liv1E and 
Liv1N) lines were characterised using a panel of ESC-associated markers Oct4, Sox2, Nanog, 
Tra-1-60 and SSEA-4 (Figure 3.7a). To functionally characterise the iPSCs we then formed 
embryoid bodies from the clones with all lines forming spheroid-like structures in non-
tissue culture coated plates (Figure 3.7b). Following re-plating, pluripotency was confirmed 
in all four lines based on expression of endoderm (AFP), ectoderm (TUJ1) and mesoderm 
(alpha-SMA) specific markers using immunofluorescence (Figure 3.7c). 
We then confirmed a switch from exogenous to endogenous OSKM expression through the 
loss of Sendai virus expression. As this virus does not integrate, it is reported to be lost at 
passages >10. To examine residual Sendai virus expression we used a qRT-PCR assay 
directed to specific tags on the 4 viruses used for reprogramming (Figure 3.8a). Our results 
showed almost complete loss of Sendai virus expression in Liv1E, Liv1R and Liv1W lines. The 
residual expression of c-Myc and Klf4 in Liv1N is still very low, ~333 fold less than the 
reprogramming plate, and would likely dissipate with further time in culture. The high 
endogenous gene expression levels of Oct4, Sox2 and Nanog (Figure 3.8b) further 
demonstrated the commitment to a pluripotent phenotype in the absence of viral 
expression.   
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Figure 3.6: Sendai virus BJ fibroblast reprogramming yields fully reprogrammed iPSCs.  
a) Schematic diagram of the Sendai virus protocol. b) Images taken of cells pre-transduction and at various 
stages of culture up to the emergence of picked colonies: day 1: magnification x100, scale bar 100µm; day 
6-25: x40, scale bar 100µm. c) Examples of colonies successfully picked onto feeder-dependent (Liv1E) and 
feeder-free (Liv1Z) culture systems. Magnification: x100, scale bar 100µm.  
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Figure 3.7: Characterisation of BJ fibroblast-derived iPSCs using embryoid bodies.  
a) BJ fibroblast-derived iPSC colony characterisation. 4 clones characterised using panel of markers: Oct4, 
Sox2, Nanog, Tra-1-60 and SSEA-4. Magnification x200, scale bar 50µm. b) i) Embryoid bodies formed for 
assessment of spontaneous differentiation capacity. ii) Embryoid bodies replated for staining analysis. 
Images present a representative well with multiple cell morphologies present. Magnification x40, x100, 
x200, scale bar: 100µm, 100µm and 10µm c) Immunofluorescence images taken of 3 markers of germ 
layers: Alpha smooth muscle actin (mesoderm), alpha fetoprotein (endoderm) and TUJ1 (Ectoderm). All 
lines presented at 20x with corresponding bright-field images. Magnification x200, scale bar 50µm. 4 
lines characterised using EB assays with 1 shown as an example.  
Abbreviations: AFP: Alpha-Fetoprotein; α-SMA: alpha smooth muscle actin; Tuj1: Neuron-specific class III 
beta-tubulin; Oct4: Octamer-binding transcription factor 4; Sox2: SRY (sex determining region Y)-box 2; 
Tra-1-60: Tumour-related antigen (TRA)-1-60; SSEA-4: Stage-specific embryonic antigen-4 
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Figure 3.8: Characterisation of BJ fibroblast-derived iPSCs using qRT-PCR.  
a) Confirmation that the Sendai virus expression has been removed through multiple passaging. 
Relative expression compared to the original reprogramming plate 30 days post-transduction. All 
samples n=1 run in duplicate b) BJ fibroblast-derived iPSC colony characterisation. 4 clones 
characterised using a panel of markers: Oct4, Sox2, Nanog by qRT-PCR. Results presented as relative 
to hESC control. N.B at time of sample derivation hESC culture was of low quality and contained 
numerous areas of differentiation. All samples n=1, run in duplicate.  
Abbreviations: Oct4: Octamer-binding transcription factor 4; Sox2: SRY (sex determining region Y)-
box 2; SeV: Sendai virus 
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Differentiation of iPSCs towards HLCs 
Once characterised, we then developed a protocol for differentiating iPSCs to hepatocyte-
like cells. The requirement, discussed further in chapter 4, was for a protocol which can be 
used in a wide range of iPSC lines; therefore we investigated one of the most widely 
established protocols used in the literature and the different variants which have been 
published. 
In an attempt to improve inter-donor, inter-clone and inter-experiment reproducibility we 
developed a single cell method for plating the iPSCs before differentiation. Initial 
experiments focussed on the survival rate and subsequent growth characteristics when 
plated in standard Essential 8 media culture media (Figure 3.9a). The results suggested high 
plating efficiency was found in the presence of ROCK inhibitor, with the cells quickly 
reforming colony-like structures when maintained in stem cell maintenance media.   
We then compared different methods of differentiation towards definitive endoderm using 
single cell differentiation model to enhance intra-line reproducibility and reduce inter-line 
variability. Depending on the cell type and line, groups have reported slightly altered 
protocols to generate the purist population of definitive endoderm cells. We therefore 
compared various combinations of Activin A and Wnt3A at several different single cell 
plating densities. Densities were chosen based on Kajiwara et al., which reported a plating 
density of 1x105 cells/cm2. Our results suggest that higher plating densities enhance 
definitive endoderm differentiation in single cell plating models (Figure 3.9b). Estimations 
of population purity were made by counting and comparing the number of Sox17 positive 
cells across 10 representative pictures of the well. This data suggested that there was little 
difference between the higher densities in these conditions; however, the use of Activin A 
and Wnt3a for 3 days followed by Activin A alone for 2 days was noted as being the most 
efficient by eye (Figure 3.9c).  
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As the only significant difference in definitive endoderm differentiation efficiency was seen 
with different cell densities, further conditions were used as part of a comparison of full 
differentiation protocols seeded at 1.5x105 cells/cm2. These protocols used were adapted 
from published protocols: Sullivan, Kajiwara and Chen, respectively (Chen et al., 2012; 
Kajiwara et al., 2012; Sullivan et al., 2010). Both the Kajiwara and Chen protocols are 
modified versions of the Sullivan protocol. Using two of our iPSCs lines, we differentiated 
these cells, following each protocol as closely as possible (Figure 3.10).  
Our results demonstrated the variation that can be found between lines and that the 
Sullivan protocol was much more effective at producing HLCs in our iPSCs than the Chen 
protocol, as determined by albumin secretion (Figure 3.11a). The use of sodium butyrate in 
the Kajiwara protocol was found to cause toxicity during the earliest stages of culture in 
Liv1W. Both the Kajiwara and Sullivan protocol successfully yielded cells which had a 
hepatocyte-like morphology and had detectable secretion of albumin. Interestingly, the 
Kajiwara protocol was able to induce albumin secretion in Liv1R, which was not possible in 
the Sullivan or Chen protocols.  
We also investigated the gene expression of HLCs produced using the Sullivan protocol. In-
keeping with current literature, the cells showed detectable expression of several hepatic-
associated genes, such as HNF4α, albumin, CK18 and A1AT; however, the expression of 
several CYP450s was below the level of detection (Figure 3.11b).  
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Figure 3.9: Optimising the single cell plating and differentiation of iPSCs to definitive endoderm.  
a) Single cell plating of iPSCs in Essential 8 Media. Magnification x40 and x100, scale bar: 100µm and 
100µm. b) Plating and differentiation of iPSCs at 5x104, 1x105 and 1.5x105 cells/cm2 at different stages of 
differentiation. No cells survived beyond 48 hours in the 5x104 cells/cm2 condition. 3+2 refers to 3 days of 
100ng/ml Activin A and 50ng/ml WNT3a followed by 2 days of 100ng/ml Activin A only. All other conditions 
have 100ng/ml Activin A and 50ng/ml Wnt3a throughout the differentiation period. Magnification x40, scale 
bar: 100µm c) Results of 10 images taken from each well in duplicate. Percentage of Sox17+ve cells 
ascertained using the cell count function in imageJ. Error bars represent SD. (*) p<0.05 paired T-test. 
Abbreviations: Sox17: SRY (sex determining region Y)-box 17.  
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  Figure 3.10: Morphological assessment of different protocols for differentiating iPSCs to Hepatocyte-
like cells.  
a) Schematic diagrams of the various protocols used for HLC differentiation. b) Morphological changes of 
two iPSC lines differentiated using three different HLC protocols at each stage of differentiation. No cells 
were left in Liv1W following the D.E stage of the Kajiwara protocol. Magnification: x40, x100, x200, x400; 
scale bar: 100µm or 10µm.  
Abbreviations: Wnt3A: wingless-Type MMTV Integration Site Family, Member 3A; HGF: Hepatocyte 
growth factor; DMSO: dimethyl sulfoxide; OSM: oncostatin M 
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Figure 3.11: Phenotyping of iPSCs differentiated to Hepatocyte-like cells using albumin ELISA and qRT-
PCR  
a) Albumin secretion of each protocol during the differentiation protocols. Albumin concentration 
measured using ELISA. b) Gene expression of key hepatic genes. The expression of mRNA copies was 
normalised against GAPDH expression, and the expression of freshly-isolated human primary 
hepatocytes was set to 1 for each gene. All samples n=2, run in duplicate. 
Abbreviations: ALB: albumin; A1AT: alpha-1-anti-tryspin; CK18: cytokeratin-18; HNF4α: hepatic nuclear 
factor 4 alpha; CYP: cytochrome P450 
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Use of Sendai virus to reprogram human hepatocytes 
To compare iPSCs derived from fibroblasts and hepatocytes, we required a protocol 
capable of reprogramming human hepatocytes.  
Our first attempts at reprogramming used viral MOIs of 3 and 5 and followed the Sendai 
virus protocol as closely as possible, allowing for cell type restrictions, including a re-plating 
step at day 7. This protocol did not generate any clones; however, encouraging cuboidal, 
dividing cells were noted, similar to those seen at the early stage of fibroblast 
reprogramming (Figure 3.12).  
Hepatocytes are known not to respond well to trypsinisation and re-plating, therefore we 
hypothesised that developing a protocol which did not require re-plating would be the 
most successful route. Further, given that the cell cycle is a vital component of 
reprogramming (Xu et al., 2013b), we also decided to use the media composition described 
by Liu et al., (Liu et al., 2010a) which contains high levels of HGF and EGF, known mitogenic 
factors.  
  
Figure 3.12: Sendai virus-based reprogramming of PHH using the standard protocol did 
not yield iPSC colonies.  
PHH pre-transduction and at day 17 post transduction following transfer to MEF-based 
culture. Magnification x100, scale bar: 100µm. 
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To assess if these conditions were feasible, we plated freshly-isolated hepatocytes onto 
ESC-qualified Matrigel coated plates in hepatocyte reprogramming media at low densities. 
The cells were then cultured and the morphology of the cells noted over a seven day 
period, representing the conditions the cells would face during the initial stages of 
reprogramming. The changes in the cells were marked, with the sub-confluent, mitogenic 
culture conditions inducing cell flattening and spreading of the hepatocytes with much 
greater survival than those cells in standard hepatocyte culture media (Figure 3.13a). The 
maintenance of the hepatic phenotype was confirmed with albumin staining, 
demonstrating that despite these morphological changes, a key hepatic marker was still 
present (Figure 3.13b).   
The optimised culture conditions appeared ideally suited for the reprogramming of 
hepatocytes. Therefore, the cells were transduced with Sendai virus at MOI 5 and MOI 10 
and examined during for the reprogramming period for colony formation (Figure 3.14). 
Toxicity was noticeable between Sendai and control wells, with greater toxicity seen at MOI 
10. At day 20, the first colonies were noted with similar, but incomplete iPSC-like 
morphology. These colonies appeared to be heterogeneous and underwent growth arrest 
during the culture period (Figure 3.15a). At day 24, one colony was noted which did 
represent the hallmark features of an iPSC colony. After tracking the colony over several 
days, the colony remained homogenous and continued to expand. This colony was picked 
onto MEF-coated plates for expansion (Figure 3.15b). Following successful attachment, the 
clone was expanded and characterised using the panel of pluripotency markers (Figure 
3.16a) and functional embryoid body analysis confirming the capacity to differentiate to all 
3 germ layers (Figure 3.16b).  
As it is difficult to ascertain any true differences between starting cell types if only one 
clone is compared, we then sought to enhance our reprogramming technique. To increase 
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the number of clones generated from subsequent donors, we increased the plating density 
from 1x105 to 5x105. Interestingly, the increased number of starting cells resulted in an 
increase in the number of clones that were successfully generated; from one iPSC clone in 
donor 1 to five and ten in donors 2 and 3, respectively. Figure 3.17 demonstrates examples 
of the iPSC lines which were generated from the PHH cultures of each donor. The 
generation of these clones allowed for the comparison between PHH- and HDF-derived 
iPSCs, presented in chapter 4.  
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Figure 3.13: Developing a technique to reprogram PHH using a high growth factor-based culture medium.  
a) Comparison of morphology and cell survival in PHH cultured in reprogramming media and standard media 
over a period of 7 days to replicate reprogramming conditions. Magnification x100, scale bar: 100µm. b) 
Immunofluorescence staining for albumin expression in PHH following 7 days of culture in reprogramming 
media. IF: Magnification x100 and x200, scale bar: 100µm and 50µm.  
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Figure 3.14: The development of partially reprogrammed clones following Sendai virus PHH 
reprogramming in optimised conditions.  
Images taken of PHH pre-transduction and at various stages of culture prior to the emergence of 
picked colonies. Magnification: x40 (day 5 and 15) and x100, scale bar: 100µm 
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Figure 3.15: Sendai virus PHH reprogramming in optimised conditions generates a single iPSC clone.  
a) Images taken of PHH-derived clones which displayed some morphological similarity to iPSCs. Cells were 
picked but no expansion was noted. b) Liv4HJ displayed all characteristics of an iPSC clone and was 
successfully picked and expanded. Magnification x40 and x100, scale bar: 100µm 
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Figure 3.16: Characterisation of PHH-derived iPSCs.  
a) Liv4HJ characterised using panel of markers: OCT4, SOX2, Nanog, Tra-1-60 and SSEA-4. b) 
Embryoid bodies formed for assessment of spontaneous differentiation capacity; 
Immunofluorescence images taken of 3 markers of germ layers: α-smooth muscle actin 
(mesoderm), TUJ1 (Ectoderm) and alpha fetoprotein (endoderm). IF images: magnification x200, 
scale bar: 50µm. Light microscopy: magnification x40, scale bar: 100µm. 
Abbreviations: AFP: Alpha-Fetoprotein; α-SMA: alpha smooth muscle actin; Tuj1: Neuron-specific 
class III beta-tubulin; Oct4: Octamer-binding transcription factor 4; Sox2: SRY (sex determining 
region Y)-box 2; Tra-1-60: Tumour-related antigen (TRA)-1-60; SSEA-4: Stage-specific embryonic 
antigen-4 
 
Chapter 3 
98 
 
  
Figure 3.17: Characterisation of PHH-derived iPSCs.  
Isolation and reprogramming of somatic cells. The morphology of PHH from each donor prior to 
reprogramming and selected examples of the iPSCs which were generated from each of these 
starting cell types/donors. PHH: magnification: x100, scale bar: 100μm; iPSCs: magnification  x40, 
scale bar: 100μm.  
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3.3 Discussion 
The data presented in this chapter demonstrates the multiple steps and optimisation 
undertaken to develop a working protocol for hepatocyte reprogramming and 
differentiation. 
Despite using two published techniques of microRNA-based cell reprogramming (Anokye-
Danso et al., 2011; Miyoshi et al., 2011), we were unable to replicate successful iPSC 
generation in any of the cell types used. Whilst no fully reprogrammed clones were found 
within our culture systems, colonies of interest did form in the cells transduced with the 
lentiviral miR-302/367 construct. Upon analysis, these colonies had detectable expression 
of the pluripotency marker Sox2, but no expression of other markers, such as Oct4 and 
Nanog. This suggests that the technique yielded partially reprogrammed colonies which 
have resulted ectoderm-like cells, based on the Sox2 expression in the absence of Oct4 and 
Nanog (Puligilla et al., 2010). Our results are in-keeping with current literature as, at the 
time of writing, no subsequent reports of miRNA-based reprogramming have been 
published (Lüningschrör et al., 2013). In contrast to the reported high efficiency of 
reprogramming of the lentiviral method, our results suggest that the technique has a very 
low efficiency of reprogramming and/or works in conditions specific to the laboratory of 
origin.  
Our investigations of the lentivirus-based technique were hampered by low viral yields 
which could not be enhanced sufficiently using concentration methods, preventing multiple 
high MOI repeats in large numbers of cells. The enhanced viral titre in the control virus 
compared to the miRNA virus suggests that the reports describing mechanisms, such as 
Drosha targeting and cytomegalovirus (CMV) promoter interference, which reduce miRNA 
viral loads in lentiviral preparations, may have been the causative factor in our low viral 
titres (Liu et al., 2010b). The same publication suggested that the replacement of the CMV 
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promoter with an inducible promoter can restore the titre levels (Liu et al., 2010b); 
however, due to the lack of positive results from the pilot experiments and the success of 
the Sendai virus, this was not pursued.  
Direct transfection of microRNAs was repeated numerous times using a variety of different 
conditions and cell types. Despite this, no reprogrammed colonies and only small 
differences in cell morphology were observable with the fibroblast cells appearing to ‘ball 
up’, perhaps representative of the mesenchymal-to-epithelial transition associated with 
reprogramming (Sancho-Martinez and Belmonte, 2013), although this may also represent 
cytotoxicity.  
Following the successful reprogramming of BJ fibroblasts using the Sendai virus delivery 
method, we used these resulting cell lines to optimise the differentiation to hepatocyte-like 
cells, assessing numerous techniques and protocols. The plating density and growth factor 
combination used to derive the definitive endoderm cell population was assessed using the 
definitive endoderm marker, Sox17. The results suggested that it was the plating density 
which had the greatest effect on the resulting differentiation efficiency, with the highest 
cell density yielding the greatest number of Sox17+ve cells. The requirement for high cell 
numbers appears to be a consequence of single cell plating as confluences as low as 50% 
have been reported in the literature previously, when differentiation is initiated using 
colony-based protocols (Sullivan et al., 2010). This is perhaps indicative that high cell 
density and paracrine factors, as seen in colony-based cultures, are required to commence 
endodermal differentiation; however, a recent paper reported a plating density of 3-4x104 
cells/cm2 (Asplund et al., 2015). This work was performed using cells which were routinely 
cultured as a monolayer and using a single cell method for passaging; therefore, the change 
from colony-based to single cell plating may be detrimental to definitive endoderm 
efficiency.  
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Of interest, plating cells at the density reported by Kajiwara et al., (1x105cells/cm2) did not 
yield high definitive endoderm differentiation efficiency (Kajiwara et al., 2012); this may be 
due to differences in laboratory conditions or iPSC line variability as we followed the same 
plating methodology as reported in this paper. However, we did use a different stem cell 
media (Essential 8 as opposed to MEF-conditioned media) to convert our iPSCs to feeder 
free culture before differentiation. To improve batch-to-batch reproducibility, Essential 8 
media does not contain bovine serum albumin (BSA) (Chen et al., 2011); consequently, the 
differentiation capacity of the cells may be affected as removal of BSA also removes fatty 
acids and other molecules which are bound to the albumin and have as yet undefined roles 
in differentiation processes. In support of this hypothesis, subsequent to the work 
presented in this thesis being completed, Stem Cell Technologies have developed an 
additional pre-treatment media to use with their definitive endoderm differentiation kits 
(product code: 05115) for those using Essential 8-based culture systems. 
Furthermore, the areas towards the edge of the culture demonstrated the greatest 
differentiation efficiency, with the central regions proving to be refractory to 
differentiation. This may be partially explained by a recent report of spatial patterning 
which is evident within ESC colonies when cultured on micro-patterned plates, used to 
define colony size and shape (Warmflash et al., 2014). Within these colonies paracrine 
factors are thought to influence the differentiation propensity of the different areas of the 
colony, with those closest to the centre associated with ectodermal markers, encircled by a 
ring of mesodermal/primitive streak-like cells and then further encircled by SOX17+ve 
endodermal cells, following BMP4 induced differentiation (Warmflash et al., 2014). This 
patterning is remarkably similar to the results seen within the differentiation of cells 
seeded at 1.5x105 cells/cm2 with a clear enrichment of Sox17+ve cells towards the edge of 
the well. Subsequent work suggested using plating densities up to 2x105/cm2 reduces the 
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zonation of the culture and further increases the differentiation efficiency (data not 
shown).       
When cells were differentiated towards and hepatic phenotype, our results suggested that 
the Kajiwara and Sullivan protocols allowed for the differentiation of albumin producing 
cells, whereas the Chen protocol did not. Furthermore, Liv1R appeared refractive to HLC 
differentiation secreting little-to-no detectable albumin across the three protocols. This is 
in-keeping with the majority of literature which demonstrate line-to-line variation with 
regard to hepatocyte differentiation potential (Jiang et al., 2013). However, the Kajiwara 
protocol was able to induce small amounts of albumin secretion in Liv1R, whereas the 
Sullivan protocol did not; therefore, for the experiments described in chapter 4, we used an 
adapted version of the Sullivan protocol with a 7, rather than 5, day hepatic endoderm 
stage.  
The transition of the Sendai virus reprogramming conditions to PHH was successful, 
producing a single clone from 1x105 cells. At the time of the experiment, this was the first 
PHH-derived iPSC to be produced using a non-integrative method; however, Takayama et 
al., have since reported a similar technique with the Sendai virus (Takayama et al., 2014).  
During the design of the experiment, we compared the two published reports of PHH 
reprogramming. Whilst Hansel et al., repeated a very low reprogramming efficiency which 
was only achievable using the OSKM factors plus Lin28 and Nanog in relatively young 
donors (Hansel et al., 2014), Liu et al., reported a relatively high efficiency which was equal 
to, if not greater than, HDF reprogramming techniques (Liu et al., 2010a). As a 
consequence, we closely followed the Liu et al., protocol, particularly with regard to the 
media composition, which contained high levels of mitogenic factors hepatocyte growth 
factor (HGF) and epidermal growth factor (EGF). Our initial results suggest that PHH 
reprogramming occurs at a very low efficiency, which is in agreement with Hansel et al. The 
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discrepancy between the efficiencies is likely the result of multiple factors regarding the 
quality of hepatocytes, which can vary dramatically between donors (Bhogal et al., 2011). 
Another likely factor is the age of the patient. Hansel et al., reported that reprogramming 
was only achievable from very young donor hepatocytes; whereas the donor age of the Liu 
et al., paper is not reported. The donor used for this initial experiment was 66 years old at 
the time of surgery and therefore the low efficiency may be a consequence of donor age 
(Trokovic et al., 2015). This hypothesis was strengthened as we were subsequently able to 
generate clones from two further donors of different ages in slightly enhanced 
reprogramming conditions (i.e. higher plating density). Interestingly, by increasing the 
starting cell density five-fold, we were able to generate 5 fold clones from donor 2 (63 
years old), suggesting the reprogramming efficiency was directly proportional to the 
starting cell number. However, in the same enhanced conditions, 10 clones were derived 
from donor 3 (27 years old). These data point towards an enhancement of hepatocyte 
reprogramming efficiency in younger donors. Thus, it is possible that the protocols 
described may have allowed reprogramming of donor hepatocytes which would have been 
refractory in the conditions reported by Hansel et al.  
Furthermore, as primary human hepatocytes are highly sensitive following isolation and, to 
the best of our knowledge, lack any truly discriminative cell surface markers, they cannot 
be sorted effectively to enhance purity. Therefore, it is not possible to rule out the 
potential that the resulting iPSC has been derived from a different cell type from the PHH-
enriched population. The aforementioned study by Takayama et al., claimed to be able to 
demonstrate PHH as the source using short tandem repeat analysis (Takayama et al., 2014); 
however, whilst this confirms the cells are from the correct donor, it is unclear how they 
can distinguish between different cell types using this technique. 
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In summary, this chapter encapsulates the work done to establish the protocols required to 
undertake the isogenic comparison of PHH and HDF-derived iPSCs in the production of 
HLCs. This comparison is presented in chapter 4. 
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Chapter 4 
Isogenic comparison of hepatocyte-like cells differentiated 
from human primary hepatocyte- and dermal fibroblast-
derived induced pluripotent stem cells 
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Introduction 
Drug induced liver injury (DILI) remains incompletely understood. This is in part due to the 
lack of a predictive in vitro model to allow the identification of compounds which go on to 
cause DILI during clinical trials or post-marketing authorisation. The gold standard for 
investigating DILI remains primary human hepatocytes (PHH); however, PHH 
dedifferentiate rapidly in culture (investigated in chapter 5) and vary greatly between 
donors (Fraczek et al., 2013). Therefore, a metabolically relevant, reproducible and 
physiologically normal source of cells would be invaluable to the pharmaceutical industry 
and academia investigating DILI.  
The development of stem cells as a source of hepatocyte-like cells (HLCs) has been an area 
of intense research since the first differentiation protocols were described in 2004 by Lavon 
et al (Lavon et al., 2004). In the intervening years, incremental improvements have seen 
enhancements in both efficiency of differentiation and phenotype maturity. Despite these 
improvements, the hepatic phenotype still remains closer to a foetal rather than an adult 
phenotype (Kia et al., 2013). This has led to researchers to look elsewhere for 
improvements in the differentiation of stem cells towards HLCs.  
One potential area of interest has been to investigate the cell of origin. Previous work has 
shown that during the reprogramming process, the hypermethylation of the genes 
associated with the somatic cell phenotype occurs at a relatively late stage of induced 
pluripotency (Koche et al., 2011). Consequently, induced pluripotent stem cells (iPSCs) 
maintain a memory of the cell from which they were derived, which can influence the 
differentiation propensity of the cell towards the lineage of origin (Lister et al., 2014).  
This phenomenon, termed epigenetic memory, was first described in two separate studies 
in 2010 (Kim et al., 2010a; Polo et al., 2010). This was subsequently found to be true of 
Chapter 4 
107 
 
other cell types, such as pancreatic β cells, which demonstrated increased PDX1 and insulin 
gene expression in spontaneously differentiated iPSCs-derived from β cells when compared 
to non-β cell-derived iPSCs and ESCs (Bar-Nur et al., 2011).  
Epigenetic memory has also been investigated using hepatocytes (table 4.1); however, no 
study has provided definitive proof of whether the starting cell type significantly impacts 
upon the hepatic differentiation capacity of iPSCs. Genotype-controlled experiments in 
mice have shown a transient advantage in HLC gene expression of albumin and CK18 in 
hepatic-derived iPSCs compared to MEF-derived iPSCs (Lee et al., 2012). However, this 
advantage was greater when derived from hepatoblasts than hepatocytes and dissipated 
with time in culture. Liu et al., published the first human comparison in 2011, (Liu et al., 
2011), demonstrating no significant advantage in hepatic phenotype when PHH-derived 
iPSCs were compared to iPSCs derived from other cell types derived from different donors, 
as measured by albumin secretion, CYP3A activity assays; however, a similar but distinct 
global epigenetic profile was reported (Liu et al., 2011). More recently Takayama et al., 
corroborated the report from Lee et al., in human cells, demonstrating a small but 
significant advantage between hepatocytes and other cell types; however, the cells were 
sourced from different donors and the advantage was again found to dissipate with time in 
culture (Takayama et al., 2014). The importance of donor-dependent genetic differences 
were further highlighted by Kajiwara et al., who showed that donor differences were the 
largest determinant of hepatocyte-like cell quality, rather than the cell of origin, albeit 
without the investigation of PHH-derived iPSCs (Kajiwara et al., 2012). These donor-
dependent differences are likely to be driven by the transcriptional variation derived from 
the genetic background of the donor influencing differentiation propensity (Rouhani et al., 
2014).  
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Authors Species 
Starting cell 
types 
Assays used 
Improved 
phenotype? 
(Liu et al., 2011) Human 
Hepatocytes 
Fibroblasts 
Keratinocytes 
BM-MSCs  
Albumin secretion 
CYP3A4 activity 
Yes,  but non-
significant 
(Lee et al., 2012) Mouse 
Mouse ESCs 
Fibroblasts 
Hepatoblasts 
Hepatocytes 
Albumin secretion 
HLC gene expression 
Yes, but transient 
(Kajiwara et al., 
2012) 
Human 
PBMCs 
Fibroblasts 
Albumin/Urea secretion 
No, donor 
dependent 
(Takayama et al., 
2014) 
Human 
Hepatocytes 
Fibroblasts 
PBMCs 
HUVECs 
Albumin secretion 
CYP3A4 activity 
TAT expression 
Yes, but transient 
 
 
 
 
Therefore, investigation of epigenetic memory in hepatocyte-derived HLCs for the study of 
human iPSCs can only be truly assessed using a thorough comparison of human, genotype-
controlled iPSCs derived from hepatocytes and non-hepatocytes isolated from the same 
donor. Herein, using the protocols established in chapter 3, we describe the comparison of 
isogenic PHH- and dermal fibroblast derived iPSCs and the hepatic differentiation potential 
of these cells.  
Hypothesis: The use of primary human hepatocyte-derived iPSCs to generate hepatocyte-
like cells yields an improved maturity in hepatocyte-like cell maturity when compared to 
HDF-derived iPSCs from the same donor.    
  
Table 4.1: Summary of the previously published investigations of starting cell type for 
hepatocyte-like cell differentiation  
Abbreviations: PBMCs: Peripheral blood mononuclear cells; HUVECs: Human umbilical vein 
endothelial cells; BM-MSCs: Bone marrow mesenchymal stem cells; ESCs: embryonic stem 
cells 
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Results 
Generation of iPSCs derived from PHH and HDFs of multiple donors. 
In order to compare the hepatic differentiation capacity of iPSCs derived from different 
donors, we first needed to reprogram both PHH and HDFs. The reprogramming of human 
hepatocytes has been reported as relatively inefficient compared to more traditional cell 
types, such as fibroblasts (Hansel et al., 2014). Therefore, we first developed a protocol 
capable of reprogramming human hepatocytes (chapter 3). 
Using this protocol, we successfully generated iPSCs from hepatocyte cultures from three 
separate donors (table 4.2). Subsequent to successful PHH-reprograming, the dermal 
fibroblasts of the corresponding donors were also reprogrammed using a well-established 
dermal fibroblast protocol, the isolation and characterisation of these cells is described in 
R. Kia’s PhD thesis (Kia, 2014). Pictures of the PHH and HDFs derived from each donor and 
schematic diagrams of the techniques used for reprogramming are shown in Figure 4.1.  
Pluripotency was assessed using a panel of embryonic stem cell-enriched markers: Oct4, 
Sox2, Nanog, Tra-1-60 and SSEA-4 (Figure 4.2). All lines examined demonstrated expression 
of each of the markers, indicating that they had established a pluripotent phenotype.  
The functional differentiation capacity of these lines was also assessed using embryoid 
body (EB) assays. This assay allows the cells to differentiate without endogenous growth 
factors in the media and, if truly pluripotent, should result in differentiation towards cell 
types from all three germ layers: ectoderm, mesoderm and endoderm. Following EB 
culture, the presence of each of these germ layers within differentiated cell population was 
investigated by immunofluorescence, using the markers TUJ1 (Neuron-specific class III 
beta-tubulin; ectoderm), α-SMA (alpha smooth muscle actin; mesoderm) and AFP (Alpha-
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Fetoprotein; endoderm) (Figure 4.3). All of the iPSC lines generated stained successfully for 
the markers, indicating that every line was functionally pluripotent. 
  
 
DONOR 1 DONOR 2 DONOR 3 
Age at surgery 66 63 27 
    
BMI 27.9 31.2 32.1 
    
Sex Male Female Male 
    
Diagnosis Colorectal carcinoma  
with liver metastases 
Colorectal carcinoma  
with liver metastases 
focal nodular 
hyperplasia 
    
Co-morbidity 
Type II diabetes mellitus 
Hypertension 
Chronic liver disease 
Type II diabetes mellitus 
None 
No. of PHH-derived 
clones 
1 5 10 
    
Table 4.2: Details of the donors from which the cells used for reprogramming were derived, 
including key parameters such as age, co-morbidities and the number of iPSC clones derived from 
each donor PHH.  
Chapter 4 
111 
 
  
Figure 4.1: Isolation and reprogramming of somatic cells.  
a) The morphology of PHH and HDFs from each donor prior to reprogramming. PHH: Magnification: 
x100, scale bar: 100µm; HDFs: magnification x40, scale bar: 100µm. b) Schematic diagram of the 
protocols used to reprogram each cell type.  PHH: Primary human hepatocytes; HDFs: Human 
dermal fibroblasts; b-FGF: basic fibroblast growth factor 
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Figure 4.2: Generation and characterisation of each iPSC line confirmed by morphology and 
immunofluorescence.  
Morphology of selected lines from each donor and starting cell type is shown next to the 
immunofluorescence images of nuclear pluripotency markers Oct4, Sox2 and Nanog and surface markers 
Tra-1-60 and SSEA-4. Immunofluorescence images: x200 magnification, 50µm scale bar. Light microscopy 
images: x100 magnification, 100µm scale bar. For each line: F – derived from HDF; H-derived from PHH; 
4: donor 1; 6: Donor 2; 7: Donor 3.  
Abbreviations: Oct4: Octamer-binding transcription factor 4; Sox2: SRY (sex determining region Y)-box 2; 
Tra-1-60: Tumour-related antigen (TRA)-1-60; SSEA-4: Stage-specific embryonic antigen-4 
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Figure 4.3: Functional pluripotency characterisation using embryoid body assay confirmed by 
immunofluorescence.  
Embryoid bodies generated from each iPSC line and stained for markers of the three germ layers 
associated with pluripotency, selected lines from each donor and starting cell type presented: Endoderm 
(AFP), Mesoderm (α-SMA) and Ectoderm (Tuj1). Immunofluorescence images: x200 magnification, 50µm 
scale bar. Light microscopy images: x40 or x100 magnification, 100µm scale bar. . For each line: F – 
derived from HDF; H-derived from PHH; 4: donor 1; 6: Donor 2; 7: Donor 3.   
Abbreviations: AFP: Alpha-Fetoprotein; α-SMA: alpha smooth muscle actin; Tuj1: Neuron-specific class III 
beta-tubulin 
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Comparing PHH and HDF-derived iPSCs gene expression and methylation status 
To fully compare the iPSCs generated from PHH and HDFs, comparisons were required at 
all stages of culture and differentiation. Therefore, we first compared the expression of 
important pluripotency-associated genes for differences in expression. Across these 
markers, Oct4 and Nanog showed similar levels of expression between both cell types of 
origin. Sox2 expression was significantly greater in the PHH-derived lines for donor 3; 
however, this was not true of donors 1 and 2. Furthermore, analysis of Wnt3, which has 
been proposed as an iPSC marker of definitive endoderm potential (i.e. high Wnt3 
expression correlates with high purity D.E formation) (Jiang et al., 2013), again showed no 
significant differences between PHH and HDF-derived iPSCs.  
As the inherent memory of iPSCs is reported to be a consequence of incomplete epigenetic 
reprogramming, we then investigated the potential differences in methylation patterns 
between PHH and HDF-derived lines at the iPSC stage. We therefore compared the 
methylation status of key hepatic genes, HNF4α and FOXA2, which would likely influence 
the differentiation status of the HLCs should they be differentially methylated. During the 
process of reprogramming, the methylation status of HNF4α in PHH is significantly 
increased by 65.8%. A significant change in HNF4α methylation during reprogramming also 
occurs in HDFs, which increased from 82.6% in HDFs to 90.6% methylation in HDF-derived 
iPSCs. FOXA2 methylation was also seen to significantly increase between both starting cell 
types and iPSCs, albeit to a lesser degree.   
Our results suggested very little difference in methylation status between the PHH and 
HDF-derived lines. Across the five CpG sites examined within the HNF4α promoter region, 
each site was consistently ~1% less methylated in the PHH-derived lines when compared to 
the HDF-derived lines. Across all lines and CpG sites investigated a mean of 1.22% less 
methylation was observed in PHH-derived samples. No differences were noted between 
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the FOXA2 iPSCs derived from PHH and HDFs. The trend noted in the HNF4α analysis was 
found to dissipate with time in culture as direct comparison of early and late passage PHH-
derived lines showed increasing levels of methylation to become more comparable to the 
status of the HDF-derived lines, with a difference of 0.42% methylation between late 
passage PHH-derived and HDF-derived iPSCs. FOXA2 also shows an increase in methylation 
(1.22%) between early and late passage PHH-derived IPSCs.  
No noticeable difference in Line1 (Line 1: Long interspersed nuclear elements 
retrotransposable element 1) methylation, a sequence which is repeated throughout the 
genome and often used as a surrogate marker of whole genome methylation status, was 
observed across the early passage iPSCs (passage <10). In fact, Line1 methylation showed 
remarkable similarity between PHH- and HDF-derived clones, which had mean methylation 
statuses of 65.35% of 65.43%, respectively.  
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Figure 4.4: Comparison of iPSC gene expression by qRT-PCR.  
a) Nanog, Sox2 and Oct4 gene expression determined by qRT-PCR and presented as 2-ΔΔCT relative to 
ESC comparator and normalised with GAPDH. b)  Wnt3 gene expression determined by q-PCR and 
presented as 2-ΔΔCT relative to ESC comparator and normalised with GAPDH. Error bars represent 
standard deviation between the means of each PHH-/HDF-derived iPSC line which were derived from 
three individual differentiation cultures. Each sample tested by qRT-PCR was loaded in duplicate. (*) 
denotes p>0.05 unpaired T test. 
Abbreviations: Oct4: Octamer-binding transcription factor 4; Sox2: SRY (sex determining region Y)-box 
2; Wnt3: Wingless-Type MMTV Integration Site Family, Member 3 
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  Figure 4.5: Comparison of methylation status using pyrosequencing analysis of HNF4α and Line1 promoter 
regions. 
 a) The changes in methylation status of HNF4α and FOXA2 in PHH (48hrs culture) and HDFs pre- and post-
reprogramming; b) the difference in HNF4α methylation status of the PHH- and HDF-derived iPSCs across the 5 
CpG sites located in the analysed sequence; c) The methylation status of HNF4α and FOXA2 which occur 
following repeat passaging of the cells during standard culture procedures. d) The changes in methylation 
status of Line1 in PHH and HDFs pre- and post-reprogramming. (*) denotes p>0.05 One way ANOVA. Error bars 
represent standard deviation between the mean values of each line for iPSCs and between donors for PHH and 
HDFs  
Abbreviations: HNF4α: Hepatic nuclear factor 4 alpha: Line1: Line 1: Long interspersed nuclear elements 
retrotransposable element 1; FOXA2: Forkhead box protein A2 
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Spontaneous differentiation comparisons of PHH and HDF-derived iPSCs 
To investigate if the cell of origin influences the inherent differentiation propensity of 
iPSCs, the endoderm-enriched gene expression of embryoid bodies were compared (Figure 
4.3). Using a previously published method for comparing iPSCs of different origins (Bar-Nur 
et al., 2011), we generated EBs and cultured them in suspension for 16 days and then 
compared the gene expression of known endoderm and hepatic markers. 
Our results suggested a very slight trend towards the enhancement of hepatic-associated 
gene expression in PHH-derived EBs in five of the genes tested, i.e. Albumin, AFP, SOX17, 
FOXA2 and CXCR4. However, GATA4 and HNF4α showed a trend towards higher expression 
in the HDF-derived clones. Despite these trends, only Sox17 showed significantly greater 
expression in PHH-derived iPSCs, although this difference was only observed in one of the 
three donors. Taken together there was very little difference in the spontaneous 
differentiation propensity of PHH and HDF-derived iPSCs across the investigated hepatic 
and endodermal-associated genes. Indeed, the greatest determinant of gene expression 
appeared to be the donor, rather than the starting cell type. 
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Figure 4.6: Comparison of endoderm and hepatic associated gene expression in PHH- and HDF derived 
embryoid bodies using qRT-PCR.  
All genes shown as 2-ΔΔCT relative to a ESC-derived EB comparator and normalised to GAPDH and Succinate 
dehydrogenase. Error bars represent standard deviation between the means of each PHH-/HDF-derived iPSC 
line which were derived from three individual differentiation cultures. Each sample tested by qRT-PCR was 
loaded in duplicate. (*) denotes p>0.05 unpaired T test. 
Abbreviations: AFP: Alpha-Fetoprotein; SRY (Sex Determining Region Y)-Box 17; FOXA2: Forkhead Box A2; 
HNF4α: Hepatic nuclear factor 4 alpha: GATA4: GATA Binding Protein 4; CXCR4: Chemokine (C-X-C Motif) 
Receptor 4. 
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Comparison of gene expression during hepatocyte differentiation from PHH and HDF-
derived iPSCs    
The differentiation of iPSCs towards hepatocyte-like cells was achieved using the protocol 
established in chapter 3 (Figure 4.7a) and successful differentiation was confirmed by 
immunofluorescence at each stage: definitive endoderm (Sox17), hepatic endoderm 
(HNF4α) and HLCs (Albumin) (Figure 4.7b).   
To fully evaluate the differentiation procedure and to assess for any inherent advantage as 
a result of the different starting cell types, we compared the gene expression at each stage 
of differentiation. Figure 4.8 demonstrates a comparison of several key markers of 
definitive endoderm. The results followed a similar pattern to previous analysis, 
demonstrating no significant differences between starting cell types when the gene 
expression of FOXA2, SOX17, GATA4 or CXCR4 was compared. Interestingly, FOXA2, SOX17 
and CXCR4 showed a larger dependence on the donor of origin than starting cell type; 
whereas, GATA4 demonstrated greater consistency in expression between donors. 
Similar analysis was also undertaken for the hepatic endoderm stages, using markers AFP 
and HNF4α as stage-specific markers. Despite a trend towards enhanced levels of both 
markers in the PHH-derived iPSCs, only HNF4α in donor 2 demonstrated significantly 
enhanced gene expression in PHH-derived hepatic endoderm (p>0.05).  
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Figure 4.7: Differentiation of all lines to hepatocyte-like cells and confirmation by 
immunofluorescence.  
a) A schematic diagram of the protocol used for the differentiation experiments, including the growth 
factors/small molecules used at each stage of differentiation. b) Immunofluorescence analysis of iPSCs 
during each stage of differentiation: Definitive endoderm (Sox17), Hepatic endoderm (HNF4α) and 
hepatocyte-like cells/primary human hepatocytes (albumin). Immunofluorescence images: x200 
magnification, 50µm scale bar. Light microscopy images: x100 magnification, 100µm scale bar. 
Abbreviations: Wnt3a: Wingless-Type MMTV Integration Site Family, Member 3A; DMSO: Dimethyl 
sulfoxide; HGF: Hepatocyte growth factor; OSM: Oncostatin M; SRY (Sex Determining Region Y)-Box 17; 
HNF4α: Hepatic nuclear factor 4 alpha. 
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Figure 4.8: Comparison of definitive endoderm-associated gene expression measured by 
qRT-PCR.  
All genes shown as 2-ΔΔCT relative to a ESC-derived control and normalised using GAPDH and 
Succinate dehydrogenase gene expression. Error bars represent standard deviation between 
the means of each PHH-/HDF-derived iPSC line which were derived from three individual 
differentiation cultures. Each sample tested by qRT-PCR was loaded in duplicate. (*) denotes 
p>0.05 unpaired T test. 
Abbreviations: GATA4: GATA Binding Protein 4; SRY (Sex Determining Region Y)-Box 17; 
CXCR4: Chemokine (C-X-C Motif) Receptor 4; FOXA2: Forkhead Box A2 
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Figure 4.9: Comparison of hepatic endoderm-associated gene expression measured by qRT-PCR  
a) HNF4α and b) AFP shown as 2-ΔΔCT relative expressed relative to PHH of the same donor and 
normalised using GAPDH and Succinate dehydrogenase. Error bars represent standard deviation 
between the means of each PHH-/HDF-derived iPSC line which were derived from three individual 
differentiation cultures. Each sample tested by qRT-PCR was loaded in duplicate. (*) denotes 
p>0.05 unpaired T test. 
Abbreviations: AFP: Alpha-Fetoprotein; HNF4α: Hepatic nuclear factor 4 alpha. 
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Comparison of the phenotype of hepatocyte-like cell differentiated PHH and HDF-derived 
iPSCs    
To establish a full phenotypic comparison between the starting cell types, we used both 
gene expression and functional analysis-based assays.  
Fully-differentiated HLCs were compared using a panel of mature and immature hepatic 
markers. The gene expression of these markers demonstrated very little difference 
between the lines generated from different cell types. Despite this, there is a general trend 
towards an improved gene expression in five of the eight genes examined in the PHH-
derived clones for the majority of genes examined (figure S6). The enhanced expression of 
HNF4α, AFP and CYP2D6 in PHH-derived HLCs is conserved between donors; whereas, the 
other markers lack conformity, with the greater expression of the marker gene differing 
between PHH and HDF-derived HLCs across the assessed donors.  
Of particular interest, CYP3A is close to the levels of PHH; however, this is most likely due 
to the combined presence of the foetal CYP3A7 and CYP3A5, rather than the mature 
CYP3A4 isoform alone. The enhanced expression of HNF4α, AFP and CYP2D6 in PHH-
derived HLCs is conserved between donors; whereas, the other markers lack conformity, 
with the greater expression of the marker gene differing between PHH and HDF-derived 
HLCs across the assessed donors. 
We also assessed the albumin secretion function of the HLCs to establish a functional 
comparison between the lines. Figure 4.11a demonstrates the increasing albumin secretion 
seen during the 22 day differentiation period. When compared at day 22 (figure 4.11b), our 
results demonstrated a non-significant trend pointing towards PHH-derived clones having 
slightly higher, but non-significant, albumin secretion in two of the three donors. The first 
donor contained Liv4FA which had exceptionally high albumin gene expression and albumin 
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secretion.  When examined together, the difference between PHH- and HDF-derived iPSC 
HLCs albumin secretion is not significantly different; however, when Liv4FA is removed 
from the data analysis, the difference between PHH and HDF-derived HLCs does become 
significant (figure 4.11c).  
CYP3A and CYP2D6 activity was also assessed using probe substrates testosterone and 
dextromethorphan, respectively (Figure 5c and d). No significant differences were found 
between the HLCs derived from the different starting cell types. Interestingly, despite the 
slightly greater CYP3A gene expression found in PHH-derived HLCs, a trend of greater CYP 
activity in the HDF-derived clones was observed. As testosterone is a substrate for all 
CYP3A isoforms (3A4/3A5/3A7), gene expression was analysed using primers which target 
the same CYP3A isoforms; however, the isoforms have known differences in their capacity 
to metabolise testosterone (Williams et al., 2002), potentially explaining the disparity 
between the CYP3A gene expression and activity. 
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Figure 4.10: Comparison of hepatocyte-like cell-associated gene expression measured by qRT-
PCR.  
Gene expression of key hepatic genes obtained by q-PCR analysis and displayed as 2-ΔΔCT relative to 
PHH of the corresponding donor. Results normalised using GAPDH and Succinate dehydrogenase. 
Error bars represent standard deviation between the means of each PHH-/HDF-derived iPSC line 
which were derived from three individual differentiation cultures. Each sample tested by qRT-PCR 
was loaded in duplicate. (*) denotes p>0.05 unpaired T test. 
Abbreviations: AFP: Alpha-Fetoprotein; HNF4α: Hepatic nuclear factor 4 alpha; A1AT: Alpha-1 
Antitrypsin; CK18: Cytokeratin 18; CYP: Cytochrome P450  
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Figure 4.11: Albumin secretion of hepatocyte-like cells using ELISA 
 a) Albumin secretion during hepatocyte-like cell differentiation at each stage of differentiation and 
every 48 hours for the final stage of differentiation. b) Isogenic comparison of albumin secretion in 
PHH and PHH- and HDF-derived HLCs at the final stage of differentiation normalised using total 
protein content of corresponding well. * denotes p>0.001 one-way ANOVA. Error bars: SD. c) i) 
Comparison of PHH and HDF-derived HLCs from all three donors and ii) with Liv4FA omitted from the 
results *p>0.05 unpaired T test. 
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  Figure 4.12: CYP activity of PHH and HDF derived HLCs 
 a) and b) CYP activity as detected using LC-MS method analysing the turnover of probe 
substrates and quantification of metabolites for a) 6β-OH-testosterone (CYP3A) and b) 
Dextrorphan (CYP2D6). (*) denotes p>0.05 one-way ANOVA. Error bars: SD.  
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Discussion 
In this chapter we have investigated the benefit of starting with primary human 
hepatocytes when deriving iPSCs for hepatocyte-like cell differentiation, using HDFs derived 
from the same donor as the gold standard comparator. We have investigated the PHH- and 
HDF-derived iPSCs potential for hepatocyte differentiation in a multi-faceted panel of 
assays to give a thorough comparison of iPSC differentiation potential.  
Our main hypothesis, that the starting cell type may influence the differentiation capacity 
of the cell, was driven by the reported epigenetic memory which remains from the somatic 
cell following reprogramming (Kim et al., 2010a; Polo et al., 2010). Our results suggested a 
slight but non-significant epigenetic memory may be found in the HNF4α promoter region. 
Throughout the analysis, a general trend towards a slight, non-significant advantage, to 
starting with primary human hepatocytes, when compared to dermal fibroblasts, was 
noted. This was perhaps most evident with HNF4α expression at the hepatic endoderm 
stage of differentiation. Therefore, the slight trend of enhanced phenotype in PHH-derived 
iPSCs at the HLC stage may be caused by the reported small, but conserved differences in 
hepatic-associated genes methylation patterns. Our findings that the noted differences in 
HNF4α methylation dissipate with time in culture are in-keeping with previous literature, 
which has demonstrated that the distinct epigenetic patterns and enhanced phenotype in a 
given cell type-derived iPSC are lost following repeat passaging (Lee et al., 2012; Takayama 
et al., 2014; Kim et al., 2010a; Polo et al., 2010).  
The albumin secretion of the HLCs also showed a trend towards enhanced albumin 
secretion in PHH-derived clones. Despite this, when all lines were compared, no significant 
differences were seen between PHH- and HDF-derived lines. This was in part due to the 
HDF-derived line, Liv4FA, which displayed much greater albumin secretion and gene 
expression than all other lines. If Liv4FA is not included in the analysis, there is significantly 
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greater HLC albumin secretion in lines derived from PHH. This highlights the inherent inter-
clone variability derived from other undefined variables can be a greater influence of HLC 
phenotype than the starting cell type. It has long been established that individual clones 
have unique characteristics; however, recent studies have suggested that this is mainly due 
to donor variations (Kajiwara et al., 2012). Our results suggest that despite iPSCs being 
derived from the same donor, inter-clone variation is still prominent.  
With the exception of Liv4FA, the variation in albumin secretion appeared to be greatest 
between PHH-derived clones, with the HDF-derived clones being relatively consistent. One 
potential explanation for this may be the source of the cells.  The isolation of PHH is 
relatively well-established; however, the lack of a bona fide cell surface marker and the 
sensitivity of the cells during the isolation process mean that, to the best of our knowledge, 
a homogenous population of hepatocytes is not currently achievable. Previous work has 
shown that our isolation process achieves an enrichment of hepatocytes from the 60% of 
cells in the liver, to ~90% of cells isolated, as determined by albumin positive cells using 
flow cytometry (Kia, 2014). Therefore, there remains a possibility that not all of the iPSC 
clones derived from the PHH-enriched population were derived from hepatocytes, thus 
causing the variability seen between PHH-derived clones. However, if PHH-derived clones 
were to be used in future experiments, the inability to guarantee a homogenous starting 
population of hepatocytes will likely remain; therefore, this work is also representative of 
the practical limitations associated with PHH as a starting cell source.  
It must also be acknowledged that the slight enhancements seen in PHH-derived clones 
may well be limited by the restricted differentiation maturity which is currently achievable 
in simple HLC culture systems. Previous work in mice has shown that the greatest 
advantage in HLC differentiation was achieved reprogramming hepatoblasts, rather than 
adult hepatocytes (Lee et al., 2012). This may be a consequence of the relatively immature 
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phenotype of HLCs. Therefore, future investigations into the starting cell type would 
require the development of protocols which produce a more mature phenotype; however, 
this in itself remains a major bottleneck in the field of HLCs (Kia et al., 2013).  
As part of our analysis, we attempted to generate CYP activity data to further compare the 
functional capacity of the HLCs. Despite the results presented demonstrating an increase 
from iPSC to HLC, the detectable amounts of metabolites were close to the assays limit of 
detection in most cases. The assay used was based on a 15 minute exposure to each 
substrate, as developed using PHH to prevent metabolite saturation; however, this may be 
insufficient time for the HLCs to turnover more readily detectable levels of the respective 
metabolite. Other groups have used exposure times of between 1 and 48 hours for 
metabolism studies and this may allow for the generation of more reliable data (Szkolnicka 
et al., 2013; Asplund et al., 2015; Ulvestad et al., 2013; Siller et al., 2015). The comparable 
CYP3A gene expression in HLCs and PHH would suggest that our HLCs should have a more 
similar level of CYP3A activity in response the probe substrate testosterone, when 
compared to PHH. However, this is not the case and the discrepancy most likely arises 
through the differences in the isoforms present in both cell types and that CYP mRNA has 
not been adequately translated into functional protein (Schwanhausser et al., 2011). 
Further work is also required to investigate the isoforms which make up the CYP3A 
expression (i.e. CYP3A4, CYP3A5 and CYP3A7) and if these genes have been translated to 
protein.  
Taken together, the lack of any major advantage to PHH-derived iPSCs is of significance to 
the field of iPSC-derived HLCs, suggesting that any trend towards enhanced expression in 
PHH-derived clones is not greater than the inter-clone variation derived from other non-
defined influencing factors. Furthermore, the access and phenotypic range of available PHH 
samples is very restricted in comparison to the easily accessible skin or blood samples used 
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in the majority of current studies. Therefore, the similarity between the cell types in all 
tested parameters is reassuring for current and future studies, particularly those which 
require specific genotypic backgrounds, i.e. for disease studies, or a large phenotypic range 
for population-representative studies.  
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5.1 Introduction 
Primary human hepatocytes (PHH) are an important tool for studying human liver disease 
and drug-induced liver injury (DILI), with other models, such as rat hepatocytes, hepatic cell 
lines and stem cell-derived hepatocyte-like cells failing to offer metabolically-competent 
and species-relevant alternatives (Godoy et al., 2013). However, accessing and culturing 
PHHs remains difficult due to inconsistent supply and an inability to stimulate sufficient 
division for in vitro expansion. Furthermore, following isolation, primary human 
hepatocytes undergo a rapid dedifferentiation process in which many unique hepatocyte 
characteristics are lost, reducing the physiological relevance of the model (Fraczek et al., 
2013; Godoy et al., 2013).  
It is thought that dedifferentiation is caused by inflammatory and proliferative-associated 
responses to both PHH isolation and subsequent in vitro culture (Elaut et al., 2006; Fraczek 
et al., 2013; Godoy et al., 2009; Zellmer et al., 2010). Current models of dedifferentiation 
hypothesise that these responses result in the down-regulation of important liver-enriched 
transcription factors (LETFs) such as hepatic nuclear factors (HNFs) HNF1α and HNF4α 
which control many of the ADME processes (absorption, distribution, metabolism, and 
excretion) and other features unique to PHHs, resulting in a loss of hepatic phenotype 
(Godoy et al., 2009; Zellmer et al., 2010); however, the exact mechanisms which govern 
these changes remain incompletely understood.  
Several approaches have been adopted to maintain the hepatocyte phenotype in culture, 
including co-culture and 3D models such as sandwich cultures, bioreactors, liver buds and 
spheroids which attempt to better replicate the in vivo hepatic environment (Darnell et al., 
2012; No et al., 2012; Tostoes et al., 2012). In addition, a wide range of growth factors, 
cytokines and small molecules have also been used to target and maintain the hepatic 
phenotype, such as those shown recently by Shan et al (Shan et al., 2013). Many of these 
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strategies have been thoroughly reviewed by both Godoy et al and Fraczek et al (Fraczek et 
al., 2013; Godoy et al., 2013). 
Despite these continued improvements and advances towards complex culture conditions 
which can maintain an improved phenotype over a period of weeks, the full in vivo 
phenotype has not yet been achieved. Therefore, there remains a real need to improve the 
understanding of the underlying causes of this process, and to identify novel 
strategies/targets for intervention. Moreover, as complex models reduce the effects of 
dedifferentiation, analysis of these systems may result in the underlying causes being 
difficult to fully ascertain. Therefore, studies of more rudimentary models which result in 
more pronounced dedifferentiation may consequently provide a greater insight into the 
partially understood and currently unknown causes of dedifferentiation.  
Crucially, increased understanding of dedifferentiation is also likely to be useful in guiding 
attempts to direct and maintain a hepatic phenotype from pluripotent cells in vitro. Current 
efforts worldwide have not taken a cell beyond a relatively immature hepatocyte (chapters 
3 and 4) (Kia et al., 2013) and it can be hypothesised that an integral part of this challenge 
is how we can capture the hepatic phenotype and prevent its loss.  
Global studies offer an insight into how cells react in a holistic sense to a particular 
condition, and whilst efforts have been made to map changes in the hepatocyte 
transcriptome during dedifferentiation (Kim et al., 2010b; Lasher et al., 2011), many 
changes key to the mature phenotype of the hepatocyte are not properly represented in 
such analysis. This is exemplified by the recent results showing that only ~40% of the 
variation in cell protein levels can be explained by differences in the corresponding mRNA 
levels (Schwanhausser et al., 2011). We have previously shown that the use of a global 
proteomic approach to phenotype rat hepatocytes can provide novel information on 
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dedifferentiation (Rowe et al., 2010) and here look to build on that study using human 
cells.  
We have therefore now followed PHHs over the first 7 days of monolayer culture, chosen 
specifically to exacerbate the effects of dedifferentiation. Using iTRAQ-based stable isotope 
labelling and pathway analysis we have identified the key changes in the PHH proteome 
during dedifferentiation and the inter-donor variability which exists not only in donor 
phenotype, but also in the subsequent dedifferentiation profile.  
Hypothesis: Mechanistic evaluation of the primary human hepatocyte proteome during 
monolayer culture will yield novel information and hypotheses regarding the 
dedifferentiation and differentiation of hepatocytes. 
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5.2. Results 
Global proteomics reveals donor-dependent variation as a major influence on 
dedifferentiation 
iTRAQ quantitative global proteomic analysis was used to assess the changes which occur 
in PHH at different time points during a 168 hour monolayer culture. Dedifferentiation and 
loss of characteristic hepatocyte morphology were confirmed by microscopy. Figure 5.1a 
shows images of the cells taken at 24, 72 and 168 hours and clearly demonstrates the 
maintenance of confluency and the loss of the typical hepatocyte polygonal morphology 
(24 hours), towards a culture with flatter and less defined epithelial characteristics at 72 
and 168 hours.  
A total of 3430 unique proteins were detected across three iTRAQ runs, with 1117 
identified across all samples (raw data is provided with the electronic version of the thesis). 
Statistical analysis using a linear model yielded significantly differentially-expressed 
proteins (DEPs) at each time point relative to freshly isolated cells. These changes highlight 
a dynamic and escalating process; 40 DEPs are seen after 24 hours, 118 after 72 hours and 
272 after 168 hours in culture (P <0.05). When displayed as volcano plots (log fold-change 
versus P value), the increasing dispersion and direction of change of the proteins over time 
in culture is strikingly evident (Figure 5.1b); interestingly, at both 24 and 72 hours of culture 
the majority of DEPs increased in expression. Despite the large number of changes 
detected within our analysis, not all functions were affected over the culture period. Figure 
5.1c demonstrates the relative stability of albumin secretion over the 168 hour culture 
period.  
Hierarchical clustering of the entire dataset shows that the dominant factor in determining 
how the samples are related is in fact the original source of the cells, rather than time in 
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culture (Figure 5.2a). This is particularly pronounced at the 24 and 72 hour time points, 
which cluster according to donor in every case. The separation from the other donors is still 
evident at 168 hours for donors 2 and 5, although these samples cluster away from the 
earlier time points; whereas, by this time the other three donors (1, 3 and 4) cluster 
together, demonstrating a convergence towards a dedifferentiated phenotype which is 
more reflective of time in culture than the cell source.  
Thus, these data suggest that phenotypic characteristics of the donor have a greater impact 
on the protein dedifferentiating expression profile of the hepatocytes than does the length 
of time in culture, particularly over the first 72 hours of culture. The variability between 
donor proteomic profiles during dedifferentiation is further shown by the heatmap in 
Figure 5.2b.  
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Donors Gender Age Reason for 
surgery 
Underlying 
diseases 
Medication iTRAQ run No. of proteins 
detected 
Donor 1 M 67 
Colorectal liver 
metastases 
Hypertension 
Asthma 
Hypercholesterolemia 
Gout 
Omeprazole 
Atorvastatin 
Tramadol 
Allopurinol 
Amlodipine 
Lisinopril 1 2439 
Donor 2 M 74 
Colorectal liver 
metastasis 
Deep venous 
thrombosis 
Benign prostatic 
hyperplasia 
Citirizine 
Finasteride 
Terazosin 
Paracetamol 
Donor 3 F 61 Cholangiocarcinoma Severe pancreatitis 
Diclofenac 
Paracetamol 
Omeprazole 2 2944 
Donor 4 M 58 
Primary 
hepatocarcinoma 
Hypertension 
Atenadol 
Allopurinol 
Donor 5 M 66 
Colorectal liver 
metastases 
Diabetes 
Meiformin 
Glicazide 
Simvastatin 
3 2347 
Table 5.1:  iTRAQ proteomic analysis.  
Details of the donors analysed in each iTRAQ run and the number of proteins detected in each separate analysis. 
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Figure 5.1: Changes in PHH morphology, proteome and function during culture 
a) Morphological changes in primary human hepatocytes over 168 hours in monolayer collagen I-
coated plate culture. Magnification: x200, scale bar represents 10µm; b) Volcano plot analysis of 
the iTRAQ detected proteins log fold change vs p-value at 24, 72 and 168 hours. Blue: significantly 
altered proteins (n=5; p≤0.05) and red: significantly altered after multiple testing correction (n=5; 
Benjamini-Hochberg ≤0.2) c) Albumin secretion during culture measured by albumin ELISA (n=4; 
errors bars: SD).   
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Figure 5.2: Hierarchical clustering and heatmap analysis of the proteomic data 
a) Hierarchal clustering analysis showing the relationship between donors and timepoints (n=5); b) 
Heatmap of each donor’s proteome during dedifferentiation relative to the freshly isolated sample. Red 
indicates down-regulation, yellow up-regulation. The intensity of colour reflects the degree of change.   
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Analysis of the dedifferentiation proteome reveals the most variable and the most stable 
proteins between donors and timepoints 
To identify the proteins with the greatest variability across the 5 donors at the different 
time points, co-efficient of variance (CV) analysis was then used (Table 5.1). This criterion 
highlights a number of proteins, including CYP2C9, which is known to vary in expression 
between individuals (Sistonen et al., 2009), and glutamine synthetase, which is associated 
with differential expression according to liver zonation (Jungermann and Kietzmann, 1996). 
In fact, zonation appears to be a large influencing factor on variation during culture as our 
pathway analysis of the most variable proteins revealed significant association with 
ketogenesis, cholesterol biosynthesis, fatty acid β oxidation and glutamine synthesis (Table 
5.2), all of these are related to the porto-central axis gradient of the lobule (Godoy et al., 
2013). 
The most stable proteins during dedifferentiation were also investigated (Table 5.3). These 
included several mitochondrial proteins within the ten most stable proteins. Thus, while 
many proteins show conserved differential expression or high levels of inter-donor 
variability, a subset of proteins remain relatively stable and consequently may retain in 
vivo-like functionality and also serve as useful normalisers for protein expression changes. 
This is particularly pertinent for hepatocyte dedifferentiation as β-actin increases in 
expression during culture (demonstrated later in the chapter, figure 5.12b).  
The proteins with the greatest up- or down-regulation at each timepoint demonstrate a 
similarity in expression to hepatocyte-like cells derived from stem cells.  
Table 5.5 highlights the most up and down-regulated DEPs at each time point, as assessed 
by log2 fold change relative to the fresh sample. Interestingly, the first noticeable effects at 
24 hours are an increase in stress-related mediator superoxide dismutase and a decrease in 
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histone proteins. Of note, hepatic-associated proteins are not universally down-regulated, 
as exemplified by alpha-1-antitrypsin and cytokeratins 8 and 18, which are up-regulated 
throughout the analysis. Interestingly, these proteins are readily detectable in hepatocyte-
like cells derived from stem cells (Rambhatla et al., 2003), whereas many of the down-
regulated proteins are not, demonstrating that simple in vitro culture systems may support 
similar expression patterns during both hepatic dedifferentiation and differentiation. 
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Uniprot 
Accession 
Number 
Name Co-efficient of variance 
24 hours 72 hours 168 hours 
P0DJI9 Serum amyloid A-2 protein 2.083909 2.078728 2.073038 
Q9NUJ1 Mycophenolic acid acyl-glucuronide esterase, mitochondrial 1.707109 1.882177 1.986591 
Q969Z3 MOSC domain-containing protein 2, mitochondrial 1.693348 1.414446 1.810794 
P15374 Ubiquitin carboxyl-terminal hydrolase isozyme L3 1.817535 1.672397 1.692353 
P26599 Polypyrimidine tract-binding protein 1 1.603233 1.62981 1.683913 
O15260 Surfeit locus protein 4 1.570576 1.70747 1.643518 
O14756 17-beta-hydroxysteroid dehydrogenase type 6 1.087739 1.350166 1.635544 
P25398 40S ribosomal protein S12 1.647474 1.709673 1.605359 
P01011 Alpha-1-antichymotrypsin 0.69682 0.419842 1.58037 
P11712 Cytochrome P450 2C9 1.199075 1.424764 1.573942 
Q96EK6 Glucosamine 6-phosphate N-acetyltransferase 1.737418 1.608963 1.542857 
Q99714 3-hydroxyacyl-CoA dehydrogenase type-2 1.296856 1.47145 1.539702 
Q96IJ6 Mannose-1-phosphate guanyltransferase alpha 1.667729 1.352937 1.514543 
Q6YN16 Hydroxysteroid dehydrogenase-like protein 2 1.467704 1.601775 1.504808 
P24752 Acetyl-CoA acetyltransferase, mitochondrial 1.136518 1.483382 1.503606 
Q16134 
Electron transfer flavoprotein-ubiquinone oxidoreductase, 
mitochondrial 1.079149 1.394389 1.491195 
P35914 Hydroxymethylglutaryl-CoA lyase, mitochondrial 1.127576 1.404124 1.4818 
O43708 Maleylacetoacetate isomerase 1.402363 1.518733 1.47866 
Q16222 UDP-N-acetylhexosamine pyrophosphorylase 1.577758 1.634465 1.468517 
O75643 U5 small nuclear ribonucleoprotein 200 kDa helicase 1.442048 1.330621 1.440199 
Q08AH3 Acyl-coenzyme A synthetase ACSM2A, mitochondrial 1.079716 1.288258 1.392047 
P15104 Glutamine synthetase 0.346635 1.048488 1.385288 
Q14558 Phosphoribosyl pyrophosphate synthase-associated protein 1 1.170621 1.090732 1.381804 
O75521 Enoyl-CoA delta isomerase 2, mitochondrial 1.328238 1.486261 1.379483 
Q15366 Poly(rC)-binding protein 2 1.700238 1.408374 1.375921 
Q9BRX8 Redox-regulatory protein FAM213A 1.179568 1.360546 1.370182 
P78329 Leukotriene-B(4) omega-hydroxylase 1 1.35427 1.396285 1.368089 
Q04446 1,4-alpha-glucan-branching enzyme 1.147705 1.039434 1.361002 
P62330 ADP-ribosylation factor 6 1.469331 1.574059 1.33387 
Q93088 Betaine--homocysteine S-methyltransferase 1 0.849564 0.876841 1.323588 
Q02338 D-beta-hydroxybutyrate dehydrogenase, mitochondrial 1.376122 1.416189 1.319087 
Q68CK6 Acyl-coenzyme A synthetase ACSM2B, mitochondrial 1.385784 1.368136 1.317599 
Q99624 Sodium-coupled neutral amino acid transporter 3 1.357665 1.157176 1.315244 
Q9BWD1 Acetyl-CoA acetyltransferase, cytosolic 1.57992 1.445088 1.291763 
P30084 Enoyl-CoA hydratase, mitochondrial 0.997547 0.988534 1.291622 
Q92820 Gamma-glutamyl hydrolase 1.219966 1.4691 1.278405 
P05141 ADP/ATP translocase 2 1.200215 1.420541 1.260025 
P02042 Hemoglobin subunit delta 1.419209 1.129662 1.243176 
Q02978 Mitochondrial 2-oxoglutarate/malate carrier protein 1.109218 1.354909 1.214753 
P18085 ADP-ribosylation factor 4 1.505917 1.29611 1.204037 
Q3LXA3 
Bifunctional ATP-dependent dihydroxyacetone kinase/FAD-AMP lyase 
(cyclizing) 1.404937 1.220907 1.196514 
Q6NVY1 3-hydroxyisobutyryl-CoA hydrolase, mitochondrial 1.384332 1.649482 1.183856 
O95394 Phosphoacetylglucosamine mutase 1.371555 1.306498 1.16418 
P09417 Dihydropteridine reductase 1.479465 1.19829 1.159391 
P37837 Transaldolase 1.519568 1.516419 1.147909 
Q96LJ7 Dehydrogenase/reductase SDR family member 1 1.382342 1.468168 1.146213 
P16219 Short-chain specific acyl-CoA dehydrogenase, mitochondrial 1.453542 1.142062 1.113124 
P07339 Cathepsin D 1.300016 1.508745 1.084154 
P07437 Tubulin beta chain 1.613412 1.035572 0.978595 
P11766 Alcohol dehydrogenase class-3 1.322958 1.114523 0.916866 
P02753 Retinol-binding protein 4 1.079394 1.343397 0.846919 
Q8TC12 Retinol dehydrogenase 11 1.451007 0.867983 0.843923 
Q13885 Tubulin beta-2A chain 1.545352 1.057663 0.821749 
Table 5.2: The most variable proteins during PHH dedifferentiation.  
Co-efficient of variance analysis used to assess the variability between proteins. Those with a CV>1.3 
at any timepoint are listed with their corresponding CV values at each timepoint.  
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Canonical Pathways  -log(p-value) 
Ketogenesis 8.15 
Isoleucine Degradation I 7.48 
UDP-N-acetyl-D-glucosamine Biosynthesis II 6.54 
Ketolysis 5.92 
UDP-N-acetyl-D-galactosamine Biosynthesis II 5.92 
Glutaryl-CoA Degradation 5.5 
Tryptophan Degradation III (Eukaryotic) 4.73 
Fatty Acid β-oxidation I 4.21 
Mevalonate Pathway I 3.33 
Remodeling of Epithelial Adherens Junctions 3.19 
Superpathway of Geranylgeranyldiphosphate Biosynthesis I (via Mevalonate) 3.09 
Valine Degradation I 3.04 
Superpathway of Cholesterol Biosynthesis 2.66 
Glutathione-mediated Detoxification 2.63 
Glutamine Biosynthesis I 2.6 
Glutamate Removal from Folates 2.6 
Ethanol Degradation II 2.52 
Noradrenaline and Adrenaline Degradation 2.47 
Estrogen Biosynthesis 2.4 
Formaldehyde Oxidation II (Glutathione-dependent) 2.3 
  
Table 5.3: Pathway analysis of the most variable proteins during dedifferentiation.  
The canonical pathways (p<0.05, Fisher exact T-test) significantly associated the most variable proteins 
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Uniprot Accession Number Name 
O75600 2-amino-3-ketobutyrate coenzyme A ligase, mitochondrial 
P31327 Carbamoyl-phosphate synthase [ammonia], mitochondrial 
Q5SRE7 Phytanoyl-CoA dioxygenase domain-containing protein 1 
O95202 LETM1 and EF-hand domain-containing protein 1, mitochondrial 
O14818 Proteasome subunit alpha type-7 
P35606 Coatomer subunit beta' 
Q16531 DNA damage-binding protein 1 
Q07954 Prolow-density lipoprotein receptor-related protein 1 
P55735 Protein SEC13 homolog 
O96008 Mitochondrial import receptor subunit TOM40 homolog 
P62249 40S ribosomal protein S16 
P56556 NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 6 
P62847 40S ribosomal protein S24 
P30533 Alpha-2-macroglobulin receptor-associated protein 
Q13586 Stromal interaction molecule 1 
Q13131 5'-AMP-activated protein kinase catalytic subunit alpha-1 
Q8NC51 Plasminogen activator inhibitor 1 RNA-binding protein 
Q8NI60 Chaperone activity of bc1 complex-like, mitochondrial 
Q16706 Alpha-mannosidase 2 
O75131 Copine-3 
Q86UE4 Protein LYRIC 
Q9H0R4 Haloacid dehalogenase-like hydrolase domain-containing protein 2 
A1L0T0 Acetolactate synthase-like protein 
Q9H0E2 Toll-interacting protein 
P35637 RNA-binding protein FUS 
P51580 Thiopurine S-methyltransferase 
Q96HS1 Serine/threonine-protein phosphatase PGAM5, mitochondrial 
P10155 60 kDa SS-A/Ro ribonucleoprotein 
O95340 Bifunctional 3'-phosphoadenosine 5'-phosphosulfate synthase 2 
Q9Y6B6 GTP-binding protein SAR1b 
O14841 5-oxoprolinase 
P23246 Splicing factor, proline- and glutamine-rich 
O95486 Protein transport protein Sec24A 
O75531 Barrier-to-autointegration factor 
Q969X5 Endoplasmic reticulum-Golgi intermediate compartment protein 1 
Q9Y2T3 Guanine deaminase 
O43390 Heterogeneous nuclear ribonucleoprotein R 
P14868 Aspartate--tRNA ligase, cytoplasmic 
P62753 40S ribosomal protein S6 
Table 5.4: The most stable proteins during PHH dedifferentiation.  
Proteins which had a co-efficient of variance of <0.3 and a mean relative fold change >0.8 and <1.2 
throughout the analysis were described as stable. 
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24 hours 72 hours 168 hours 
Up-regulated Down-regulated Up-regulated Down-regulated Up-regulated Down-regulated 
Uniprot 
Accession 
Number 
Name 
Log2 
fold 
change 
Uniprot 
Accession 
Number 
Name 
Log2 
fold 
change 
Uniprot 
Accession 
Number 
Name 
Log2 
fold 
change 
Uniprot 
Accession 
Number 
Name 
Log2 
fold 
change 
Uniprot 
Accession 
Number 
Name 
Log2 
fold 
change 
Uniprot 
Accession 
Number 
Name 
Log2 
fold 
change 
P01011 Alpha-1-
antichymotryp
sin 
3.293 P62805 Histone H4 -1.809 P04179 Superoxide 
dismutase [Mn], 
mitochondrial 
3.54 Q71DI3 Histone H3.2 -2.914 P07355 Annexin A2 4.377 P11509 Cytochrome 
P450 2A6 
-3.628 
P01009 Alpha-1-
antitrypsin 
2.947 Q71DI3 Histone H3.2 -1.689 P01011 Alpha-1-
antichymotrypsin 
3.383 O14832 Phytanoyl-CoA 
dioxygenase, 
peroxisomal 
-2.465 P04179 Superoxide 
dismutase 
[Mn], 
mitochondrial 
4.249 P10632 Cytochrome 
P450 2C8 
-3.616 
P02679 Fibrinogen 
gamma chain 
2.432 P10412 Histone H1.4 -1.395 P10909 Clusterin 3.367 P62805 Histone H4 -2.27 P10909 Clusterin 4.204 Q02928 Cytochrome 
P450 4A11 
-3.551 
P04179 Superoxide 
dismutase 
[Mn], 
mitochondrial 
2.307 P36957 Dihydrolipoyllysine-
residue 
succinyltransferase 
component of 2-
oxoglutarate 
dehydrogenase 
complex, 
mitochondrial 
-1.140 P43490 Nicotinamide 
phosphoribosyltra
nsferase 
3.24 P11509 Cytochrome 
P450 2A6 
-2.248 P37802 Transgelin-2 3.699 P11168 Solute carrier 
family 2, 
facilitated 
glucose 
transporter 
member 2 
-3.528 
P43490 Nicotinamide 
phosphoribosyl
transferase 
2.283 Q96CM8 Acyl-CoA synthetase 
family member 2, 
mitochondrial 
-1.001 P07355 Annexin A2 3.046 P10412 Histone H1.4 -2.204 P35579 Myosin-9 3.439 P54868 Hydroxymethy
lglutaryl-CoA 
synthase, 
mitochondrial 
-3.159 
P02671 Fibrinogen 
alpha chain 
2.115 P11509 Cytochrome P450 
2A6 
-0.959 P01009 Alpha-1-
antitrypsin 
2.654 P11168 Solute carrier 
family 2, 
facilitated 
glucose 
transporter 
member 2 
-2.137 P60903 Protein S100-
A10 
3.412 P31513 Dimethylanilin
e 
monooxygenas
e [N-oxide-
forming] 3 
-3.088 
P02763 Alpha-1-acid 
glycoprotein 1 
2.086 P05386 60S acidic ribosomal 
protein P1 
-0.866 P37802 Transgelin-2 2.583 P05177 Cytochrome 
P450 1A2 
-2.076 P43490 Nicotinamide 
phosphoribosyl
transferase 
3.407 P07099 Epoxide 
hydrolase 1 
-2.955 
P02675 Fibrinogen 
beta chain 
2.054 P46777 60S ribosomal 
protein L5 
-0.845 P26038 Moesin 2.431 P22307 Non-specific 
lipid-transfer 
protein 
-1.851 P26038 Moesin 3.370 P45954 Short/branche
d chain specific 
acyl-CoA 
dehydrogenas
e, 
mitochondrial 
-2.911 
P08107 Heat shock 70 
kDa protein 
1A/1B 
2.028 P14920 D-amino-acid 
oxidase 
-0.776 P02679 Fibrinogen gamma 
chain 
2.243 O43772 Mitochondrial 
carnitine/acylc
arnitine carrier 
protein 
-1.760 P21333 Filamin-A 3.314 P49326 Dimethylanilin
e 
monooxygenas
e [N-oxide-
forming] 5 
-2.880 
P07602 Proactivator 
polypeptide 
1.653 P62750 60S ribosomal 
protein L23a 
-0.625 P35579 Myosin-9 2.23 P08684 Cytochrome 
P450 3A4 
-1.724 P09493 Tropomyosin 
alpha-1 chain 
3.194 P04040 Catalase -2.879 
Table 5.5: The most differentially expressed proteins during PHH dedifferentiation. 
The 10 most up and down-regulated proteins by log2 fold change at each timepoint 24, 72 and 168 hours relative to freshly isolated PHH. 
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Pathway analysis reveals the key changes and dynamic profile of dedifferentiation  
Pathway enrichment analysis was used to identify the affected functions and pathways 
which underlie dedifferentiation.  
Heatmap analysis of the biological functions at the three post-isolation time points (Figure 
5.3) revealed the differential dynamics of the pathway groups. Many of the pathways 
follow a linear pattern of increasing activation or inhibition; however some, such as the cell 
survival pathways, display different dynamics, as they are predicted to be activated at 72 
hours, but not at 24 or 168 hours. Figure 5.4 displays the canonical pathways at the 
assessed time points. Whilst metabolic pathways display a trend of increasing significance 
during culture, acute phase response signalling and ROS/NOS production are significantly 
affected at 24 hours, but not at 168 hours.  
Upstream regulation analysis (i.e. transcription factors, cytokines, growth factors and 
receptors) was then used to predict which regulators were activated or inhibited (Figure 
5.5). The results suggest an activation of proliferative and inflammatory regulators and 
inhibition of metabolic-associated factors. Moreover, many energy production-associated 
factors are down-regulated at 168 hours including PPARα, insulin receptor, KLF15 and the 
mitochondrial transcription factor TFAM. A list of the most significantly perturbed 
pathways and functions at the three time points is shown in Table 5.6. 
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Figure 5.3: Biological functions associated with the dedifferentiation by pathway 
analysis  
Pathway analysis of DEPs. If score 2 ≥ Z-score ≤ -2 the function is predicted to be 
activated or inhibited, respectively. Red: up-regulated, green: down-regulated. 
Intensity of colour correlates with greater Z-activation score.  
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Figure 5.4: Canonical pathways perturbed during dedifferentiation. 
Results displayed as –Log (P values), pathway included if p<0.05 at any of the assessed timepoints. Colour 
Intensity corresponds to the significance value 
Abbreviations: RXR: retinoid X receptor; PPAR: peroxisome proliferator-activated receptors; FXR: farnesoid X 
receptor Nrf2: nuclear factor (erythroid-derived 2)-like 2; HIF-1: hypoxia-inducible factor; FAK: focal adhesion 
kinase; LPS: lipopolysaccharide; interleukin-1; LXR: liver X receptor; VEGF: vascular endothelial growth factor. 
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Figure 5.5: Upstream regulation analysis of PHH during dedifferentiation. 
Upstream regulators predicted to be either activated or inhibited by Z activation score (2 ≥ Z-score ≤ -
2). Red: activated, green: inhibited, in order of significance.   
 
Abbreviations: MAPKs: mitogen-activated protein kinases; NFκB: nuclear factor kappa-light-chain-enhancer of 
activated B cells; IL: Interleukin; IFN: Interferon; OSM: Oncostatin M; EGF: Epidermal growth factor; INSR: Insulin 
receptor; IGF-1R: Insulin growth factor receptor 1; HSF2; Heat shock factor protein 2; PPAR: Peroxisome 
proliferator-activated receptor; ERK: Extracellular signal-regulated kinase; HNF: Hepatic nuclear factor; TGF-β: 
Transforming growth factor β; TNF: Tumour necrosis factor; VEGF: Vascular endothelial growth factor; PRL: 
Prolactin; NFκBIA: NFκB inhibitor; PXR: Pregnane X receptor; RXR: Retinoid X receptor; NRIP1: Nuclear receptor-
interacting protein 1; HIF1α: Hypoxia-inducible factor 1-alpha; SRF: Serum response factor; NR2F1: nuclear 
receptor subfamily 2, group F, member 1; MKL2: MKL/Myocardin-Like 2; PCK1: Phosphoenolpyruvate 
carboxykinase 1; GNA12: Guanine nucleotide binding protein (G protein) alpha 12; SMARCB1: WI/SNF-related 
matrix-associated actin-dependent regulator of chromatin subfamily B member 1; TFAM: Mitochondrial 
transcription factor A; KLF15: Krüppel-like factor 15; CFTR: Cystic fibrosis transmembrane conductance 
regulator; MAFB: V-maf musculoaponeurotic fibrosarcoma oncogene homolog B; SCAP: Sterol regulatory 
element-binding protein cleavage-activating protein; CD: Cluster of differentiation; F2: Coagulation factor II 
(thrombin) 
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24 hours  72 hours  168 hours 
Cellular and molecular pathways 
    
• Cellular Movement  
• Cell-To-Cell Signalling and Interaction  
• Cellular Growth and Proliferation  
• Cellular Development  
• Cellular Assembly and Organization  
•  • Cell Death and Survival  
• Cellular Movement  
• Cellular Assembly and Organization  
• Cellular Function and Maintenance  
• Cell Morphology  
 • Energy Production  
• Lipid Metabolism  
• Small Molecule Biochemistry  
• Cellular Function and Maintenance  
• Cell Morphology   
 
Toxicity pathways 
    
• Positive Acute Phase Response Proteins 
• LXR/RXR Activation 
•  • Positive Acute Phase Response Proteins 
• NRF2-mediated Oxidative Stress Response  
• CYP450 Panel - Substrate is a Xenobiotic (Human)  
• Aryl Hydrocarbon Receptor Signaling  
• Hypoxia-Inducible Factor Signalling 
 • NRF2 oxidative stress response 
• Fatty acid metabolism 
• LPS/IL-1 mediated inhibition of RXR function 
• Xenobiotic metabolism signalling 
• Positive acute phase response proteins 
• CYP450 panel – substrate is Xenobiotic (Human) 
Networks 
    
• Developmental Disorder, Hematological Disease, 
Hereditary Disorder 
• Lipid Metabolism, Small Molecule Biochemistry, 
Molecular Transport 
• Cellular Assembly and Organization, Amino Acid 
Metabolism, Small Molecule Biochemistry 
•  • Post-Translational Modification, Protein Folding, 
Drug Metabolism 
• Cellular Assembly and Organization, Cellular Function 
and Maintenance, Cell Morphology 
• Protein Synthesis, Cell Death and Survival, Cellular 
Assembly and Organization 
• Drug Metabolism, Developmental Disorder, 
Hematological Disease 
• Nucleic Acid Metabolism, Small Molecule 
Biochemistry, Drug Metabolism 
 • Cell Death and Survival, Neurological Disease, Cancer  
• Small Molecule Biochemistry, Drug Metabolism, 
Nucleic Acid Metabolism 
• Lipid Metabolism, Molecular Transport, Small 
Molecule Biochemistry 
• Lipid Metabolism, Small Molecule Biochemistry, 
Vitamin and Mineral Metabolism 
• Cellular Assembly and Organization, Cell 
Morphology, Cellular Function and Maintenance 
Table 5.6: Pathway/network analysis.  
Top 5 most significantly altered (p<0.05; Fisher exact T test) cellular and molecular functions, canonical pathways, toxicity functions and networks 
associated with the DEPs at 24, 72 and 168 hours by Ingenuity pathway analysis. 
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Analysis of mitochondrial functional profile reveals donor-variation in the bio-energetic 
profile  
Pathway analysis predicted a perturbation of energy production and mitochondrial 
mechanics; therefore, we investigated the mitochondrial proteome in further detail. The 
expression of proteins with known mitochondrial associations demonstrated a general 
downward trend of the DEPs (bold) with time in culture, particularly at 168 hours, with 
superoxide dismutase II being a notable exception (Figure 5.6). However, a number of key 
mitochondrial proteins, such as mitochondrial import receptor subunits, remained largely 
unchanged (Table 5.4). This indicates that the large-scale down-regulation of mitochondrial 
proteins represents an alteration in function between freshly isolated cells and 168 hours 
rather than a generalised loss of mitochondrial mass between these time points.  
Pathway analysis was then used to assess the mitochondrial proteomic dataset DEPs. This 
analysis revealed predicted roles for 5' AMP-activated protein kinase (AMPK) signalling, a 
master regulator of energy metabolism, which increases in significance during time in 
culture (Figure 5.7a). Furthermore, a negative regulator of mitochondrial fusion, OMA-1 is 
also predicted to be down-regulated (Figure 5.7b). 
To assess how these changes impacted mitochondrial function, oxygen consumption rate 
(OCR) and extracellular acidification rate (ECAR) at 24 and 168 hours were investigated. 
Across 5 donors, a clear variation in individual bioenergetic OCR profiles is observed at 24 
hours (Figure 5.8a), with the 168 hour profile showing greater dependence on the 24 hour 
profile, rather than time in culture. Analysis of glycolytic consumption, as measured by 
ECAR, shows much greater donor-dependent variation (Figure 5.8b), which may be 
attributable to the known gradient of glycolysis across the porto-central axis, and is 
consistent with our findings regarding the most variable proteins. Despite this variation, a 
trend emerges: basal glycolysis shows an increase during culture in donors with lower basal 
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glycolysis, whereas those with higher basal levels at 24 hours decrease; suggestive of a 
convergence towards a culture-dependent level of basal glycolysis. 
Furthermore, many of the tested OCR parameters remain remarkably stable between 24 
and 168 hours (Figure 5.8c), despite the large-scale changes to the mitochondrial 
proteome. ECAR measurements showed similar stability; however, there was a general 
trend of increased glycolytic parameters, including the only significantly altered factor, 
namely glycolytic reserve (Figure 5.8d).  
Further investigation of the proteomic data revealed a significant down-regulation of three 
complex I subunits, whereas the remaining nine detected subunits were not significantly 
differentially expressed. To assess the functional consequence of these changes, rotenone 
was used as a model of complex I mitochondrial perturbation. A significant increase in PHH 
resistance to rotenone toxicity in all donors at 168 hours regardless of background bio-
energetic (OCR/ECAR) profile (Figure 5.9) was found. Together these data suggest that, 
despite the variability seen between donors, a conserved change in essential mitochondrial 
function is observed as a result of time in culture.  
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Figure 5.6: Mitochondrial changes during dedifferentiation.  
Log2 fold change of mitochondrial proteins. Red: up-regulated, green: down-regulated. Intensity 
of colour: log2 fold change. Bold proteins: differentially expressed at 168 hours (p<0.05). 
 
Superoxide dismutase [Mn], mitochondrial
Hydroxyacyl-coenzyme A dehydrogenase, mitochondrial
Glutamate dehydrogenase 1, mitochondrial
Apoptosis-inducing factor 1, mitochondrial
Glycine dehydrogenase [decarboxylating], mitochondrial
Hydroxymethylglutaryl-CoA synthase, mitochondrial
Dimethylglycine dehydrogenase, mitochondrial
ES1 protein homolog, mitochondrial
Short/branched chain specific acyl-CoA dehydrogenase, mitochondrial
10 kDa heat shock protein, mitochondrial
Fumarate hydratase, mitochondrial
Carbamoyl-phosphate synthase [ammonia], mitochondrial
Sterol 26-hydroxylase, mitochondrial
ATPase inhibitor, mitochondrial
Succinyl-CoA ligase [GDP-forming] subunit beta, mitochondrial
Carnitine O-palmitoyltransferase 2, mitochondrial
mitochondrial carnitine/acylcarnitine carrier protein
Ornithine carbamoyltransferase, mitochondrial
NADH dehydrogenase [ubiquinone] iron-sulfur protein 4, mitochondrial
Alanine--glyoxylate aminotransferase 2, mitochondrial
Succinate-semialdehyde dehydrogenase, mitochondrial
GrpE protein homolog 1, mitochondrial
Sulfite oxidase, mitochondrial
Methylmalonyl-CoA epimerase, mitochondrial
ATP synthase-coupling factor 6, mitochondrial
Sarcosine dehydrogenase, mitochondrial
Cytochrome b-c1 complex subunit 2, mitochondrial
Glutaminase liver isoform, mitochondrial
Dihydrolipoyllysine-residue acetyltransferase component of pyruvate dehydrogenase complex, mitochondrial
Coproporphyrinogen-III oxidase, mitochondrial
GTP:AMP phosphotransferase, mitochondrial
Enoyl-CoA hydratase domain-containing protein 2, mitochondrial
Acyl-CoA synthetase family member 2, mitochondrial
Medium-chain specific acyl-CoA dehydrogenase, mitochondrial
4-aminobutyrate aminotransferase, mitochondrial
Cytochrome c oxidase subunit 4 isoform 1, mitochondrial
Methylmalonate-semialdehyde dehydrogenase [acylating], mitochondrial
Ferrochelatase, mitochondrial
Adenylate kinase 2, mitochondrial
Methylmalonyl-CoA mutase, mitochondrial
Heat shock protein 75 kDa, mitochondrial
Acyl-coenzyme A synthetase ACSM3, mitochondrial
Phosphoenolpyruvate carboxykinase [GTP], mitochondrial
Dihydrolipoyl dehydrogenase, mitochondrial
Sulfide:quinone oxidoreductase, mitochondrial
NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 10, mitochondrial
Glycine amidinotransferase, mitochondrial
Agmatinase, mitochondrial
Aldehyde dehydrogenase, mitochondrial
Isoleucine--tRNA ligase, mitochondrial
Dynamin-like 120 kDa protein, mitochondrial
Dihydrolipoyllysine-residue succinyltransferase component of 2-oxoglutarate dehydrogenase complex, mitochondrial
Choline dehydrogenase, mitochondrial
Very long-chain specific acyl-CoA dehydrogenase, mitochondrial
Cytochrome c oxidase subunit 5B, mitochondrial
Succinate dehydrogenase [ubiquinone] iron-sulfur subunit, mitochondrial
Enoyl-CoA delta isomerase 1, mitochondrial
ATP synthase subunit alpha, mitochondrial
3-ketoacyl-CoA thiolase, mitochondrial
Malonyl-CoA decarboxylase, mitochondrial
Adenylate kinase isoenzyme 4, mitochondrial
NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 5
Complement component 1 Q subcomponent-binding protein, mitochondrial
2,4-dienoyl-CoA reductase, mitochondrial
Acylpyruvase FAHD1, mitochondrial
ATP synthase subunit b, mitochondrial
NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 6
Aspartate aminotransferase, mitochondrial
Kynurenine/alpha-aminoadipate aminotransferase, mitochondrial
Pyruvate carboxylase, mitochondrial
Probable 2-oxoglutarate dehydrogenase E1 component DHKTD1, mitochondrial
Leucine-rich PPR motif-containing protein, mitochondrial
Aldehyde dehydrogenase X, mitochondrial
NAD(P) transhydrogenase, mitochondrial
3-hydroxyisobutyrate dehydrogenase, mitochondrial
Peptidyl-prolyl cis-trans isomerase F, mitochondrial
Propionyl-CoA carboxylase alpha chain, mitochondrial
Cytochrome b-c1 complex subunit 6, mitochondrial
2-oxoglutarate dehydrogenase-like, mitochondrial
Isochorismatase domain-containing protein 2, mitochondrial
Adrenodoxin, mitochondrial
[3-methyl-2-oxobutanoate dehydrogenase [lipoamide]] kinase, mitochondrial
Citrate lyase subunit beta-like protein, mitochondrial
Cytochrome b-c1 complex subunit Rieske, mitochondrial
mitochondrial fission 1 protein
Acyl-CoA synthetase short-chain family member 3, mitochondrial
mitochondrial ornithine transporter 1
NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 4
Calcium-binding mitochondrial carrier protein Aralar2
2-oxoglutarate dehydrogenase, mitochondrial
Glutaredoxin-related protein 5, mitochondrial
2-methoxy-6-polyprenyl-1,4-benzoquinol methylase, mitochondrial
Delta(3,5)-Delta(2,4)-dienoyl-CoA isomerase, mitochondrial
NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 9, mitochondrial
Phosphate carrier protein, mitochondrial
Thioredoxin reductase 2, mitochondrial
Methylcrotonoyl-CoA carboxylase beta chain, mitochondrial
Glycine cleavage system H protein, mitochondrial
Citrate synthase, mitochondrial
ATP synthase subunit delta, mitochondrial
2-amino-3-ketobutyrate coenzyme A ligase, mitochondrial
Enoyl-CoA hydratase, mitochondrial
Cytochrome c oxidase subunit 5A, mitochondrial
Cob(I)yrinic acid a,c-diamide adenosyltransferase, mitochondrial
Acetyl-CoA acetyltransferase, mitochondrial
Hydroxyacylglutathione hydrolase, mitochondrial
mitochondrial import receptor subunit TOM70
Acyl-coenzyme A synthetase ACSM5, mitochondrial
ATP synthase subunit e, mitochondrial
Ubiquinone biosynthesis protein COQ9, mitochondrial
Cytochrome c oxidase subunit 7A2, mitochondrial
Probable 4-hydroxy-2-oxoglutarate aldolase, mitochondrial
Thioredoxin-dependent peroxide reductase, mitochondrial
mitochondrial inner membrane protein
mitochondrial dicarboxylate carrier
NADH dehydrogenase [ubiquinone] flavoprotein 1, mitochondrial
Trifunctional enzyme subunit beta, mitochondrial
Single-stranded DNA-binding protein, mitochondrial
Malate dehydrogenase, mitochondrial
NADPH:adrenodoxin oxidoreductase, mitochondrial
Enoyl-CoA delta isomerase 2, mitochondrial
Probable D-lactate dehydrogenase, mitochondrial
Neurolysin, mitochondrial
Cytochrome b-c1 complex subunit 1, mitochondrial
NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13
mitochondrial import inner membrane translocase subunit TIM44
Propionyl-CoA carboxylase beta chain, mitochondrial
Isocitrate dehydrogenase [NADP], mitochondrial
NADH dehydrogenase [ubiquinone] flavoprotein 2, mitochondrial
L-2-hydroxyglutarate dehydrogenase, mitochondrial
Succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial
Enoyl-CoA hydratase domain-containing protein 3, mitochondrial
ATP synthase subunit g, mitochondrial
Glutathione reductase, mitochondrial
Lon protease homolog, mitochondrial
Pyruvate dehydrogenase E1 component subunit beta, mitochondrial
Succinyl-CoA ligase [ADP-forming] subunit beta, mitochondrial
NADH dehydrogenase [ubiquinone] iron-sulfur protein 2, mitochondrial
NADH dehydrogenase [ubiquinone] iron-sulfur protein 8, mitochondrial
Serine hydroxymethyltransferase, mitochondrial
mitochondrial import inner membrane translocase subunit TIM50
Isovaleryl-CoA dehydrogenase, mitochondrial
3-hydroxyisobutyryl-CoA hydrolase, mitochondrial
Inorganic pyrophosphatase 2, mitochondrial
Histidine triad nucleotide-binding protein 2, mitochondrial
Acyl-coenzyme A synthetase ACSM2B, mitochondrial
Trifunctional enzyme subunit alpha, mitochondrial
Short-chain specific acyl-CoA dehydrogenase, mitochondrial
Ornithine aminotransferase, mitochondrial
Alpha-aminoadipic semialdehyde synthase, mitochondrial
ATP synthase subunit d, mitochondrial
Succinyl-CoA ligase [ADP/GDP-forming] subunit alpha, mitochondrial
Electron transfer flavoprotein-ubiquinone oxidoreductase, mitochondrial
Tricarboxylate transport protein, mitochondrial
LETM1 and EF-hand domain-containing protein 1, mitochondrial
mitochondrial import receptor subunit TOM40 homolog
Lipoamide acyltransferase component of branched-chain alpha-keto acid dehydrogenase complex, mitochondrial
60 kDa heat shock protein, mitochondrial
Serine beta-lactamase-like protein LACTB, mitochondrial
2-oxoisovalerate dehydrogenase subunit alpha, mitochondrial
ATP synthase subunit O, mitochondrial
Delta-1-pyrroline-5-carboxylate dehydrogenase, mitochondrial
mitochondrial-processing peptidase subunit beta
NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 9
D-beta-hydroxybutyrate dehydrogenase, mitochondrial
Pyruvate dehydrogenase E1 component subunit alpha, somatic form, mitochondrial
Acyl-coenzyme A synthetase ACSM2A, mitochondrial
mitochondrial carrier homolog 2
Aconitate hydratase, mitochondrial
ATP synthase subunit beta, mitochondrial
Chaperone activity of bc1 complex-like, mitochondrial
ATP synthase subunit gamma, mitochondrial
Methylmalonic aciduria type A protein, mitochondrial
Diablo homolog, mitochondrial
mitochondrial 2-oxoglutarate/malate carrier protein
Serine/threonine-protein phosphatase PGAM5, mitochondrial
mitochondrial-processing peptidase subunit alpha
Cytochrome c1, heme protein, mitochondrial
Methylcrotonoyl-CoA carboxylase subunit alpha, mitochondrial
DnaJ homolog subfamily A member 3, mitochondrial
Protein ETHE1, mitochondrial
Mycophenolic acid acyl-glucuronide esterase, mitochondrial
3-oxoacyl-[acyl-carrier-protein] synthase, mitochondrial
Hydroxymethylglutaryl-CoA lyase, mitochondrial
Peroxiredoxin-5, mitochondrial
Elongation factor Tu, mitochondrial
MOSC domain-containing protein 2, mitochondrial
Electron transfer flavoprotein subunit alpha, mitochondrial
Stress-70 protein, mitochondrial
Name 24 hours 72 hours 168 hours
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Figure 5.7: The Pathway analysis of mitochondrial DEPs during dedifferentiation 
a) Canonical pathway analysis of mitochondrial proteins Results displayed –Log (P 
values), pathway included if p<0.05 at any of the assessed timepoints. Intensity of purple 
corresponds to the significance value; b) Upstream regulators of mitochondrial changes 
predicted to be activated or inhibited by IPA software displayed. Red regulators are up-
regulated, green regulators are down-regulated. Upstream regulators were included if Z 
activation scores (2 ≥ Z-score ≤ -2). 
Abbreviations: GCK: Glucokinase; OMA1: Metalloendopeptidase OMA1. AMPK: 5' AMP-
activated protein kinase; PEDF: Pigment epithelium-derived factor. 
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Figure 5.8: Seahorse analysis of the bioenergetic profile of PHH during culture 
a) Oxidative phosphorylation and b) glycolysis parameters as percentages of maximal oxygen 
consumption rates and extracellular acidification rate, respectively; Relative fold change of c) 
oxidative phosphorylation and d) glycolysis parameters. (*) p<0.05 paired T-test. 
 
Abbreviations: OCR: Oxygen consumption rate; ECAR: Extracellular acidification rate 
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  Figure 5.9: Assessing changes in mitochondrial sensitivity to Complex I inhibitor 
Rotenone over time in culture 
ATP levels at 24 (♦) and 168 hours (■) following rotenone treatment. Results: 
percentage of control, (*) p<0.05 two tailed paired T-test and (†) p<0.05 Wilcoxson 
test signed rank test (n=5).  
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Assessment of ADME proteins during dedifferentiation reveals selective protein down-
regulation 
A well-known feature of hepatocyte dedifferentiation is the loss of the metabolic 
phenotype. To distinguish whether this is a selective or global loss of metabolic 
competence, several protein subsets generated in this analysis were compared: 168 hour 
DEPs, 168 hour non-DEPs, most stable proteins and the most variable proteins. PANTHER 
analysis was used to compare the associated biological function categories of each subset 
(Figure 5.10). This analysis revealed similar percentages of proteins in each class, with the 
greatest proportion of proteins associated with metabolism in all subsets, indicating a 
selective, rather than wholesale alteration, in the hepatocyte metabolic profile.  
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Figure 5.11 shows the known phase I, II and III drug metabolising enzymes (Guo et al., 
2011) which were detected by proteomic analysis. The heatmap highlights the loss of 
metabolic competence with the majority of Phase I enzymes following a relatively linear 
pattern of down-regulation towards 168 hours. Phase II/III enzymes appear to show greater 
stability with some phase III proteins, including multidrug resistance protein 1 (MDR1) and 
major vault protein (MVP), demonstrating an up-regulation during culture.   
Figure 5.12a demonstrates the dedifferentiation pattern of the cytochrome P450s detected 
by iTRAQ over the 168 hour period. The general trend relative to freshly isolated PHHs is 
downward, however, with the exception of CYP1A2, CYP2A6 and CYP27A1, all the detected 
CYP proteins maintained or increased in expression at 24 hours in relation to the freshly 
isolated cells, showing that at 24 hours the metabolic potential of PHH is mostly 
maintained. Some CYPs displayed greater stability, such as 2C18 and 4F11, whilst 2B6 and 
2C9 demonstrated downward trends, but showed greater variation between the donors. 
Western blotting for CYP proteins 2D6, 2E1, 1A2 and the cytoskeletal protein β-actin were 
consistent with the iTRAQ results, further demonstrating a downward trend with noted 
variation in the individual dedifferentiation profiles (Figure 5.12b). Furthermore, analysis of 
CYP450 activity using probe substrates for CYP3A and 2D6 show a loss of functional 
capacity that is in line with the loss of protein recorded by iTRAQ and western 
immunoblotting (Figure 5.12c).   
In contrast to the CYPs, the protein expression of the transporters identified as being 
important for drug influx and efflux in the liver (Zamek-Gliszczynski et al., 2012) is relatively 
stable throughout the 168 hour culture. Only 2 of the 9 detected transporters are 
significantly down-regulated at 168 hours (P<0.05; Figure 5.13), interestingly these are both 
influx transporters (OATP1B1 and OATP1B3). The general trend of the other detected drug 
influx transporters is also downwards, as are the trends for efflux transporters MRP6 and 
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BSEP. Conversely, the remaining efflux transporters (MDR1, MRP2 and MRP3) show a 
maintenance or upward trend in expression during culture.   
Comparison of the trend in the CYP and transporter proteins with previously published 
hepatocyte monolayer gene expression data (Richert et al., 2006) allows further 
investigation of the loss of metabolic competence (Table 5.7). All CYPs with a reported gene 
expression >30% at 72 hours maintained protein expression >60% at 168 hours. 
Conversely, at 72 hours, the mRNA of CYP1A2, 2A6, 2B6, 2C8, 2E1, 3A4, 4A11, 4F2, 4F3 and 
27A1 is reported to drop to below 10% of freshly isolated PHH (Richert et al., 2006). When 
the protein expression of these CYPs is compared, the majority, with the exception of 
CYP4F2 and 4F3, show significant down-regulation at 168 hours, suggesting that the loss of 
CYPs can be mainly associated with reduced transcription. This association is shown in 
Figure 5.14, demonstrating that whilst all CYPs protein expression at 168 hours is not 
significantly correlated with mRNA expression at 72 hours (Figure 5.14a); there is a 
significant correlation between mRNA at 72 hours and protein at 168 hours for the 
significantly down-regulated CYPs (Figure 5.14b). This rule was found to be less true of the 
transporters investigated in this study, with BSEP, OAT2 and OCT1 all having mRNA <10% at 
72 hours; however, despite a downward trend, they are not significantly down-regulated at 
168 hours.  
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Figure 5.12: Loss of CYP proteins and metabolism during dedifferentiation of PHH.  
a) CYP450s over 168 hours (n=5); error bars: SD; One-way ANOVA: (*) p<0.05, (#) 
p<0.01); b) Western blots for CYP450s and β-actin c) Metabolic function of CYP3A 
(testosterone) and CYP2D6 (dextromethorphan) and detection of respective metabolites 
(6β-OH-testosterone and dextrorphan) detected by LC-MS-MS (n=3 donors; error bars: 
SD). One-way ANOVA: (*) p<0.05. 
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Figure 5.13: ADME transporters protein expression during dedifferentiation.  
Error bars SD,* significant p<0.05 by one-way ANOVA 
 
Abbreviations: BSEP: bile salt export pump; MDR: multiple drug resistance protein; MRP: 
multidrug resistance-related protein; OAT: organic anion transporting polypeptide; OATP: 
organic anion transporter; OCT: organic cation transporter 
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Protein expression 
% of freshly isolated cells 
 Protein degradation  
mRNA expression 
% of freshly isolated cells 
CYP450 
Protein expression 
24hrs 
Protein expression 
72hrs 
Protein expression 
168hrs 
 
Average half-life by 72 
hour trend (hrs) 
Average half-life by 168 
hour trend (hrs) 
 
mRNA expression at 72hrs 
(Richert et al., 2006) 
1A2 66.94 28.88 22.08  48.54 89.29  7.17 
2A6 52.68 21.68 9.06  42.37 76.92  4.78 
2B6 119.38 95.1 81.22  2500 555.56  3.21 
2C8 110.8 54.44 12.72  96.15 96.15  1.38 
2C9 247.56 205.00 138.32  - -  33.30 
2C18 92.43 94.90 92.52  500 1000  277.60 
2C19 101.96 93.85 52.72  714.28 200  17.89 
2D6 89.22 60.22 30.86  92.59 116.28  11.92 
2E1 113.94 67.64 26.44  142.85 119.05  2.99 
2J2 106.37 105.35 103.23  2500 -  30.80 
3A4 106.78 34.48 74.38  63.29 192.31  8.58 
4A11 93.52 52.46 9.96  80.65 90.91  1.88 
4F2 201.00 154.69 66.05  - -  7.72 
4F3 104.98 84.23 64.95  277.78 250  4.67 
4F11 112.84 88.4 76.76  555.56 384.62  79.38 
4F12 116.3 97.54 83.08  - 625  17.00 
7B1 101.55 84.60 63.93  263.18 238.10  77.32 
27A1 64.01 44.69 29.98  59.52 102.04  6.18 
51A1 167.27 168.21 96.22  - -  100 
Transporter 
Protein expression 
24hrs 
Protein expression 
72hrs 
Protein expression 
168hrs 
 
Average half-life by 72 
hour trend (hrs) 
Average half-life by 168 
hour trend (hrs) 
 
mRNA expression at 72hrs 
(Richert et al., 2006) 
  
       
BSEP 93.12 70.73 67.66  128.21 217.39  6.03 
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MDR1 113.23 132.66 143.25  - -  305.33 
MRP2 95.98 97.78 90.95  1250 1000  182.66 
MRP3 121.02 123.91 134.63  - -  162.10 
MRP6 154.21 81.57 56.16  12500 227.27  40.78 
OAT2 83.33 60.57 57.04  89.29 161.29  5.75 
OATP1B1 85.57 42.50 50.26  64.1 131.58  12.27 
OATP1B3 115.59 71.76 30.38  172.41 128,21  6.10 
OCT1 101.26 79.37 68.09  200 250  6.23 
 
Table 5.7: Comparison of proteomic CYP and drug transporter expression profile during dedifferentiation with previously reported gene 
expression and protein degradation rates.  
Protein half-life calculated using linear regression at 72 and 168 hours of culture. Gene expression data is derived from previously published 
literature using similar monolayer culture conditions (Richert et al., 2006).  
Abbreviations: BSEP: bile salt export pump; MDR: multiple drug resistance protein; MRP: multidrug resistance-related protein; OAT: organic 
anion transporting polypeptide; OATP: organic anion transporter; OCT: organic cation transporter 
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Figure 5.14: Correlation between protein expression at 168 hours and mRNA 
expression at 72 hours 
 a) all CYPs and b) CYPs which are significantly down-regulated at 168 hours. 
Gene expression data is derived from previously published literature using 
similar monolayer culture conditions (Richert et al., 2006). P<0.05 classed as 
significant according to linear correlation analysis.  
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Pathway analysis of ADME proteins reveals the pathways and transcription factors 
predicted to underlie the loss of specific metabolic functions 
Targeted analysis of the transcription factors which are associated with the ADME DEPs 
revealed the specific regulators which are significantly perturbed and may cause the loss of 
ADME proteins during dedifferentiation (Table 5.8). In-keeping with published literature 
(Fraczek et al., 2013), HNF1α, C/EBP and HNF1β were amongst the most significantly 
associated regulators with the loss of metabolic competence. Interestingly, FECH 
(Ferrochelatase), a key enzyme in the production of heme, found to be significantly down-
regulated at 168 hours (Table 5.S2), is highly associated with the differentially expressed 
ADME proteins. SMARCB1 is also significantly associated with the ADME proteomic profile 
at 168 hours.  
Investigation into the predicted transcription factor binding sites of differentially expressed 
and non-differentially expressed CYPs revealed the factors that may underlie the selectivity 
found in the loss of xenobiotic CYPs (Table 5.9). This analysis predicted binding sites for 
HSF2 to be highly enriched in the CYPs which were not differentially expressed; whereas, 
ZEB1, FOXO1 and NF-Y binding sites are almost exclusively predicted to be located 
upstream of the differentially expressed CYPs.  
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Upstream Regulator p-value of overlap 
HNF1A 0.000873 
FECH 0.00813 
C/EBP 0.0111 
SMARCB1 0.0111 
STAT1 0.0111 
STAT6 0.0123 
FOXA1 0.0123 
TNF 0.0382 
Ins1 0.0411 
HNF1B 0.0411 
Greater expression in 
maintained CYP promoters 
Greater expression in down-
regulated CYP promoters 
HSF2 Nuclear factor Y 
MITF ZEB1 
Androgen receptor FOXO1 
COUP-TF2 TBK-1 
ATF6 myogenin / NF-1 
Brachyury  
FXR/RXR-alpha  
NK3 Homeobox 1  
Otx2  
TATA Box Binding Protein  
TBX5  
Table 5.8: Upstream regulator pathway analysis of the ADME DEPs.  
Most significantly associated upstream regulators of ADME DEPs (p<0.05) as associated by IPA 
ingenuity software. 
Abbreviations: FOXA2: Forkhead Box A2; HNF4α: Hepatic nuclear factor 4 alpha: Ins1: Insulin 1; 
TNF: Tumor necrosis factor; STAT: signal transducer and activator of transcription; SMARC: 
SWI/SNF related, matrix associated, actin dependent regulator of chromatin; C/EBP: 
CCAAT/enhancer binding protein; FECH: Ferrochelatase  
 
Table 5.9: Predicted transcription factor binding using Mapper2 software.  
The transcription factors with enriched predicted binding in the upstream regions of either the 
differentially expressed or non-differentially expressed Cytochrome P450s. The transcription factors 
were included if enrichment was ≥4 CYPs from either group and are ordered according to the 
amount of enrichment. Analysis of LETFs promoter regions shows the transcription factors with 
predicted binding in the greatest number of LETFs. Transcriptions factors are ordered according to 
the number LETFs with predicted binding sites.    
Abbreviations: FOX: forkhead Box; HSF: heat shock factor; MITF: microphthalmia-associated 
transcription factor; COUP-TF: chicken ovalbumin upstream promoter-transcription factor; ATF: 
activating transcription factor; RXR: retinoid X receptor; FXR: farnesoid X receptor; Otx2: 
orthodenticle homeobox 2; TBX: T-box transcription factor; ZEB1: zinc finger e-box binding 
homeobox 1; TANK-binding kinase 1; NF-1: neurofibromatosis type 1 
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Pyrosequencing reveals the changes to epigenome of the cell during dedifferentiation are 
highly specific 
To investigate the process of xenobiotic dedifferentiation further, we then assessed some 
of the key genes associated with drug metabolism, namely CYPs and LETFs. In silico 
predictive tools (http://cpgislands.usc.edu/) were used to identify CpG islands found within 
the promoter regions of each gene. Interestingly, of the CYPs investigated, only CYP2E1 had 
a predicted CpG island close to the promoter region of the gene, whereas, CYP1A2, 
CYP2A6, CYP2B6, CYP2D6, CYP3A4 and CYP3A7 did not. Conversely, many of the LETFs had 
highly enriched regions of CpG sites and numerous predicted CpG islands close to or within 
the promoter region of the gene. These included: HNF6, C/EBP family and the FOXA family. 
We also found that both HNF1α and HNF4α had regions of enriched CpG sites which fell 
short of the arbitrary cut off values used by the prediction tool; however, due to their 
known importance during dedifferentiation, we also included these genes in our analysis. 
Therefore, our selected gene set consisted of: CYP2E1, HNF1α, HNF4α, HNF6, C/EBPα, 
FOXA2 and Line1 (a repeated genomic sequence which indicates global methylation status 
of the tissue; Line1: Long interspersed nuclear elements retrotransposable element 1). 
Samples collected from tissue, directly after isolation and after 24 and 168 hours of culture 
were subjected to pyrosequencing. Despite the presence of CpG islands, the genes HNF6, 
C/EBPα and FOXA2 showed no methylation at the tissue or culture timepoints examined. 
Furthermore, despite multiple attempts, including re-designing of the primers, the 
sequencing primers for CYP2E1 and HNF1α failed to anneal to the PCR product and 
therefore the methylation status of the gene could not be determined.  
Interestingly, Line1 showed very consistent methylation of ~70% throughout the isolation 
and culture periods, suggesting little change in global methylation status during this period 
(Figure 5.15a). HNF4α showed a consistent pattern of methylation during the 
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dedifferentiation process. The tissue methylation status of HNF4α was consistently ~50%, 
however, this changed dramatically upon isolation, falling to ~25%. These levels then 
increased to ~35% and decreased back to ~25% during the culture period, although these 
changes at these timepoints demonstrated greater variation between donors (Figure 
5.15b).  
 
  
Figure 5.15: Methylation status of PHH during dedifferentiation by pyrosequencing.  
a) Line1 and b) HNF4α methylation of CpG sites during isolation and culture as determined by 
pyrosequencing. (*) p>0.05 one-way ANOVA; n=4 donors with 5 CpG sites at each timepoint).  
Abbreviations: HNF4α: Hepatic nuclear factor 4 alpha: Line1: Long Interspersed Nuclear 
Elements Retrotransposable Element 1 
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5.3. Discussion 
In this chapter we have demonstrated the first use of global proteomics as a tool for 
investigating primary human hepatocyte dedifferentiation, identifying new targets and 
generating new hypotheses for future examination in simple and complex culture models.  
Throughout the analysis, differentially-expressed proteins and associated pathways were 
found at every time point, suggesting that these mechanisms are well-conserved across 
donors. The number of significantly differentially expressed proteins increased at each 
timepoint, which, together with the clustering analysis, suggests an increasing deviation 
from the freshly-isolated donor phenotype. Grouping of these data showed that 
dedifferentiation is not solely a change in expression of whole protein classes, but that it is 
a complex, differentially-controlled and active process, in which selected pathways and 
functions from many classes are up- or down-regulated.  
Cytochrome P450s have been strongly associated with a loss of expression during culture 
(Rodriguez-Antona et al., 2002), and this is further demonstrated here by the top three 
most down-regulated proteins at 168 hours: CYP2A6, CYP2C8 and CYP4A11. However, this 
study allows for these changes to be put into the context of the global cell proteome, 
revealing the strikingly selective nature of dedifferentiation. Even within single P450 
families, selectivity can be seen. For example, whilst CYP2A6 and CYP2C8 are the most 
down-regulated proteins, CYP2C18 and CYP2J2 remain unaltered by culture conditions. Of 
further interest, CYP2A6 has been reported to be the largest discriminant between foetal 
and adult hepatocytes (Rowe et al., 2013); here we show CYP2A6 to be the largest 
discriminator between freshly isolated and 168 hour cultured hepatocytes. 
Understanding how this specificity works is a key question in determining new strategies 
for hepatocyte culture and for stem cell differentiation protocols. By comparing predicted 
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transcription factor binding, we have been able to generate a list of enriched transcription 
factors associated with either differentially expressed or non-differentially expressed CYPs. 
Future investigations to elucidate the roles of these factors (e.g. HSF2, SP1 and ZEB1) may 
lead to a greater understanding of the selective loss/maintenance of metabolic 
competence during dedifferentiation.  
Comparisons between differentially-expressed and non-differentially expressed drug 
metabolizing proteins revealed no single factor which could mediate all the ADME-
associated proteomic changes. The results corroborate previous reports showing the 
importance of HNF1α alongside HNF1β, C/EBP and FOXA1 in dedifferentiation (Padgham et 
al., 1993). The association of the enzyme ferrochelatase is also of interest. Ferrochelatase 
catalyses the final step of the heme production pathway and thus its loss of expression 
would likely reduce the intracellular heme concentration. CYPs are dependent on heme for 
function and its loss during culture has been reported in mouse hepatocytes (Singh and 
Veltri, 1991). HNF1α has been shown to regulate ferrochelatase expression (Muppala et al., 
2000) and may provide an additional indirect mechanism by which HNF1α can alter ADME 
protein expression.  
Despite being a well-accepted major determinant of hepatic function (Odom et al., 2004), 
the lack of association of HNF4α with differentially expressed ADME proteins is consistent 
with HNF4α over-expression studies in rat hepatocytes, which failed to re-establish 
xenobiotic metabolic function (Naiki et al., 2005). However, our epigenetic analysis 
revealed changes to the promoter region of HNF4α, suggesting reduced methylation 
between tissue and cultured cells, which usually indicates increased transcription. Further 
investigation revealed that this promoter region investigated was actually related to the 
foetal-associated HNF4α isoforms and may indicate a mechanism by which the isolated 
PHH is driven towards an immature and less xenobiotic metabolically active phenotype 
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(Mizuguchi et al., 1998; Drewes et al., 1996). This may, in part, explain the similarity 
between the hepatic markers detectable in stem cell-derived HLCs and those maintained 
during PHH dedifferentiation (Rowe et al., 2013; Baxter et al., 2015).  
One potential cause of the change in the hepatocyte ADME and proteome-wide phenotype 
is through alterations in the accessibility of DNA to transcriptional machinery. Our results 
strongly predict a down-regulation of SMARCB1, a member of the BAF complex which is 
thought to remodel chromatin structure (Wilson and Roberts, 2011). SMARCB1 been 
shown to be essential for hepatocyte differentiation (Gresh et al., 2005) and recent work 
has also linked another member of the BAF complex, SMARCA4, to the enhancement of the 
ESC-derived HLC phenotype (Mobus et al., 2015). Alterations in chromatin accessibility and 
transcription factor binding is one of the key first steps in the reprogramming of somatic 
cells to induced pluripotent stem cells (Papp and Plath, 2013) and similar fundamental 
mechanisms may play a role in the acquisition of the dedifferentiated phenotype. Efforts to 
intervene epigenetically using histone deacetylase and DNA methyltransferase inhibitors 
have been successful in maintaining expression of hepatic functions, although the exact 
mechanisms are unclear (Fraczek et al., 2013; Fraczek et al., 2012). Taken together, these 
results highlight the importance of epigenetic regulation in the dedifferentiation process; 
however, the consequences of these changes and the mechanisms which underlie them 
remain unclear and require further investigation.   
Energy production is another fundamental cellular process affected by dedifferentiation 
that is highlighted by this study. The proteomic and functional data suggest a dramatic 
remodelling of the bio-energetic proteome during monolayer culture. These changes lead 
to a reduction in many mitochondrial-associated proteins, particularly those involved in 
lipid and fatty acid metabolism. Previous work has implicated AMPK signalling and 
mitochondrial fusion as part of the adaptation and repolarization of hepatocytes in 
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sandwich culture following isolation (Fu et al., 2013). Here we have additionally shown 
both AMPK and mitochondrial fusion pathways to be associated with the bio-energetic 
adaption to a monolayer culture system. Furthermore, given the remarkable stability of 
oxidative phosphorylation following plating, during a period of substantial phenotypic 
change, it appears that these essential processes are preferentially maintained, potentially 
at the expense of non-survival-essential proteins/functions. One possible driving factor of 
these findings is the MEK/ERK pathway, which is highlighted by this and other studies 
(Zellmer et al., 2010) as a factor in dedifferentiation and has previously been shown to 
reduce rotenone toxicity in neuronal cells (Jiang et al., 2006) and alter both mitochondrial 
function (Ripple et al., 2013) and lipid/fatty acid metabolism (Yousefi et al., 2012).  
Our analysis revealed that the early stages of dedifferentiation are predominantly donor-
dependent with the inter-individual variation that exists in the starting donor phenotype 
being maintained throughout the first 72 hours of culture. Hepatocytes are known to vary 
between donors (due to both genotypic and environmental factors) (Bhogal et al., 2011) 
and in function depending on their location/zone in the lobule porto-central axis (Allen et 
al., 2005); both of these factors also appear to influence the dedifferentiation profile during 
culture. Similarity to the isolated donor phenotype dissipates with time in culture in all 
cases, and a convergence towards a reproducible dedifferentiated phenotype was 
observed. Taken together, these data suggest that the strictly-defined culture system 
promotes a specific protein expression profile and, as a consequence of the variable PHH 
phenotype at isolation, the proteome changes required to achieve this dedifferentiated 
phenotype are also variable. This information has profound implications for the use of 
hepatocytes for early drug discovery and prediction of DILI; the majority of toxicological 
endpoints are assessed within 72 hours of isolation, thus the variable dedifferentiation of 
hepatocytes demonstrated in this study is likely to have an impact on attempts to achieve 
consistent biological assessment of multiple chemical variables (e.g. libraries of new drugs).  
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Many of the earliest changes in protein expression during dedifferentiation are related to 
cell survival and the maintenance of homeostatic functions. The up-regulation of stress-
induced survival pathways may be considered as a double-edged sword, on the one hand 
preventing apoptosis/necrosis and allowing cells to survive during culture, whilst on the 
other, playing an important role in the loss of the hepatic phenotype. Negative regulation 
of the hepatic phenotype has been reported to be true for the MEK/ERK and NFκB 
pathways (Elaut et al., 2006; Fraczek et al., 2013), and are predicted to be up-regulated by 
this study. Additionally, the most significantly predicted up-regulated factor at 168 hours 
was heat shock factor 2 (HSF2). Overexpression studies have shown HSF2 to inhibit 
erythroid differentiation, but to our knowledge, HSF2 has not previously been linked to the 
hepatic differentiation status (Leppä et al., 1997). Such results emphasise the apparent 
trade-off between cell survival and a mature hepatic phenotype in traditional in vitro 
systems. Therefore, reducing cellular stress at all stages of culture, particularly during 
isolation, may be the most successful method of maintaining both cell viability and the 
hepatic phenotype.  
Whilst some of the results yielded in this study may be specific to monolayer culture, the 
use of a rudimentary culture system has allowed the identification of a wide array of known 
and novel mechanisms through which dedifferentiation influences hepatic phenotype. We 
believe this approach enables a holistic understanding of the hepatocyte dedifferentiation 
process, and the knowledge gained in this study has the potential to enhance complex 
culture systems towards an improved physiological phenotype. 
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Chapter 6 
The role of Nrf2 in the differentiation and dedifferentiation 
of human hepatocytes 
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6.1 Introduction 
Current culture systems for primary human hepatocyte (PHH) and hepatocyte-like cells 
(HLCs) are unable to fully support the hepatic phenotype. In order to improve in vitro 
hepatic models, various different strategies have been attempted. These have included our 
attempts presented in chapters 4 and 5, small compound screens, spheroid cultures and 
the use of multiple cell types in co-culture systems (Li et al., 2014; Trask et al., 2014; Shan 
et al., 2013; Tostoes et al., 2012; Gieseck III et al., 2014), which have resulted in improved, 
but not freshly isolated PHH-comparable, phenotypes. It is therefore clear that more work 
is needed to further understand the roadblocks which result in an inability to maintain or 
acquire the hepatic phenotype in vitro. 
One potential area for investigation is the role of nuclear factor erythroid 2-related factor 2 
(Nrf2). Nrf2 is a transcription factor and key exponent of the cellular response to oxidative 
stress (Bryan et al., 2013). Under basal conditions, Nrf2 is bound by the cysteine rich Kelch-
Like ECH-Associated Protein 1 (Keap1), which targets Nrf2 for ubiquitination and 
subsequent degradation (Itoh et al., 2003). During oxidative stress, Keap1 is altered and can 
no longer bind to Nrf2, allowing translocation to the nucleus and binding to the antioxidant 
response element (ARE) located in the promoter regions of the genes controlled by Nrf2 
(Bryan et al., 2013).   
The Nrf2 transcription factor’s role in responding to oxidative stress is well described; 
however, it has also been shown to have a direct role in the differentiation of certain cell 
types. For example, the fate determination of haematopoietic cells has been shown to be 
dependent on the Nrf2/Keap1 complex (Murakami et al., 2014). Nrf2 has also been 
implicated in the differentiation of cell types such as osteoclasts and adipocytes 
(Chartoumpekis et al., 2011; Kanzaki et al., 2013). 
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With regard to the liver, the Notch-Nrf2 axis has been shown to be important in murine 
liver development, more specifically in driving a cholangiogenic lineage specification 
following Notch stimulation (Wakabayashi et al., 2013). Furthermore, Nrf2 may also 
influence the maintenance of the hepatic phenotype. Overexpression of Nrf2 in a mouse 
model reported P15 as a novel target of Nrf2 (Kohler et al., 2013). P15 has been previously 
been shown to prevent hepatocyte proliferation and potentially promote the quiescent 
mature hepatocyte phenotype in vivo (Awad et al., 2000).  
Reactive oxygen species (ROS), a key activator of Nrf2, has also been reported to play a role 
during differentiation towards mesoendodermal lineages (Ji et al., 2010) and also in HLC 
differentiation from mesenchymal stem cells (Khajeniazi et al., 2013). However, 
understanding how essential the maintenance of ROS at specific intra-cellular levels to HLC 
differentiation has yet to be achieved. For example, CYP2E1, a protein which is often 
lacking in HLC cultures, is known to be down-regulated in the presence of oxidative stress 
(Morel et al., 2000). It is thought that ROS may also act as a signalling intermediate; thus, a 
mechanism which can control that, i.e. the Nrf2 antioxidant response pathway, may 
provide an interesting point for perturbation as an indirect mediator of differentiation 
maturity.  
Nrf2 may also interact with important nuclear receptors associated with hepatic function, 
such as peroxisome proliferator-activated receptor alpha (PPARα). Studies have shown an 
Nrf2-dependent altered lipid metabolism and a decrease in fatty acid mobilisation in 
adipose tissue mediated through PPARα signalling cascades, perhaps suggesting a degree 
of upstream regulation (Xu et al., 2013a).  
Within this chapter, we report the use of clustered regularly interspaced short palindromic 
repeats (CRISPR)/Cas9-based manipulation of Nrf2. CRISPR/Cas9 is a relatively new 
technology and has been the subject of much excitement due to its ease of use and wide-
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ranging capacity, allowing for vast libraries of potential guide RNAs (gRNAs) to be 
developed (Zhou et al., 2014). The system is based on a bacterial protection mechanism 
against foreign nucleic acids, where the foreign nucleic acid sequence is recognised through 
previous exposure and ‘cut’ by the Cas9 nuclease, yielding the DNA sequence inactive 
(Wiedenheft et al., 2012). Using this biological process, gRNAs can be designed to target 
specific parts of the genome, aligning the Cas9 nuclease with the sequence of interest, and 
subsequently inducing a double stranded break (DSB) (Sander and Joung, 2014). The 
efficiency of DSBs is thought to be relatively high, ranging from 1-50% depending on the 
delivery method, cell type used and other experimental variables (Sander and Joung, 2014). 
The DSB is then repaired by non-homologous end-joining (NHEJ), which is highly error 
prone and results in the insertion of variable length indels, causing frame-shift mutations 
and consequently loss of gene function. More advanced systems involve the exogenous 
introduction of donor sequences for homology directed repair (HDR). Using 
complementary flanking sequences to target the position of the DSB, HDR can introduce 
point mutations or genes of choice for selection or knock-in purposes (Sander and Joung, 
2014).  
Taken together, such work supports Nrf2 as a potentially key determinant of hepatic 
development and maturity. We therefore hypothesised that Nrf2 may influence the hepatic 
phenotype and that mechanistically evaluating the relationship using systems such as 
CRISPR/Cas9 may yield important information regarding the role of Nrf2 during hepatocyte 
differentiation and dedifferentiation.  
Hypothesis: Nrf2 regulates the hepatocyte phenotype during differentiation and 
dedifferentiation 
  
Chapter 6 
183 
 
  
Figure 6.1: Schematic diagram of CRISPR/Cas9 mechanism. 
1. The section of genomic DNA is chosen for manipulation and the CRISPR constructs are designed to 
target this section of DNA. 2. CRISPR/Cas9 constructs target the genomic DNA using guide RNA inserted 
in the CRISPR backbone (TracrRNA-crRNA). Cas9 nuclease then cuts upstream of a PAM sequence. 3. 
The cuts result in a double stranded break, which can be repaired by NHEJ or HDR (see text for NHEJ). 
Homology arms targeting either side of the DSB allow for the insertion of the gene or indel of interest 
by HDR. 4. Repaired DNA with the inserted gene of interest. 
 
Abbreviations: DSB: Double-stranded break; NHEJ; Non-homologous end-joining; HDR: Homology 
directed repair; PAM: Protospacer adjacent motif; GFP: Green fluorescent protein 
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6.2 Results 
To investigate if Nrf2 can affect the maintenance and acquisition of the hepatic phenotype, 
we first established how Nrf2-related proteins changed in expression during the loss of 
phenotype seen during PHH dedifferentiation.  
Using the data generated in chapter 5, the up-/down-regulation of differentially expressed 
proteins was compared with the previously described Nrf2 relationship, based on published 
knock-out mice studies (Kitteringham et al., 2010; Walsh et al., 2014) and the ingenuity 
knowledgebase (table 6.1). The altering expression profile of the differentially expressed 
proteins suggests, in the main, that Nrf2 is down-regulated during culture.  
As Nrf2 was not detected in the proteomic experiment, to test this hypothesis we then 
investigated the protein expression of Nrf2 during the culture period. Interestingly, given 
the down-regulation of many related proteins, Nrf2 showed remarkable stability during 
culture, increasing slightly in some of the donors (figure 6.2a and b). At each timepoint, 
Nrf2 was found to be inducible following a 2 hour exposure with bardoxolone methyl 
(CDDO-me), with the degree of induction increasing between 24 and 72/168 hours (figure 
6.2b).  
Analysis of downstream proteins ectonucleoside triphosphate diphosphohydrolase 5 
(ENTPD5) and heme oxygenase (HO-1) further corroborated the findings in table 1, 
demonstrating down-regulation during culture (figure 6.3). However, NAD(P)H 
Dehydrogenase, Quinone 1 (NQO1) demonstrated an up-regulation, which was more in-
keeping with the pattern seen with Nrf2 protein expression (figure 6.3). Furthermore, in 
non-dosed conditions, Keap1 protein expression mirrored Nrf2 expression at all timepoints 
(n=2), as demonstrated by the significant correlation between the two proteins during 
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culture (figure 6.2c). Interestingly, of the Nrf2-related proteins, only HO-1 appeared to 
show increased expression when following induction with CDDO-me.  
Continuous exposure to CDDO-me through supplementation in the culture media was able 
to produce an increase in Nrf2 expression over the culture period, without loss of efficacy 
(figure 6.4). Of note, as with the 2 hour induction, the cells appear to become more 
inducible during the culture period, increasing in their degree of Nrf2 induction.  
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Accession no. Association Positive/negative Nrf2 regulation 
Protein name 
Up-/down-regulated at 
168 hours Predicted Nrf2 activation state 
P-value 
IPA/KO 
study +/- +/- +/- 
P04179 IPA + Superoxide dismutase [Mn], mitochondrial + + 9.95E-08 
P11509 IPA + Cytochrome P450 2A6 - - 1.77E-07 
Q16836 KO - Hydroxyacyl-coenzyme A dehydrogenase, mitochondrial - + 9.02E-06 
P07099 KO/IPA + Epoxide hydrolase 1 - - 2.46E-05 
Q14764 KO + Major vault protein + + 6.60E-05 
Q13451 IPA + Peptidyl-prolyl cis-trans isomerase FKBP5 + + 0.00017 
O95831 KO + Apoptosis-inducing factor 1, mitochondrial - - 0.00018 
P04040 IPA/KO + Catalase - - 0.00019 
P63104 KO + 14-3-3 protein zeta/delta + + 0.00026 
P14625 IPA Unknown Endoplasmin - N/A 0.00044 
Q00796 KO + Sorbitol dehydrogenase - - 0.00050 
P02679 KO + Fibrinogen gamma chain + + 0.00128 
P21980 KO - Protein-glutamine gamma-glutamyltransferase 2 + - 0.00198 
P05177 IPA/KO + Cytochrome P450 1A2 - - 0.00203 
P31948 IPA + Stress-induced-phosphoprotein 1 + + 0.00209 
P55072 IPA + Transitional endoplasmic reticulum ATPase + + 0.00212 
O00264 KO + Membrane-associated progesterone receptor component 1 - - 0.00237 
P43490 KO + Nicotinamide phosphoribosyltransferase + + 0.00262 
P07900 IPA Unknown Heat shock protein HSP 90-alpha + N/A 0.00307 
Q02318 KO + Sterol 26-hydroxylase, mitochondrial - - 0.00308 
Q96I99 KO 
+ 
Succinyl-CoA ligase [GDP-forming] subunit beta, 
mitochondrial - 
- 
0.00333 
O14832 KO + Phytanoyl-CoA dioxygenase, peroxisomal - - 0.00383 
P18669 KO - Phosphoglycerate mutase 1 + - 0.00423 
P00338 KO - L-lactate dehydrogenase A chain + - 0.00423 
Q9HAV7 KO/IPA - GrpE protein homolog 1, mitochondrial - + 0.00510 
P23141 KO + Liver carboxylesterase 1 - - 0.00532 
P06753 KO - Tropomyosin alpha-3 chain + - 0.00576 
P23528 KO + Cofilin-1 + + 0.00577 
P30040 IPA + Endoplasmic reticulum resident protein 29 - - 0.00634 
O75356 KO/IPA + Ectonucleoside triphosphate diphosphohydrolase 5 - - 0.00690 
P09210 IPA + Glutathione S-transferase A2  - - 0.00713 
Q9BPW8 KO + Protein NipSnap homolog 1 - - 0.00901 
P62826 KO - GTP-binding nuclear protein Ran + - 0.01000 
P14314 KO + Glucosidase 2 subunit beta - - 0.01011 
P48643 KO/IPA - T-complex protein 1 subunit epsilon + - 0.01242 
Q14749 KO - Glycine N-methyltransferase - + 0.01256 
P22760 KO - Arylacetamide deacetylase - + 0.01369 
Q06278 IPA + Aldehyde oxidase - - 0.01439 
P15104 KO + Glutamine synthetase - - 0.01597 
Q96CM8 KO/IPA + Acyl-CoA synthetase family member 2, mitochondrial - - 0.01626 
P11310 KO 
- 
Medium-chain specific acyl-CoA dehydrogenase, 
mitochondrial - 
+ 
0.01648 
P80404 KO + 4-aminobutyrate aminotransferase, mitochondrial - - 0.01669 
Q15185 KO - Prostaglandin E synthase 3 + - 0.01702 
P23284 KO/IPA + Peptidyl-prolyl cis-trans isomerase B - - 0.01709 
Q02252 KO 
+ 
Methylmalonate-semialdehyde dehydrogenase [acylating], 
mitochondrial - 
- 
0.02075 
P08263 IPA + Glutathione S-transferase A1 - - 0.02209 
O75795 KO + UDP-glucuronosyltransferase 2B17 - - 0.02395 
P06737 KO + Glycogen phosphorylase, liver form - - 0.02462 
P05091 KO + Aldehyde dehydrogenase, mitochondrial - - 0.02824 
P36957 KO - 
Dihydrolipoyllysine-residue succinyltransferase component 
of 2-oxoglutarate dehydrogenase complex, mitochondrial 
- + 0.03211 
P22102 KO + Trifunctional purine biosynthetic protein adenosine-3 + + 0.03493 
Table 6.1: Nrf2 related differentially expressed proteins during PHH dedifferentiation 
Proteins cross-referenced from chapter 5 differentially expressed proteins at 168 hours against Nrf2 
knockout studies and IPA knowledgebase for known Nrf2 interactions (Walsh et al., 2014; Kitteringham et 
al., 2010). The predicted activation state of Nrf2 was then ascertained given the expression of the protein 
during dedifferentiation. 
C
h
ap
te
r 6
 
 
C
h
ap
ter 6
 C
h
ap
ter 6
 
 
Chapter 6 
187 
 
Figure 6.2: PHH Nrf2 expression and inducibility increases during culture 
a) Western blot of Nrf2 expression in PHH during 168 hour culture (+) with and (-) without a 2 hour 
induction with 100nM CDDO-me (-) or 0.5% (v/v) DMSO as a vehicle control. b) Densitometry of Nrf2 
during culture relative to expression at 24 hours and Nrf2 induction relative to the control samples at 
each timepoint normalised to β-actin; n=3 donors. (*) denotes p<0.05 by paired T-test. 
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Figure 6.3: PHH Nrf2 up-/downstream proteins show differential expression and inducibility patterns 
during culture 
a)  Western blots of Nrf2 up-/downstream protein expression in PHH during 168 hour culture (+) with and 
(-) without a 2 hour induction with 100nM CDDO-me (-) and 0.5% (v/v) DMSO as a vehicle control. b) 
Protein expression of down-stream targets of Nrf2 during culture, shown relative to the expression at 24 
hours; n=2. c) Relationship between Nrf2 and key regulator Keap1 and the correlation between these two 
proteins during culture (n=2 donors). Significance calculated using linear correlation. 
Abbreviations: Nrf2: nuclear factor (erythroid-derived 2)-like 2, Keap1: Kelch-Like ECH-Associated Protein 
1; NQO1: NAD(P)H Dehydrogenase, Quinone 1; HO-1: Heme oxygenase; ENTPD5: Ectonucleoside 
Triphosphate Diphosphohydrolase 5.   
Chapter 6 
189 
 
 
  
Figure 6.4: Comparison of CDDO-me induction and media supplementation during culture 
a) Nrf2 western blots of PHH subjected to acute or chronic exposure through media supplementation of 
CDDO-me during culture; (-) 0.5% (v/v) DMSO control in induction and normal culture in 
supplementation, (+) 100nM CDDO-me. b) Densitometry comparison of induction and supplementation 
relative to their respective controls normalised to β-actin; n=1 donor. 
Abbreviations: Nrf2: nuclear factor (erythroid-derived 2)-like 2 
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Phenotypic comparison of PHH cultured in the presence of CDDO-me 
We next established if the increase in Nrf2 was functionally important using the Nrf2 
downstream protein, NQO1. NQO1 followed a similar pattern to Nrf2, demonstrating 
increasing expression during the culture period in response to CDDO-me (Figure 6.5). The 
results suggest a cumulative effect over the culture period, with the 168 hour CDDO-me 
supplemented PHH demonstrating significantly greater NQO1 expression than both the 
non-dosed 168 hour time-matched control and the dosed cultures at the earlier timepoints. 
This was despite Nrf2 showing little difference in induction between 72 and 168 hours 
(figure 6.2).   
We then investigated the effect of Nrf2 induction on specific aspects of cell phenotype 
which are not directly related to Nrf2 induction. CYP3A4 is a key metabolic enzyme which is 
perturbed during dedifferentiation (chapter 5) and, to the best of our knowledge, has no 
known relationship to Nrf2 expression. Across 3 donors we found that CYP3A4 was 
negatively regulated by the supplementation with CDDO-me; however, this degree of 
down-regulation varied between donors and was only found to be significantly 
differentially expressed at 48 hours (p<0.05; figure 6.5).  
Albumin secretion is a well-established marker of hepatic phenotype and is often used to 
screen newly established culture conditions. Our results suggested that, across 4 donors, 
albumin secretion was not altered by Nrf2 induction over the period of culture (Figure 
6.5d).  
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Figure 6.5: Effect of CDDO-me media supplementation on the hepatic phenotype 
a) Western blots of NQO1, CYP3A4 and β-actin during culture with and without CDDO-me 
supplementation. Combined densitometry of b) NQO1 and c) CYP3A4 during culture with and 
without supplementation of CDDO-me; n=3 donors. (*) denotes p<0.05 by paired T-test vs 
time-matched control; (#) denotes p<0.05 by one-way ANOVA compared to other CDDO-me 
treated timepoints. d) Comparison of normal and CDDO-me supplemented culture albumin 
secretion detected by ELISA and shown as a relative fold change to the values at 24 hours; 
n=4 donors. 
Abbreviations: Nrf2: nuclear factor (erythroid-derived 2)-like 2; NQO1: NAD(P)H 
Dehydrogenase, Quinone 1. 
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Nrf2 during hepatocyte-like cell differentiation 
As Nrf2 has known roles in cell differentiation and appears to have a negative impact on 
the hepatic phenotype, we investigated the role of Nrf2 during pluripotent stem cell 
differentiation towards hepatocyte-like cells. We first compared the protein levels of Nrf2 
in both embryonic (ESC) and induced pluripotent stem cells (iPSCs) with their 
corresponding HLCs. We found that in all cases the level of Nrf2 protein expression 
increased from stem cell to HLC to levels which were greater than in freshly isolated PHH 
(Figure 6.6a-d).  
We also investigated the gene expression of Nrf2 to understand how the levels of Nrf2 may 
be changing during the differentiation period. Our results suggested an initial decrease in 
Nrf2 gene expression compared to iPSCs at the definitive endoderm stage; however, this 
preceded a slight increase at the hepatic endoderm stage, followed by a larger 3-fold 
increase in Nrf2 gene expression at the HLC stage of differentiation (Figure 6.6e).  
The functional consequence of the increase in Nrf2 expression was then assessed. NQO1 
expression was found to be increase during HLC differentiation in a similar pattern to Nrf2 
protein expression, with slight increases in NQO1 protein expression occurring from iPSC to 
hepatic endoderm stages, followed by a much larger increase between the hepatic 
endoderm and hepatocyte-like cell stages (figure 6.7).   
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  Figure 6.6: Nrf2 protein and gene expression increases during HLC differentiation 
a-c) Nrf2 western blots of a) Bath ESCs and HLCs b) Cellectis iPSCs and HLCs c) Liverpool iPSCs, definitive 
endoderm, hepatic endoderm and HLCs. d) Combined densitometry of the protein expression of Nrf2 during 
differentiation; n=5 iPSC lines; n=5 iPSC lines. (*) denotes p<0.05 by one-way ANOVA. e) qRT-PCR analysis of 
Nrf2 during HLC differentiation. 2-ΔΔCT displayed as relative fold change to iPSCs normalised to GAPDH; n=2 
wells of a single differentiation experiment.  
Abbreviations: Nrf2: nuclear factor (erythroid-derived 2)-like 2 
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Manipulating Nrf2 during HLC differentiation with siRNA 
As our results with primary hepatocytes suggest that Nrf2 negatively regulates key aspects 
of hepatic phenotype, and that current HLC differentiation protocols do not achieve a 
mature hepatic phenotype, we hypothesised that knock-down of Nrf2 during the final stage 
of differentiation may positively impact the phenotypic maturity of HLCs.  
Therefore, we attempted to alter Nrf2 expression using siRNA-based knockdown during the 
final stage of differentiation. We first investigated how effective the knockdown method 
was using hepatic endoderm-stage cells and various transfection methods. Our results 
suggested that knockdown was achievable with all techniques, with a reverse transfection 
method demonstrating the greatest knockdown in protein expression (Figure 6.8a and b).  
As the final period of differentiation is 12 days and the reverse transfection techniques 
requires re-plating of the cells, we decided to use a protocol which incorporated multiple 
Figure 6.7: NQO1 protein expression increases during HLC differentiation 
a) and b) NQO1 western blots of a) Cellectis iPSCs and HLCs b) Liverpool iPSC, definitive 
endoderm, hepatic endoderm and HLCs. c) Combined densitometry of NQO1 during HLC 
differentiation; n=3 iPSC lines. (*) denotes p<0.05 by one-way ANOVA 
Abbreviations: NQO1: NAD(P)H Dehydrogenase, Quinone 1; 
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forward transfections of siRNA during the culture period (Figure 6.8c). We compared the 
effects of 2x and 3x transfections of Nrf2 siRNA during the final stage of differentiation; 
however, when the Nrf2 protein expression was investigated, no knockdown was evident 
(Figure 6.8d and e). 
Furthermore, the gene expression data showed little difference compared to vehicle and 
non-transfected control differentiations (Figure 6.8f). It was therefore decided that siRNA-
based knockdown during differentiation was not an effective method of investigating the 
role of Nrf2, due to a lack of maintainable efficacy during the differentiation protocol.  
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Figure 6.8: Manipulation of Nrf2 with siRNA during HLC differentiation. 
a) Western blot and b) densitometry of Nrf2 protein expression normalised to β-actin following FT: 
forward transfection and RT: reverse transfection of siRNA targeted to Nrf2 against non-transfected 
and vehicle controls; n=1. c) Schematic diagram of the protocol used for multiple Nrf2 siRNA 
transfections during HLC differentiation. d) Western blot and e) densitometry of Nrf2 at the final stage 
of differentiation following multiple (2x or 3x) transfections of Nrf2 siRNA with controls; n=1 
differentiation experiment; β-actin western blot failed and therefore equal protein loading was 
confirmed by ponceau red stain (data not shown) f) qRT-PCR of Nrf2 at the final stage of 
differentiation following multiple (2x or 3x) transfections of Nrf2 siRNA with no transfected and 
vehicle controls. 2-ΔΔCT displayed as relative fold change to iPSCs normalised to GAPDH; n=2 wells of a 
single differentiation experiment. Error bars: SEM. 
Abbreviations: Nrf2: nuclear factor (erythroid-derived 2)-like 2 
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CRISPR/Cas9 knockdown of Nrf2 in A549s 
To take the investigation forward, we therefore decided to attempt a CRISPR/Cas9-based 
method of manipulating the iPSCs to knockdown Nrf2. To achieve this, we used a 
commercially available kit from Santa Cruz. As this was a new system, not previously used 
in the laboratory, we first attempted the technique using the lung carcinoma cell line A549. 
A549s have a mutated Keap1 gene which prevents binding to Nrf2 and targeting for 
degradation; consequently, these cells have very high basal Nrf2 protein expression (Singh 
et al., 2006).  
We established the concentrations of the selection gene, puromycin, to use in the selection 
of the knockout cells. In-keeping with previous literature (Zhu et al., 2007), A549s were 
found to be susceptible to 1.5µg/ml puromycin (data not shown). We then optimised the 
transfection using a non-coding CRISPR/Cas9 control plasmid with green fluorescent 
protein (GFP) tag. Using fluorescence microscopy, it was found that a good transfection 
efficiency was achievable using the manufacturer suggested conditions (figure 6.9a). 
Using these conditions, we transfected 3 x CRISPR/Cas9 plasmids targeted to different 
points in the exon regions of the Nrf2 gene and a HDR plasmid containing the puromycin 
selection gene. Transfections of both conditions were confirmed with fluorescence 
microscopy (CRISPR/Cas9 plasmid: GFP; HDR plasmid: RFP (red); figure 6.9b and c). The 
transfected cells were then selected by puromycin and individual colonies picked and 
expanded. We were also able to generate puromycin-resistant cells at much lower 
efficiency in the HDR-only control well, most likely through random integration of the HDR 
plasmid into the cell genome; these cells were used as an additional control in subsequent 
assays.  
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Figure 6.9: Transfection of A549 with CRISPR and HDR plasmids 
a) Optimisation of control CRISPR plasmid transfection using fluorescence 
microscopy. Magnification x100, scale bar: 100µm. b) Transfection of A549s with 
NRF2 CRISPR/Cas9 plasmids (GFP) alone using fluorescence microscopy. 
Magnification x200, scale bar: 50µm c) Combined transfection of Nrf2 CRISPR-
Cas9 (GFP) and HDR plasmids (RFP) confirmed by fluorescence microscopy. 
Magnification x200, scale bar: 50µm. 
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Analysis of A549s transfected with CRISPR/Cas9 plasmids.  
Analysis of the selected A549 selected clones showed mixed results (Figure 6.10). For 
example, KO4 and KO7 demonstrated an increase in expression of Nrf2 compared to wild-
type A549s; whereas KO1 showed a reduction, although no clone showed complete 
knockout at the protein level. All knockout lines showed lower Nrf2 protein expression than 
the HDR-only control, which was included as a better representative control of the 
selection culture conditions.   
To test if this change in Nrf2 expression had functional consequences, we also investigated 
the protein expression of NQO1 (Figure 6.10). All clones which received the CRISPR/Cas9 
plasmid showed reduced in NQO1 expression, the degree of which varied between clones. 
Therefore, despite Nrf2 protein expression remaining, its functional capacity appears to 
have been reduced.  
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Optimising CRISPR/Cas9 knockdown in iPSCs 
The transfection of pluripotent stem cells is known to be difficult (Villa-Diaz et al., 2010). 
Therefore, further optimisation of the transfection technique was required before 
CRSIPR/Cas9 could be attempted.  
Figure 6.10: Nrf2 and NQO1 protein expression in A549s following CRISPR/Cas9 transfection 
and isolation 
a) Western blots for Nrf2, NQO1 and β-actin in A549 wild type (WT), HDR-only and knock out 
lines. b) and c) densitometry for NRF2 and NQO1 western blots. Results normalised to β-actin 
and shown relative to A549 WT. Each clone: n=1.  
Abbreviations: Nrf2: nuclear factor (erythroid-derived 2)-like 2; NQO1: NAD(P)H 
Dehydrogenase, Quinone 1. 
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Several conditions were investigated based on a recent paper which describes methods for 
enhancing plasmid transfection of ESCs (Villa-Diaz et al., 2010). These conditions were: 
forward transfection, reverse transfection, modified reverse transfection (transfection 
complexes plated with Matrigel) and 1% DMSO. Our results demonstrated no GFP+ve cells 
in the various conditions analysed (Figure 6.11a).  
We therefore attempted a different transfection reagent, Lipofectamine 3000. We found 
that this technique allowed for the transfection of the control plasmid, albeit at low 
efficiency (Figure 6.11b). No difference in efficiency was found across the various 
conditions, although reverse transfection was noted to cause greater toxicity. Therefore, 
forward transfection using Lipofectamine 3000 was taken forward for transfection of the 
Nrf2 CRISPR/Cas9 plasmids.   
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Figure 6.11: Transfection of iPSCs with non-coding CRISPR plasmid using different 
transfection reagents. 
a) UltraCruz and b) Lipofectamine 3000. Various transfection techniques, cell density 
and with or without 1% DMSO investigated by fluorescence microscopy for uptake of 
GFP containing non-coding CRISPR/Cas9 control plasmid (GFP). Magnification x200, 
scale bar: 50µm 
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CRISPR/Cas9 knockdown of Nrf2 in iPSCs 
Using the optimised conditions, we then attempted to derive a Nrf2 knockout iPSC line 
using the CRISPR/Cas9-HDR system. Figure 6.12a demonstrates successful transfection of 
the CRISPR/Cas9 and HDR plasmids into the iPSCs using fluorescence microscopy. The 
efficiency was noted to be low, but this was in-keeping with the optimisation results 
presented in figure 6.11. A small degree of cell death was noted between pre- and post-
transduction (figure 6.12b); however, this was not greater than the cell death observed in 
the vehicle control.  
Following puromycin selection (0.5mg/ml), large-scale cell death was noted throughout the 
cultures with very few cells remaining. After extended culture, one clone was noted at day 
18 post-transfection (Figure 6.12c). This was subsequently tracked over 7 days to ascertain 
its growth and morphological characteristics. Our results showed little-to-no growth of the 
colony during this period.  
Furthermore, live staining analysis of cell surface markers at day 25 of culture revealed no 
expression of the iPSC marker Tra-1-60. The immunofluorescence images demonstrate a 
diffuse signal which lacked the defined staining seen in previously stained Liv1W cells. 
Subsequent attempts to expand this clone further using manual picking resulted in no 
attachment or propagation.  
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Figure 6.12: Successful transfection of iPSCs with CRISPR/Cas9 and HDR plasmids 
using optimised conditions did not result in expandable Nrf2 KO clones  
a) i) Fluorescence microscopy of CRISPR/Cas9 Nrf2 plasmid (GFP) and HDR plasmid 
(RFP) in transfected cells. Magnification x200, scale bar: 50µm. b) Phase contrast 
images of i) pre-transfection; ii) 24 hours post-transfection with CRISPR/Cas9 Nrf2 and 
HDR plasmids; iii) 24 hours post-transfection vehicle control. Magnification x40, scale 
bar: 100µm. c) Morphological and immunofluorescence assessment of CRISPR/Cas9 
transfected cells after puromycin selection. IF: Magnification x200, scale bar: 50µm 
Cells selected with 0.5mg/ml puromycin. Phase contrast images: 200x magnification; 
scale bar 10µm.  
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6.3 Discussion 
The work presented in this chapter represents an attempt to better understand the role of 
Nrf2 in hepatocyte differentiation and dedifferentiation.  
Our initial hypothesis was based on the hepatocyte dedifferentiation work reported in 
chapter 5. Of the differentially expressed proteins at 168 hours, the Nrf2-related proteins 
suggested that Nrf2 function was inhibited. However, upon investigation of the Nrf2 
protein expression, the level was maintained or increased during culture. One known 
mechanism of Nrf2 regulation is via the protein Keap1 (Itoh et al., 2003). Our results show 
the protein expression of Keap1 closely mirrors that of Nrf2 during the culture period. This 
suggests that as Nrf2 increases, so does Keap1 and vice versa in a homeostatic-like 
response. Moreover, the downstream protein NQO1 continues to rise during culture, 
suggestive of a cumulative effect of Nrf2 activation. Furthermore, despite little apparent 
change in the ratio between Nrf2 and Keap1 protein expression levels, some Nrf2-related 
proteins reduce in expression, whilst others increase, a suggesting a degree of Nrf2 
dysregulation during PHH culture. Investigating the nuclear versus cytoplasmic Nrf2 protein 
expression levels may further elucidate the mechanisms of action contributing to the Nrf2-
related protein expression profile described in table 6.1.  
One potential factor which could generate a selective Nrf2-related protein profile and is 
known to be both active during dedifferentiation and interact with Nrf2, is NFκB. The cross-
talk between these two factors has been reported in numerous papers (Buelna-Chontal and 
Zazueta, 2013), which describe how both factors can inhibit the other through various 
mechanisms. One of these potential mechanisms is through the NFκB-mediated p65-
dependent recruitment of HDAC3 to the binding area of Nrf2 (antioxidant response 
element: ARE), causing hypoacetylation of the ARE in the promoter region and inhibiting 
Nrf2-dependent expression (Liu et al., 2008a). This would allow for a selective loss of Nrf2-
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related proteins which have Nrf2 and NFκB binding sites in close proximity. Further work 
elucidating these mechanisms may explain the up- and down-regulation of Nrf2-related 
proteins despite no clear change in Nrf2 protein content.  
The reduction of CYP3A4 protein expression following Nrf2 induction with CDDO-me was 
an intriguing result as, to the best of our knowledge, this interaction has not been 
previously reported in hepatocytes. It is perhaps unsurprising given the free radicals which 
are produced by the cytochromes P450 even in the absence of substrate (Zangar et al., 
2004). Therefore, as Nrf2 is the master-regulator of the response to oxidative stress, a 
mechanism to reduce CYP3A4 protein and consequently free radical production is logical. 
Another potential cause of the loss of CYP3A4 is through Nrf2’s relationship with the 
proteasome (Chapple et al., 2012), as it has previously been shown that proteasome 
inhibition causes the suppression of CYP3A4 protein expression (Zangar et al., 2003). 
Further work is required to confirm that this a Nrf2-mediated mechanism, including siRNA 
targeting Nrf2 and Keap1 to modulate protein expression, with a reduced possibility for the 
off-target effects associated with pharmacological modulation. One known off-target effect 
of CDDO-me is as an inhibitor of NFκB (Shishodia et al., 2006); however, NFκB is thought to 
reduce CYP3A4 expression (Zangar et al., 2008), therefore its inhibition is unlikely to be the 
cause of reduced CYP3A4 protein expression.  
Nrf2’s role in hepatic differentiation is of emerging importance. Recent work has pointed 
towards Nrf2 being a downstream effector of Notch signalling (Wakabayashi et al., 2013), 
skewing the bipotent decision between hepatocyte and cholangiocyte lineages towards the 
latter. Therefore, if true, Nrf2 expression in hepatocytes is likely to have a detrimental 
effect in terms of mature phenotype. Our results suggest that a similar mechanism may be 
inhibiting the generation of HLCs which are restricted to the hepatic lineage during the final 
maturation phase (Baxter et al., 2010). Our analysis was conducted across four different 
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starting pluripotent lines (one ESC and three iPSCs) and three different differentiation 
protocols from three different laboratories, suggesting that the phenomenon is highly 
conserved across cell types and protocols. In general, the greatest Nrf2 expression was 
seen in the HLCs generated from the University of Bath and the lowest in those supplied 
from Cellectis. The inverse was true in terms of cell morphology and homogeneity, further 
suggesting that Nrf2 negatively regulates HLC purity and phenotype. 
As part of our studies, we attempted to establish whether the observed correlation was a 
functional relationship; however, we were unable to develop an efficacious method for 
manipulating Nrf2 expression in iPSCs or during HLC differentiation. This difficulty is likely 
to be multi-faceted. 
For example, across the A549 knockout lines generated, no complete loss of Nrf2 was 
detected; however, the loss NQO1 expression across all lines suggested that Nrf2 function 
was disrupted. This may be due to numerous causes. The CRISPR/Cas9 system used was 
purchased from Santa Cruz and contained three CRISPR plasmids which cut the gene in 
three separate exon locations and three homology-dependent repair plasmids which 
inserts the puromycin selection gene into the cut areas. However, due to difficulties in 
producing the HDR plasmids, only one of the three HDR plasmids were received from Santa 
Cruz and could therefore be used. This reduced the chances of success in creating a 
complete knockout clone. When HDR is not used as a repair option, the cell uses a NHEJ 
repair mechanism which is prone to error and therefore often results in a mutated gene 
and loss of expression (Maruyama et al., 2015). However, it may also result in a  mutated 
protein which is still produced but has reduced efficacy or is non-functional (Sander and 
Joung, 2014).  
Another potential cause of incomplete Nrf2 knockout in all lines is the known importance 
of Nrf2 to cancer cell lines proliferation and survival (Lister et al., 2011). Thus, all clones 
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with complete knockout may have entered apoptosis or been out-grown, resulting in only 
those clones which had incomplete knockout being both puromycin-resistant and capable 
of expansion in culture. The lack of complete knockdown may also be caused by 
heterogeneous population of cells which may be addressed through single cell cloning to 
derive a homogenous population (Longo et al., 2013). We did not follow this path for two 
reasons: firstly, the knockdown of Nrf2 often causes a dramatic reduction in cell growth 
properties and it is therefore likely to be difficult to derive a single cell clone; secondly, the 
A549 cell line was not to be used to address our hypothesis.  
We therefore continued our investigation using the CRISPR/Cas9 in our established iPSC 
lines. Following the development of a technique allowing for transfection of iPSCs, we 
attempted to derive an Nrf2 knockout iPSC line. However, we were unable to generate any 
clones using the puromycin selection technique. This may be due to the combined effect of 
low transfection efficiency and the single HDR plasmid meaning that no cell received the 
correct combination of CRISPR/Cas9 and HDR.  
Nrf2 has recently been shown to have an important role in maintaining pluripotency in 
embryonic stem cells (Jang et al., 2014). Therefore, knockdown of Nrf2 may have negative 
consequences in terms of pluripotent capacity. As pluripotent stem cells are thought to be 
highly sensitive to cell stress and a disruption of the Nrf2 pathway may lead to apoptosis 
through enhanced levels of oxidative stress, changes in cell cycle and/or changes to the 
pluripotent regulatory network (Gonzales et al., 2015; Liu et al., 2013). However, it must be 
noted the Nrf2 knock out mouse model is non-lethal (Kitteringham et al., 2010). The 
combined effect of these factors with the low efficiency of transfection makes the 
generation of Nrf2 knockout iPSCs a particularly difficult prospect. Further work may look 
into the use of different delivery mechanisms, such as using nucleofection rather than 
cationic liposome-based methods (Byrne et al., 2015; Chatterjee et al., 2011) or even viral 
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constructs to enhance delivery efficiency. It has previously been shown that adenovirus 
delivery of FOXA2 and HNF1α during HLC differentiation can enhance the hepatic 
phenotype (Takayama et al., 2012); therefore, a similar mechanism of delivering Nrf2 siRNA 
may prove to be a more successful delivery method. Alternatively, the pharmacological 
inhibitor brusatol may be used (Olayanju et al., 2015).  
Taken together, this chapter has demonstrated novel unreported roles for Nrf2 in both 
hepatocyte differentiation and dedifferentiation in vitro. The importance of Nrf2 to 
maintaining and acquiring the hepatic phenotype remains to be determined and concerted 
efforts are being made within our laboratory to ensure a method of mechanistically 
assessing the role of Nrf2, particularly during HLC differentiation, is achieved. 
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Chapter 7 
General discussion 
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7.1 Introduction 
The research presented in this thesis represents our attempts to better understand and 
enhance in vitro models of hepatotoxicity. The need for this work stems from the inability 
of current culture systems to adequately support the mature hepatic phenotype, 
preventing effective screening and triaging of potentially dangerous compounds in drug 
development pipelines (Godoy et al., 2013). Furthermore, due to a lack of clinical 
relevance, post-toxicity mechanistic studies investigating how and why DILI occurred are 
also often not achievable with current hepatotoxicity models. As a consequence, DILI 
remains a huge burden on healthcare systems around the world and has large financial 
costs for pharmaceutical companies.   
Our work has utilised a combination of innovative techniques and novel insights which 
should serve to enhance the understanding of hepatic models. We have established a 
range of reprogramming and differentiation protocols and used these to investigate the 
potential for utilising the inherent epigenetic memory which is found in iPSCs to improve 
the differentiation of hepatocyte-like cells (HLCs). We also used a step-back approach to 
investigate primary human hepatocytes (PHH) dedifferentiation from a proteomic 
perspective, attempting to understand which factors are driving the dramatic loss of 
phenotype during culture. This is particularly pertinent as current culture systems cannot 
maintain a fully mature hepatic phenotype; therefore, attempts to derive stem cell-based 
hepatic models are likely to fail given the inability of the culture system to support the 
desired phenotype. A noticeable trend in the PHH dedifferentiation proteomic dataset was 
the loss of Nrf2-related proteins during culture. Nrf2 is a transcription factor with well-
described roles in the response to oxidative stress; however, a growing body of work also 
suggests roles for Nrf2 during development (Wakabayashi et al., 2013). We aimed to 
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investigate this in relation to PHH and HLCs through pharmacological and genetic 
manipulation techniques.  
This chapter aims to summarise the work presented hitherto and put the results presented 
into the context of the field of hepatotoxicity whilst also discussing how the research could 
be taken forward to further enhance the development of more clinically representative 
models of hepatotoxicity.  
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7.2 Implications and future perspectives 
7.2.1 Assessing the importance of the starting somatic cell for iPSC generation   
Chapters 3 and 4 represent our attempts to develop and optimise reprogramming 
techniques for different cell types for the subsequent generation of HLCs. Across three 
donors we found only slight, non-significant, advantages to starting with PHH over human 
dermal fibroblasts (HDFs). The lack of significant differences between starting cell types 
points towards the importance of other factors being of similar or greater influence in 
determining the quality of hepatic differentiation.  
The methods developed in chapter 4 and used in chapter 5 to differentiate our iPSCs to 
HLCs were based on numerous published protocols; however, it should be acknowledged 
that the protocol used is not as complex as some more recently reported techniques.  One 
such example is a protocol developed by Aspund et al., describing a method which greatly 
reduces the inter-clone variation in HLC differentiation capacity (Asplund et al., 2015). The 
use of such a protocol may allow for reduced impact of other factors which influence HLC 
differentiation and give a clearer understanding of the influence of starting cell type. 
Furthermore, the use of a 3D culture system, such as spheroid-based models (Takayama et 
al., 2013; Subramanian et al., 2014), which enhances hepatic phenotype may generate 
HLCs of greater maturity and further accentuate the small differences seen between the 
starting cell types in the monolayer system used in this study.  
To allow for a full understanding of the differentiation capacity of the iPSCs generated, we 
attempted to assess the cells at all stages of culture and use a wide-range of assays that go 
above and beyond previously reported investigations into epigenetic memory and HLCs. 
Despite this, a fuller understanding of the differences, if any, between the cells may be 
achieved by incorporating more experimental approaches. These include global 
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assessments of cell phenotype, e.g. iTRAQ proteomics. An omic-based approach would 
allow an unbiased investigation of phenotype, rather than the panel-based approach 
presented in this thesis. Establishing the protein expression and inducibility of CYPs would 
also be of interest to understanding the pharmacological profile of the cells in basal and 
induced states. Furthermore, the use of toxicity assays with known hepatotoxins may 
further allow for functional differences to be ascertained. However, comparison of 
toxicological phenotypes is perhaps premature given the clear lack of mature 
pharmacological phenotype in the HLCs generated, making any results using the relatively 
blunt endpoint of toxicity difficult to interpret.  
Notwithstanding the potential of using an improved differentiation protocol or any further 
differences found in future assessments, any improvement in phenotype must be weighed 
against the restricted phenotypic range of, and the specialised techniques and 
infrastructure required to isolate, PHH. Furthermore, the cell-type specific advantage 
reported previously in hepatocytes and other cell types has been shown to be transient 
(Lee et al., 2012; Takayama et al., 2014). The epigenetic studies performed in chapter 4 
demonstrate this convergence of PHH-derived clones towards HDF-derived clones 
methylation status as passage number increases. Therefore, taken together, the data 
presented in these chapters does not provide enough evidence to warrant the use of PHH 
over HDFs as a starting cell type due the inherent disadvantages of using PHH over HDFs. 
Of these disadvantages, phenotypic restriction is perhaps the most pertinent for the use of 
PHH-derived iPSCs for use in modelling DILI. The comparative ease at which HDFs of 
peripheral mononuclear blood cells (PBMCs) can be accessed and isolated means that 
donors of interest can be specifically chosen based on the study requirements (Agu et al., 
2015; Aasen and Belmonte, 2010). This opens up the possibility for disease-specific 
modelling of genetic conditions, which has been shown to be possible in HLCs in the case of 
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alpha-1-antitrypsin disease (Yusa et al., 2011; Wilson et al., 2015). Moreover, for such 
conditions, HLCs may also be used for studies of drug efficacy, whilst further studies may 
wish to look at other genetic traits which will likely influence liver function, such as type I 
diabetes.  
Uniquely, iPSCs also offer the possibility to model idiosyncratic DILI in vitro (Krueger et al., 
2014). Idiosyncratic DILI is currently beyond the remit of all other non-iPSC in vitro models 
due to the inability to ‘choose’ the phenotype of the model. Much work is still required to 
fully realise the potential, but incremental steps are being made in developing such models. 
For example, recent work by Takayama et al., showed that CYP2D6 gene expression in HLCs 
was dependent on the donor profile (Takayama et al., 2014). CYP2D6 is of particular 
interest as high frequency polymorphisms within the population result in different rates of 
metabolism and clearance for drugs using this pathway, such as tamoxifen (Hoskins et al., 
2009). This variation was shown in the HLCs with differential toxicity profiles observed in 
response to tamoxifen (Takayama et al., 2014). Such panel screening methods would be 
highly informative for drugs which are predicted to interact with proteins with known 
variation across populations.    
Furthermore, despite reports that mitochondrial function is significantly lower than in PHH, 
(Yu et al., 2012), mitochondrial-based diseases have also been modelled using HLCs (Li et 
al., 2015). iPSC-derived HLCs generated from patients suffering from Alpers-Huttenlocher 
syndrome, a disorder caused by mutations in mitochondrial DNA polymerase gamma, 
showed enhanced susceptibility to valproic acid. This mirrored the hepatotoxicity observed 
in the clinic. Moreover, the authors were then able to use these cells to establish the cause 
of the toxicity: the increase occurrence of mitochondrial permeability transition pore 
opening, and using cyclosporine A, rescue the toxicological phenotype (Li et al., 2015). This 
study highlights the capacity of iPSC-derived HLCs for generating novel information 
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regarding existing diseases/disease-specific toxicity susceptibility and developing new 
strategies to treat these conditions. 
Therefore, given the wide-ranging potential of the phenotypic-range associated with iPSCs 
derived from easily accessible cell types, the reported small and transient phenotypic 
advantage associated with using of PHH as a starting cell type is not great enough to 
warrant replacement of HDF and PBMC-derived iPSCs in future studies.    
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7.2.2 The roadblocks inhibiting the generation of mature hepatocyte-like cells from 
pluripotent stem cells 
The work presented in chapter 4 demonstrated that there was little-to-no enhancement of 
hepatic phenotype when different starting cell types were used. Therefore, as we have 
established that current protocols are using the most appropriate starting cell type, it is 
clear that the development of better differentiation techniques which can produce 
hepatocyte-like cells with a mature phenotype are required.  
Chapter 6 presented our attempts to interrogate the role of Nrf2 during hepatocyte 
differentiation and dedifferentiation. The results demonstrated a potentially negative 
relationship between Nrf2 and the hepatic phenotype. This is generally in-keeping with a 
broader rule that in times of cell stress, the hepatic phenotype, particularly in terms of 
xenobiotic metabolism, is down-regulated. This is likely to be caused by a combination of 
the hepatocyte attempting to reduce total cellular stress and focus the cells available 
resources on cell survival associated functions. 
Much work is being focussed on the development of models which better represent the 
hepatic niche for the final maturation stage of differentiation. However, the initial stages of 
differentiation remain relatively undeveloped since the first use of Activin A (D'Amour et 
al., 2005). This is of particular importance given the work by Chen et al., who showed that 
despite similarities, Nodal- and Activin A-based differentiation to definitive endoderm, both 
of which are active in normal development, yielded cells with similar but different 
phenotypes (Chen et al., 2013). The work went on to describe later stage functional 
differences in endodermal cells ability to form insulin/c-peptide-expressing cells in vivo. Of 
note, it has previously been shown that the Activin A/Nodal signalling pathway can alter 
chromatin marks of key developmental genes in ESCs (Bertero et al., 2015). 
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This raises interesting questions in terms of producing HLCs, i.e. how important are the 
intermediate phenotypes during differentiation? And how do they compare to the in utero 
situation? (Figure 7.1). Most differentiation assays use a panel of markers to confirm the 
cells are definitive or hepatic endoderm, yet comparing this to the relevant stage of 
development is particularly difficult. The advent of laser-capture microscopy may allow 
transcriptomic profile of each developmental stage to be compared with the in vitro 
equivalents. Perhaps more pertinent are the epigenetic changes that occur in the enhancer 
regions of each gene before expression is turned on. This is true during cellular 
reprogramming (Papp and Plath, 2013) and similar mechanisms have been shown to 
influence endodermal differentiation to pancreatic cells (Wang et al., 2015). If the profile of 
primed genes and enhancer regions differs between in utero and in vitro conditions, then 
the inability to produce a fully mature hepatocyte is perhaps unsurprising. Whilst the exact 
mechanisms have not been delineated, the downstream epigenetic effects have been 
investigated. Park et al., showed that the promoter regions of CYP1A1, CYP1A2, CYP1B1, 
CYP2D6, and CYP2E1 were hypermethylated in HLCs but hypomethylated in PHH (Park et 
al., 2015). This work suggests that the epigenetic profile of the cell has not followed the 
standard pattern of differentiation, either through a failure to prime these genes for 
expression at earlier stages of differentiation or an inability to promote a more mature 
phenotype in current culture conditions.  
This hypothesis is given further credence by the recent paper which reported the 
development of iMPCs (induced multi-potent progenitor cells; somatic cells reprogrammed 
to an expandable definitive endoderm cell type) (Zhu et al., 2014). As part of this research 
the authors successfully used a Notch inhibitor to improve differentiation of the iMPCs 
towards hepatocyte-like cells. However, when Notch inhibition was attempted with iPSC-
derived HLCs, no enhancement in phenotype was noted (Zhu et al., 2014). Therefore, the 
cells which are maintained as endodermal cells have a different inherent response to the 
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same culture conditions, suggesting different capacity for the cell to react to a 
developmentally relevant cue. Further work is required to investigate the differences 
between these cell types at the endodermal stage of differentiation.  
The Notch/Wnt axis is well-described in the bi-potent cell-fate decision made during liver 
development and regeneration (Chapple et al., 2012); however, to the best of our 
knowledge, manipulating this pathway has not been routinely used to enhance hepatic 
maturation. The work described in chapter 6 may provide a mechanism to explain the 
differences between development and in vitro differentiation. A proposed down-stream 
mediator of Notch signalling is Nrf2 (Wakabayashi et al., 2013). The high levels of Nrf2 
during the maturation of HLCs from iPSCs suggests either that Notch signalling is highly 
active in these cells or that cellular stress is high at this late stage of in vitro differentiation. 
As a consequence, Notch/Wnt manipulation may fail to result in an improved phenotype 
through a failure of upstream pathway manipulation to alter Nrf2 expression levels beyond 
the required threshold or that the high Nrf2 expression in HLCs is unrelated to the 
Notch/Wnt axis and is instead due to the cellular stress of in vitro differentiation; however, 
the detrimental downstream effects on phenotype are the same. Manipulation of Nrf2 
during differentiation is on-going in our laboratory as we strive to better understand its 
role in hepatic differentiation.  
The use of microbial-derived lithocholic acid and vitamin K2 has recently been shown to 
enhance the metabolic phenotype of HLCs (Avior et al., 2015). Such work highlights the 
need to look ‘outside of the box’ in terms of standard developmental models. For example, 
during pre- and post-natal development, the immune system is primed against multiple 
antigens through exposure to environmental or vaccine-derived pathogens (Salzman, 2014; 
Ygberg and Nilsson, 2012). It may therefore be the case that the metabolic qualities of the 
liver need to be ‘primed’ using the relevant substrates; ostensibly, standard maturation 
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media does not represent the physiological conditions, i.e. the media is both static and 
does not contain the by-products of ingested material, e.g. substrates such as caffeine or 
products of the microbiome, such as the aforementioned lithocholic acid (Avior et al., 
2015). This hypothesis shares similarities with an idea proposed by Zanger et al  (Zangar et 
al., 2004; Zangar et al., 2003), whom suggested a mechanism of selective CYP regulation 
based on the presence of a substrate for that isoform.  
  
Figure 7.1: Comparison of liver development and in vitro differentiation towards the hepatic 
lineage. 
Schematic diagram demonstrating the points of comparison used during the differentiation of HLCs. 
Orange arrows represent commonly used comparators at the stage of interest; black arrows represent 
points of comparison which are not currently used and may be used to derive further information. 
Immunofluorescence image is a PHH spheroid culture stained for albumin (red) and Hoechst 33342 
stain (blue). Scale bar 10µm.  
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7.2.3 Current utilities for hepatocyte-like cells from pluripotent stem cells 
As demonstrated by chapters 3 and 4, the lack of a fully mature hepatic phenotype 
currently precludes the use of HLCs for the investigation of studies which require a high 
metabolic capacity; however, HLCs should not be viewed as a one-for-all model and have 
been shown to be fit-for-purpose in numerous research areas which do not require the bio-
activation/metabolism of compounds or substrates. 
For example, the use of HLCs has been shown to be of benefit when investigating direct 
apoptosis-driven toxicity, with HLCs demonstrating a more similar apoptotic pathway 
profile to cryopreserved hepatocytes, than those seen in the Huh7 cell line (Sjogren et al., 
2014). The same study also demonstrated the long-term stability of cytochrome P450 
metabolism over a 7 day period. As demonstrated in chapter 3, CYP metabolism in PHH 
drops markedly during culture, restricting analysis to acute exposure. Therefore, the 
metabolic stability of HLCs, albeit at lower levels than PHH, may allow for the investigation 
of chronic exposure to compounds.   
Other uses include the modelling of cholesterol metabolism. Krueger et al., demonstrated 
the expression of a range of apolipoproteins required for all aspects of cholesterol 
metabolism in HLCs, including the active secretion of cholesterol into the culture medium 
(Krueger et al., 2013). Furthermore, they reported reduced cholesterol secretion in 
response to statins, demonstrating a model capable of predicting perturbation of an 
important hepatocyte function when exposed to a given compound.  
HLCs have also been reported as being amenable for use modelling hepatitis C (HCV) 
infection, supporting the full life-cycle of the virus (Carpentier et al., 2014; Schwartz et al., 
2012; Roelandt et al., 2012). Consequently, the efficacy of drugs targeting the HCV life cycle 
could be tested in a HLC-based model system. In addition, the aforementioned study using 
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iPSCs-derived from patients suffering from Alpers-Huttenlocher syndrome (Li et al., 2015), 
demonstrates the possibility of using HLCs to model hepatocyte mitochondrial function and 
response to chemical perturbation. 
Taken together, it is clear that whilst HLCs are not yet fit for all purposes, they are capable 
of modelling many liver-unique functions and associated toxicity, diseases and/or chemical 
perturbations within a stable, physiologically relevant and genotypically normal hepatic 
model.  
7.2.4 Deriving novel information from the proteomic assessment of primary human 
hepatocyte differentiation  
The results described in chapter 5 demonstrate the dynamic and selective proteomic 
changes which occur during dedifferentiation. This assessment is the first of its kind to 
assess human hepatocyte dedifferentiation in a proteomic context; however, despite this, 
the majority of the results generated were in-keeping with previous studies which have 
investigated dedifferentiation using rodent cells (Kim et al., 2010b; Rowe et al., 2010; 
Zellmer et al., 2010). The similarity suggests that the mechanisms of dedifferentiation are 
conserved across species and the proteomic changes we observed mirror transcriptional 
changes described in other studies. Consequently, our study confirms the translatability of 
these findings in both rodent-to-human and mRNA-to-protein contexts.   
Unlike previous omic studies, our work did not attempt to compare two or more culture 
systems (Kim et al., 2010b; Rowe et al., 2010) and instead aimed to directly address the 
driving mechanisms of dedifferentiation. Through this approach we were able to 
investigate the transcription factors which may underlie the loss of the xenobiotic hepatic 
phenotype, producing some potential insights into the sudden loss of cytochrome P450 
expression in monolayer culture systems. We found that binding sites for ZEB1, a known 
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transcriptional repressor which induces epithelial-mesenchymal transition (Liu et al., 
2008b), were exclusively located of the CYPs which were down-regulated during culture. 
Therefore, it is tempting to speculate that the EMT forced upon PHH in monolayer culture, 
causes an up-regulation of ZEB1 and consequently binding to, and inhibition of, selected 
CYPs. This provides a hypothetical mechanism by which the enhancements of CYP 
expression seen in 3D culture systems may work (Tostoes et al., 2012).   
Furthermore, FOXO1, which is the main target of insulin signalling (Matsumoto et al., 
2006), is another transcription factor which has a predicted binding site in the upstream 
region of the down-regulated, but not maintained, CYPs. Insulin is used in the culture 
media to boost glucose uptake and improve plating efficiency, morphology and 
functionality following isolation and during culture (Mooradian and Mariash, 1987; Klein et 
al., 2002; Fraczek et al., 2013). However, as insulin was present in the media throughout 
this study and the CYPs which have FOXO1 predicted binding sites in the gene promoter 
region were significantly down-regulated, it may be hypothesised that FOXO1 also plays a 
role in the loss of xenobiotic phenotype. This may be a reflection of the static nature of 
culture system used, with insulin a constitutive part of the culture media; whereas, the 
situation in man is much more dynamic. Recently, Siller et al., demonstrated the advantage 
of using pulses of growth factors during HLC differentiation (Siller et al., 2015) and the 
same technique may better reflect the physiological waves of insulin which are released 
upon food intake in man.   
Of further interest, several factors associated with the maintained CYPs are related to 
developmental processes (i.e. MITF, COUP-TFII, Brachyury, TBX5, OTx2 and the androgen 
receptor) or stress responses (i.e. HSF2 and ATF6). Some have hypothesised that the 
process of dedifferentiation is a reversion to a less mature phenotype (Baxter et al., 2015; 
Rowe et al., 2013) caused by the cellular stress of isolation and culture, with similar effects 
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noted following injury prior to regeneration (Kakizaki et al., 2007). This is also in-keeping 
with our analysis of the foetal HNF4α promoter becoming demethylated following isolation 
and culture. The presence of binding sites for these transcription factors in the upstream 
regions of the maintained CYPs may therefore indicate a mechanism by which stress and/or 
developmental associated factors are able to maintain CYPs that are essential to cell 
survival and accommodate the loss of other factors, such as HNF1α activity, which non-
essential CYPs (i.e. xenobiotic-associated) cannot.   
The investigation of proteome represents a global assessment of the functional unit of the 
cell, i.e. the protein; however, the presence of a protein does automatically indicate that it 
is functional. For example, phosphorylation and ubiquitination can strongly influence 
protein function, as can the location of the protein within the cell. Therefore, to fully 
understand the changes of dedifferentiation, post-translational modifications must also be 
taken into account. The importance of such modifications is highlighted by figure 7.2. This 
data represents the networks which Ingenuity pathway analysis associated with the 
dedifferentiation process at 168 hours, with the inference being that the more connected 
the protein, the more pivotal a role it plays in the process being investigated. Highlighted 
by black boxes are the proteins Ubiquitin C and Sumo2. These proteins are central to the 
network and therefore are likely to have an important role in the process of 
dedifferentiation.   
SUMOylation of HNF4α has been reported by Zhou et al., during hepatic differentiation and 
was shown to alter protein stability in an ubiquitin-dependent manner (Zhou et al., 2012). 
Thus, changes in the post-translational modification of proteins are likely to be another key 
determinant driving the loss of hepatic phenotype during culture and utilising post-
translational proteomics may yield greater information regarding the process (Mann and 
Jensen, 2003).  
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Figure 7.2: Combining interconnected networks associated with dedifferentiation at 168 
hours of culture highlight potential roles for Ubiquitin C and Sumo2. 
IPA Ingenuity generated networks from the differentially expressed proteins combined using 
the merge network function. Proteins in green: down-regulated. Proteins in red: Up-
regulated. Grey proteins: non-differentially expressed proteins. White proteins: non-
detected proteins inserted to make network.  Purple lines: Inter-network relationships. Grey 
lines: Individual network relationships. 
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There is little doubt that complex co- and 3D-culture systems offer enhanced phenotypic 
maintenance; however, by using a simple culture system in a step-back approach, we have 
been able to identify novel factors which may be targeted by changes in culture techniques 
or through the use of small molecules. Expanding the scope of this study and building upon 
the hypotheses generated will yield greater information regarding the importance of these 
factors in the maintenance of PHH.  
PHH dedifferentiation is a complex and multi-faceted process (summarised in figure 7.3). At 
the earliest timepoints, stress-associated factors dominated the up-regulated pathways 
and proteins. These pathways likely drive the loss of phenotype but are also imperative for 
ensuring cell survival and inhibition often leads to loss of viability (Fremin et al., 2012); 
therefore, addressing the source of the stress is an important consideration. Perhaps the 
greatest cause of this stress is the collagenase-based digestion and ischemia-reperfusion 
injury which the cells are subjected to during isolation (Elaut et al., 2006). As a 
consequence, the cells are compromised prior to being placed into the various culture 
systems. Given the resources which are being directed towards the incremental 
development of complex hepatic culture models, replacing or developing the relatively 
crude collagenase digestion technique offers an area which has the potential for giant leaps 
in the maintenance of the hepatic phenotype in vitro.   
  
Figure 7.3: Dynamic waves of hepatocyte dedifferentiation. Schematic diagram of the 
time-dependent changes of specific protein groups during dedifferentiation. 
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7.3. Final comments 
To conclude, the hypotheses investigated in this thesis will be commented on individually. 
Hypothesis 1:  
The use of primary human hepatocyte-derived iPSCs to generate hepatocyte-like cells 
yields an improved maturity in hepatocyte-like cell phenotype when compared to HDF-
derived iPSCs from the same donor.    
Comment: HLCs differentiated from PHH-derived iPSCs of 3 donors showed little to no 
significant difference in the expression of genes at all stages of culture or differentiation 
compared to HDF-derived iPSCs. This was also true of methylation and functional analysis 
studies. Therefore, we found this hypothesis to be false. Future investigations may wish to 
confirm these findings in more advanced models or using omic technologies.    
Hypothesis 2:  
Mechanistic evaluation of the primary human hepatocyte proteome during monolayer will 
yield novel information and hypotheses regarding the dedifferentiation process. 
Comment: Global proteomic analysis of PHH during culture provided novel understanding of 
the driving mechanisms of dedifferentiation process. These findings should provide the basis 
of further investigations into the effect that these factors have in both simple and complex 
culture systems.    
Hypothesis 3: 
 Nrf2 regulates hepatocyte phenotype during differentiation and dedifferentiation 
Comment: Investigation into the role of Nrf2 in hepatocyte dedifferentiation demonstrated 
a potentially negative relationship between Nrf2 induction and key metabolic protein 
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CYP3A4. The levels of Nrf2 were also found to increase during the differentiation of 
pluripotent stem cells to HLCs. Future work is now required to manipulate the levels of Nrf2 
during HLC differentiation to mechanistically evaluate its role in the process. 
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